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Abstract  v 
Abstract 
Strontium is known to have a positive effect on bone by concomitantly 
increasing bone formation and decreasing bone resorption, thereby providing a 
sustained skeletal benefit. Strontium ranelate (SrR) has been shown to reduce the risk 
of both vertebral and non-vertebral fractures in patients with postmenopausal 
osteoporosis. Strontium malonate (SrM) is currently being developed as a novel 
pharmaceutical for the treatment and prevention of osteoporosis. SrM potentially 
provides considerable advantages over SrR with respect to Sr content, bioavailability 
and ease of administration.  
SrM was tested in three animal studies: 1) a 4-week study in dogs using SrM 
doses of 0 (control), 300, 1000 and 3000 mg kg-1 day-1, 2) a 26-week study in rats, 
and 3) a 52-week study in dogs, both using SrM doses of 0 (control), 100, 300 and 
1000 mg kg-1 day-1. Femurs, vertebrae, skullcaps and teeth from the treated animals 
were examined for treatment-related changes in concentrations of Sr, Ca, Mg and P 
using inductively coupled mass spectrometry (ICP-MS). Bone mineral density 
(BMD) was determined using dual energy X-ray absorptiometry (DEXA), and the 
biomechanical properties of the bones were assessed using bending and compression 
tests. A procedure was developed for determination of Mg, P, Ca and Sr in diluted 
serum using ICP-MS in combination with an Apex-Q desolvation unit. The Apex 
inlet system reduced the generation of oxides in the ICP and improved the sensitivity 
for Sr by a factor of 14 compared with a conventional cross-flow nebuliser. Rh was 
found to be a suitable internal standard for all four analytes. Reliable estimates of the 
measurement uncertainties were achieved by pooling calibration data obtained on 
different days. 
Treatment with SrM resulted in a dose-dependent increase in Sr contents in all 
analysed tissues. The highest concentrations were found in rat incisor, which 
contained an average of 45 ± 11 mg g-1 Sr in the highest dose group, corresponding 
to a 450-fold increase compared with placebo. The Sr/(Sr+Ca)mol% in the four 
groups were respectively 0.015, 1.2, 5.8 and 7.7 for incisors and 0.015, 0.6, 1.9 and 
5.0 for femurs. Sr concentrations in rat incisor and rat femur were strongly correlated 
with approx. 30% less Sr found in the femurs. A strong correlation between serum Sr 
and incisor Sr was also observed. In dogs, the highest concentrations of Sr were 
found in skullcap after 52 weeks of treatment, with an average of 28 ± 12 mg g-1 Sr 
in the highest dose group, corresponding to a 350-fold increase compared with 
placebo. The Sr/(Sr+Ca)mol% in the four treatment groups were respectively 0.011, 
2.5, 3.8 and 4.4 for femurs; 0.019, 3.3, 4.7 and 6.5 for calvaria and 0.013, 0.75, 1.1 
and 1.6 for molar teeth. Sr concentrations in femur and molar were correlated. Sr 
concentrations in dog femur mid-shaft after 4 weeks were approx. 1/3 of the 
vi  Abstract 
 
concentrations after 52 weeks, suggesting that initial incorporation of Sr proceeded 
by a faster mechanism than the long-term incorporation. In both rats and dogs, long-
term treatment with SrM was associated with decreased concentrations of Ca and P 
in the mineralised tissues. EXAFS measurements indicated that Sr had substituted Ca 
in the bone apatite structure, but that Sr also coordinated to other atoms, most likely 
oxygen in collagen and water. The incorporation of Sr into the HAp increased with 
increasing dose. 
A simple stoichiometric model was proposed for incorporation of Sr into the 
hydroxyapatite (HAp) matrix of bones and teeth. The model showed excellent 
agreement with the analytical data and demonstrated that at least a part of the 
perceived loss of Ca and P was caused by the increased weight of HAp following 
adsorption and incorporation of Sr. It was found that respectively 70 – 72% of femur, 
78% of rat incisor and 85% of dog molar was made up by HAp. 
The maximum strength of the dog femurs (three-point bending) was significantly 
reduced (19%) in the highest dose group, indicating a weakening of the apatite 
structure. A non-significant increase (9%) in strength was seen in the low and 
medium dose groups. Measurements of bone mineral density (BMD) using DEXA 
was found to be heavily influenced by presence of Sr in the mineralised matrix, and 
linear correction of 9% was determined for a 1:10 molar ratio of Sr:HAp. The 
corrected BMD increased significantly in dog femur mid-shaft in the group treated 
with 300 mg kg-1 day-1 SrM. The corrected BMD was found to be strongly correlated 
with bone strength, indicating that the increase in corrected BMD following SrM 
treatment was associated with concomitant increase of bone strength. 
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Dansk resumé 
Strontium har en positiv effekt på knoglevæv, idet Sr på samme tid øger 
knogledannelsen og mindsker knogleresorptionen. Herved opnås en vedvarende, 
gavnlig virkning på knoglerne. Behandling med strontiumranelat (SrR) har vist sig at 
nedbringe hyppigheden af både vertebrale og non-vertebrale knoglebrud hos 
patienter, der lider af osteoporose (knogleskørhed). Strontiummalonat (SrM) er under 
udvikling som et nyt lægemiddel til behandling og forebyggelse af knogleskørhed, 
og SrM har som medicinalprodukt en række potentielle fordele frem for SrR i form 
af bedre biotilgængelighed, højere strontiumindhold og lettere indtagelse. 
SrM blev undersøgt i tre dyrestudier: 1) et 4-ugers studie i hunde med SrM doser 
på 0 (kontrol), 300, 1000 og 3000 mg kg-1 dag-1, samt 2) et 26-ugers studie i rotter og 
3) et 52-ugers studie i hunde, begge med SrM doser på 0, 100, 300 og 1000 mg kg-1 
dag-1. Lårbensknogler (femur), lændehvirvler (lumbar vertebra), hjerneskal (calvaria) 
og tænder fra de behandlede dyr blev undersøgt for behandlingsrelaterede ændringer 
med hensyn til indhold af Sr, Mg, P og Ca ved brug af ICP-MS (inductively coupled 
plasma-mass spectrometry). Knoglernes mineraldensitet (BMD, bone mineral 
density) blev målt ved brug af DEXA (dual energy X-ray absorptiometry), og 
knoglestyrken blev undersøgt ved hjælp af mekaniske bøjnings- og 
kompressionstests. Der blev udviklet en metode til måling af Sr, Mg, P og Ca i 
fortyndet serum baseret på ICP-MS koblet til et Apex-Q prøveintroduktionssystem. 
Apex-systemet reducerede dannelsen af oxider i ICP’en og forbedrede sensitiviteten 
for Sr med en faktor 14 i forhold til en konventionel forstøver. Rh var velegnet som 
intern standard for alle fire analytter. En realistisk vurdering af måleusikkerheden 
blev opnået ved at pulje kalibreringsdata fra flere forskellige måledage. 
SrM-behandlingen førte til en dosisafhængig stigning i strontiumindhold i alle 
analyserede væv. De højeste koncentrationer blev fundet i rottefortænder, hvor den 
gennemsnitlige Sr-koncentration i den højeste dosisgruppe var 45 ± 11 mg g-1, 
svarende til en stigning på 450 gange i forhold til kontrolgruppen. I rotterne var 
molforholdet Sr/(Sr+Ca)mol% i de fire behandlede grupper hhv. 0,015; 1,2; 5,8 og 
7,7 i fortænder og 0,015; 0,6; 1,9 og 5,0 i lårben. Der var en stærk korrelation 
mellem Sr-koncentrationerne i serum og i fortænder. Sr-indholdet i fortænder og 
lårben var ligeledes korreleret, og lårbenene havde ca. 30 % lavere Sr-indhold end 
tænderne. I hundene blev de højeste Sr koncentrationer fundet i hjerneskal, hvor 
gennemsnittet i den højeste dosisgruppe var 28 ± 12 mg g-1 Sr, svarende til en 
stigning på 350 gange i forhold til kontrolgruppen. Sr/(Sr+Ca)mol% i de fire 
behandlede grupper var hhv. 0,011; 2,5; 3,8 og 4,4 for lårben, 0,019; 3,3; 4,7 og 6,5 
for hjerneskal og 0,013; 0,75; 1,1 og 1,6 for kindtænder. Der var korrelation mellem 
Sr-koncentrationerne i lårben og tænder. Sr-koncentrationen i lårbensskaftet var efter 
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4 uger ca. 1/3 af koncentrationen efter 52 uger, hvilket tyder på at den indledende 
inkorporering af Sr finder sted via en hurtigere mekanisme end langtids-
inkorporeringen. I både rotter og hunde var langtidsbehandling med SrM forbundet 
med fald i Ca- og P-koncentrationerne i de mineraliserede væv. Målinger med 
EXAFS (Extended X-ray Absorption Fine Structure) viste at Sr substituerede Ca i 
knoglehydroxyapatit, men at Sr også var bundet til andre atomer, sandsynligvis 
oxygen i kollagen og vand.  
En enkel, støkiometrisk model for strontiums inkorporering i hydroxyapatit 
(HAp) i knogler og tænder blev foreslået. Modellen viste fremragende 
overensstemmelse med de analytiske resultater og demonstrerede at en del af det 
observerede tab af Ca og P skyldes, at inkorporering og adsorption af Sr øger vægten 
af HAp. Modellen viste at hhv. 70 – 72 % af lårbenene, 78 % af rottefortænderne og  
85 % af hundekindtænderne bestod af HAp. 
Styrken i hundelårbensknoglerne (tre-punkts bøjning) var signifikant reduceret 
(19%) i den højeste dosisgruppe, hvilket indikerer en svækkelse af HAp-strukturen. 
Der blev desuden set en ikke-signifikant (9 %) stigning i knoglestyrken i lav- og 
mellem-dosisgrupperne. Måling af BMD ved brug af DEXA blev påvirket meget af 
tilstedeværelse af Sr i den mineraliserede matrix, og en lineær korrektion på 9 % for 
et molforhold for Sr:HAp på 1:10 blev fundet. Den korrigerede BMD var signifikant 
forøget i lårbensskaftet i hunde behandlet med 300 mg kg-1 dag-1 SrM. Korrigeret 
BMD var stærkt korreleret med knoglestyrke, hvilket indikerer at stigningen i 
korrigeret BMD efter behandling med SrM var forbundet med en stigning i 
knoglestyrke.
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List of words and abbreviations 
 
Anterior Front, frontal 
BMC Bone Mineral Content 
BMD Bone Mineral Density 
Calvaria Skullcap 
Caudal Back, towards the rear 
Cortical bone Same as compact bone 
cps Counts per second 
Cranial  Towards the head 
CRM Certified Reference Material 
DEXA Dual Energy X-ray Absorptiometry 
Diaphysis The shaft (mid-section) of a long bone 
DPA Dual-Photon Absorptiometry 
ETAAS Electrothermal Atomic Absorption Spectrometry 
EXAFS Extended X-ray Absorption Fine Structure 
FAAS Flame Atomic Absorption Spectrometry 
FAES Flame Atomic Emission Spectrometry 
Femur Thighbone 
FSP Fundamental Sampling Principle 
GUM Guide to the expression of Uncertainty in Measurement 
Hypocalcaemia A condition characterised by abnormally low concentrations of calcium 
in the blood. 
ICP-AES Inductively Coupled Plasma Atomic Emission Spectrometry 
ICP-MS Inductively Coupled Plasma Mass Spectrometry 
IRMM Institute for Reference Materials and Measurements 
IS Internal Standard 
NIST National Institute for Standards And Technology 
NNA Neutron Activation Analysis 
OLSR Ordinary Least-Squares Regression 
Osteomalacia A bone condition in adults characterised by softening of the bone due to 
inadequate mineralisation. Similar to rickets in children. 
Pixi Proton Induced X-Ray Emission 
Posterior Back, towards the rear 
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QUAM Quantifying Uncertainty in Analytical Measurement  
Rachitis Same as rickets 
Rickets  A softening of bone in children, usually as a result of vitamin D or 
calcium deficiency. Similar to osteomalacia in adults. 
RM Reference Material 
SRM Standard Reference Material 
Tibia Shinbone 
TOS Theory Of Sampling 
Trabecular bone Same as cancellous or spongy bone. 
UV/Vis Ultraviolet-visible light 
WLSR Weighted Least-Squares Regression 
XRF X-ray Fluorescence 
 
Specific remarks 
For brevity, the term “serum Sr” is often used in this thesis as an abbreviated 
form of “the concentration Sr in serum”. Likewise, “femur BMD” reads “the bone 
mineral density in femur. Similar abbreviations are “femur Ca”, “tooth Sr”, etc. 
Animal studies are referred to as e.g. “4-week dog” for a study in dogs with a 
treatment time of 4 weeks. 
Throughout the report, “Sr” and “Sr2+” as well as “strontium” and “strontium 
ions” are used interchangeably. It is implied that strontium always exists in oxidation 
state +II in aqueous solutions and biological systems.  
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 1 Introduction 
 
CHAPTER ONE 
Introduction 
 
This chapter gives a brief introduction to the background, aims and methodology 
of the present project. It also presents the outline of the dissertation.  
1.1 Project background 
Strontium is widely distributed throughout the biosphere due to the widespread 
geochemical occurrence and high bioavailability of the element. Although not 
considered an essential nutrient, strontium has been known to have an effect on 
calcified tissue since the beginning of the last century [1]. The first clinical trials with 
strontium were performed in 1952 by Shorr and Carter [2], who found that the 
element improved remineralisation of bone in humans. In recent years, strontium’s 
positive effect on bone has been documented by numerous in vitro and in vivo 
studies. As a result, strontium ranelate (SrR) (Figure 1.1) was approved in the EU in 
2004 as a drug for treatment of osteoporosis, a bone disease that affects millions of 
people worldwide. Strontium ranelate is produced by the French company Servier 
under the commercial names Protelos®, Protos®, Protaxos®, Bivalos® and Osseor®, 
and it is the only strontium-based prescription drug currently available.  
The present work is a continuation of a collaboration started in 2003 between the 
then Danish company Nordic Bone A/S and the Analytical Chemistry Group (ACG) 
at the Department of Chemistry, Technical University of Denmark. Nordic Bone 
contacted Dr. Andersen of the ACG in search of a suitable strontium compound to be 
developed as a novel and competitive antiosteoporotic drug. The ACG initiated 
investigations of a range of potential candidate compounds, of which strontium 
malonate (SrM) (Figure 1.1) was chosen for further testing and designated the 
compound code NB S101. A high-yield synthesis of anhydrous strontium malonate 
was developed by Christgau et al. [3] and the compound was characterised by its 
crystal structure [4].  
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Following the initial toxicological tests of strontium malonate, Nordic Bone A/S 
changed its name to Osteologix A/S (now Osteologix, Inc.), and the company 
commenced the extensive statutory, preclinical trials in animals. Upon completion of 
these toxicological studies, the clinical phase 1-3 trials were initiated. The phase 1 
and phase 2 trials have now been successfully completed, and phase 3 trials are 
currently in progress. In August 2010, Osteologix announced that it had granted 
Servier an exclusive license to develop and commercialise strontium malonate 
outside the U.S. 
As a pharmaceutical, strontium malonate has several advantages over strontium 
ranelate. SrM provides better strontium bioavailability [5, 6], a higher strontium 
content (SrM: 46% Sr (w/w) vs. SrR: 34% Sr (w/w)), and the anion is more readily 
synthesised. Perhaps most importantly, SrM can be formulated in a tablet, which 
eases the administration as compared to the existing SrR treatment. SrR is purchased 
as granules wrapped in single-dose sachets containing 2 grams of strontium ranelate, 
and the drug is taken orally once daily as a suspension in a glass of water. 
Strontium ranelate Strontium malonate 
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Figure 1.1 Structures of strontium ranelate [7] and strontium malonate [4]. 
1.2 Project objectives 
The discovery of strontium’s potency as an antiosteoporotic pharmaceutical 
agent generated much interest and research in the field, but the exact mechanism by 
which strontium exerts its effect on bone remains unclear. The objective of the 
present work was firstly to test the potential of strontium malonate as a new 
strontium-based pharmaceutical by evaluation of its bioavailability and toxicity. 
Secondly, the aim was to gain insights into the incorporation of strontium in bone 
and to examine the effect of strontium treatment on the properties of serum, teeth and 
bones in animals.  
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Using a range of different analytical techniques, we studied the structure, 
elemental composition and the mechanical properties of bone and teeth in animals 
treated with high doses of strontium. In order to ensure correct, well-founded clinical 
conclusions, the measurement uncertainties associated with the analytical results 
were evaluated, and quality control schemes were applied throughout the study.  
1.3 Methodology 
As explained above, the initial tests of strontium malonate included several 
preclinical trials in animals (rats and dogs). These toxicological studies presented a 
unique opportunity to examine the in vivo effect of strontium treatment on the 
elemental composition and mechanical properties of bone. Upon request of the ACG, 
Osteologix kindly agreed to amend the study protocol to include removal of selected 
tissue samples at necropsy. Thus, after completion of each animal study, skeletal 
parts such as femur, skull, tibia, vertebrae and incisors were removed, wrapped in 
cotton gauze soaked with isotonic water and shipped to the ACG for analysis. The 
samples were examined for strontium-induced changes in inorganic tissue 
composition and mechanical properties, using various analytical techniques such as 
mass spectrometry and bone densitometry. Procedures for sample preparation and 
analysis were established and optimised, and the validity of the obtained results was 
ensured via measurement uncertainty budgets and continuous quality control (QC). A 
thorough knowledge of the performance of the applied analytical methods was 
considered to be a fundamental prerequisite for a correct clinical interpretation of the 
data. Therefore, the concepts of metrology and QC were regarded as essential, 
integrated parts of the project. Also, it was important to process the analytical results 
using appropriate statistical methods.  
By these means, the impact of treatment factors (strontium dose, duration of 
treatment and gender) on measured values (i.e. bone Sr content, bone mineral 
density, bone cell activity and bone strength) could be investigated. In order to obtain 
a correct evaluation of strontium’s effect on the mineral density of bone, it was 
necessary to establish a correction factor for densitometric measurements of 
strontium-rich bones. Furthermore, correlations between incorporation of Sr in 
different skeletal sites were studied. Finally, a model for ion exchange in the 
inorganic bone phase was developed and tested on the available data. 
 
 
4 Chapter 1 
1.4 Dissertation outline  
The first part of this dissertation consists of 4 introductory chapters, presenting 
overviews of strontium’s biological role, analytical methods for determination of 
strontium as well as an introduction to some of the apparatus that was applied in the 
project. Then follows detailed discussions of the optimisation and uncertainty 
evaluation of ICP-MS measurements, after which the results from two animal studies 
are presented. The final chapter contains some concluding remarks and an outlook.  
1.4.1 Introduction to analysis and biological effect of strontium 
Chapter 2 is a review of the biological role of strontium, including its geological and 
biological prevalence, the mechanism of uptake and effect in the organism, as well as 
its incorporation into calcified tissues. The chapter also includes sections on bone 
physiology and osteoporosis, and the results of clinical trials with strontium malonate 
are briefly described. 
Chapter 3 presents an overview of analytical procedures for determination of 
strontium in biological tissues found in the literature. The focus is on spectrometric 
methods as well as the procedures necessary for sample preparation. Applications of 
metrology and reference materials in clinical studies are also discussed. 
Chapter 4 provides an introduction to three experimental techniques that have been 
used extensively through this study: inductively coupled plasma mass spectrometry, 
dual energy X-ray densitometry and mechanical strength measurements.  
1.4.2 Instrumental optimisation, metrology and quality assurance 
Chapter 5 deals mainly with the instrument optimisation and protocol development 
for ICP-MS determination of Mg, P, Ca and Sr in serum samples from rats treated 
with strontium ranelate. The serum samples were analysed as a part of two studies on 
strontium’s effect on fracture healing and bone regeneration, both coordinated by Dr. 
Annemarie Brüel at Aarhus University [8]. 
Chapter 6 presents discussions of sampling procedures, measurement uncertainty 
and quality control related to the ICP-MS analyses. 
1.4.3 Animal studies  
Three animal studies were conducted on strontium malonate. The first of these 
investigations was a short-term study in which 24 dogs were treated with high doses 
of strontium malonate for 4 weeks [9]. Femur bones, teeth and bone marrow were 
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analysed for strontium and calcium, and the results of the analysis are reprinted in 
Appendix II. For brevity, this study is referred to as “4-week dog” in this report.  
Chapter 7 describes a long-term study in rats (“26-week rat”). 160 rats were treated 
with Sr for 26 weeks. The study includes ICP-MS and densitometric analyses of 
femur bones and incisors, as well as a model for incorporation of Sr in the inorganic 
bone phase. The study was planned and executed in collaboration with Søren R. 
Sørensen [10]. 
Chapter 8 describes a long-term study in dogs (“52-week dog”). 40 dogs were 
treated with Sr for 52 weeks. The study includes ICP-MS and densitometric analyses 
as well as biomechanical measurements. A correction factor is presented for 
calculation of true densitometric results in the presence of high concentrations of Sr. 
1.4.4 Concluding remarks 
Chapter 9 summarises the results that have been presented in the previous chapters 
and outlines suggestions for future work. 
1.4.5 Appendix 
Appendix I considers analysis of phosphate in fresh-waters using stopped-flow 
analysis. The work was carried out during two complementary visits respectively to 
University of Plymouth, UK, (six months duration) and Monash University, 
Melbourne, Australia (three weeks duration).  
Appendix II is a reprint of the published results from the short-term study in dogs 
[11]. 
Appendix III presents equations used for regression calculations. 
 
   
  
2 Strontium in biological systems 
 
CHAPTER TWO 
 
Strontium in biological systems 
2.1 Introduction 
Compared with the two lighter group II elements calcium and magnesium, 
strontium has attracted relatively little attention in the fields of clinical chemistry and 
human biology. In recent years, however, the development of the drug strontium 
ranelate (Protelos™) has stimulated an increasing interest in the biological 
significance of the element. The purpose of this chapter is to provide an overview of 
the biological and clinical role of strontium, including uptake, distribution, excretion, 
toxicology and clinical effect. Emphasis is put on the element’s impact on bone 
remodelling and role as an antiosteoporotic drug. The chapter also provides 
background information on bone physiology and osteoporosis, and the final section 
presents an overview of clinical studies on strontium ranelate. 
2.2 Chemistry 
Strontium is a member of the alkaline earth elements (Group 2 in the periodic 
table). The atomic number is 38 and the atomic weight is 87.62. In many chemical 
aspects (size, oxidation potential, solubility of salts), the properties of Sr occupy an 
intermediate position between Ca and Ba. Sr has a high oxidation potential, and the 
Sr atom easily looses the two electrons in the 5s orbital, producing the Sr2+ ion (Sr  
Sr2+ + 2e-, E=2.89 V). Like the other alkali earth metals, Mg, Ca and Ba, Sr exists 
solely in oxidation state +II in aqueous chemistry and biological systems. Freshly cut 
elemental Sr has a silvery-white colour, but on exposure to air the colour changes to 
a dark yellow, due to formation of strontium oxide (SrO). Naturally occurring 
strontium consists exclusively of the four stable isotopes 84Sr, 86Sr, 87Sr and 88Sr, but 
a large number of radioactive isotopes are known [12, 13]. 
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Inorganic Sr compounds have several commercial uses as components in 
ceramics, magnets and television faceplate glass. When heated, strontium burns with 
a crimson colour, a property that has been exploited by the application of strontium 
salts in pyrotechnics [14]. The most important of the radioactive Sr isotopes are the 
beta-emitters 89Sr and 90Sr, which both have commercial uses (Table 2.1). The 
amount of reported applications of organic Sr compounds is limited, but the 
introduction of strontium ranelate as an antiosteoporotic drug has led to a growing 
interest in synthesis and crystal structures of strontium(II) salts [4, 15]. 
Table 2.1 Commercial uses of radioactive Sr isotopes. 
Isotope Physical half-life [16] Use 
85Sr 64.85 days Calcium tracer for studies of bone formation [17, 18] 
89Sr 50.52 days Palliation of pain from metastatic bone cancer [19] 
90Sr 29.1 years Present in nuclear fall-out and spent fuel-rods from 
nuclear reactors [20] 
 
2.3 Occurrence 
Discovered in a mine near the Scottish town of Strontian in 1790, strontium was 
isolated for the first time in 1808. Strontium is widely distributed throughout the 
environment. It constitutes about 0.02-0.03% of the earth’s crust, placing it among 
the 20 most common elements on earth. Owing to its high oxidation potential, 
elemental Sr does not exist in nature. The most important Sr minerals are the white 
or blue-white celestite (SrSO4) and the white strontianite (SrCO3), both shown in 
Figure 2.1. Sr is also found in isomorphs with aragonite (CaCO3) and witherite 
(BaCO3), and all Ca minerals usually contain small amounts of Sr [14]. The average 
Sr/Ca ratio in the earth’s crust was estimated to 8 mg Sr per 1000 mg Ca, albeit with 
large regional differences [13]. In 1955, Bowen and Dymond [21] found Sr/Ca ratios 
in the range of 1.2-500 mg Sr per 1000 mg Ca in English soils, with the higher values 
found in sandy, acid soil with low Ca content and in soils rich in celestite. Sr is the 
most abundant trace metal in seawater, reaching concentrations of up to 8 mg L-1, 
while fresh waters such as rivers and springs contain lower concentrations (1-800 µg 
L-1) [22, 23]. Groundwater can contain considerably higher Sr concentrations. One 
drilling in the Copenhagen area was reported to contain 53 mg L-1 [24].  
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Figure 2.1 Photographs of the naturally occurring strontium minerals celestite (a) [25] and strontianite 
(b) [26]. (a) is released into the public domain and (b) is copyright © 2006 by Amethyst Galleries, 
Inc., reprinted with permission. 
The radioactive isotope, 90Sr, is a major environmental contaminant after atomic 
bomb tests and in cleanup of decommissioned nuclear facilities [27]. Together with 
131Cs, 90Sr was the major contributor to radioactive contamination of the environment 
after the Chernobyl nuclear power plant accident [28]. With a half-life of 29 years, 
the isotope may cause long-term internal irradiation damages if it is accumulated in 
the body [29], and it is linked to bone cancer, cancer of the soft tissue near the bone 
and leukaemia [20]. Because of its deleterious effects, 90Sr has been studied 
extensively, but the radioactive Sr isotopes will not be discussed further in this 
report. It is merely imperative to note that the radiation hazards related to these 
isotopes are not present in the medical application of stable Sr.  
2.4 Sources 
The wide environmental distribution makes Sr a natural constituent of food and 
beverages. High amounts of Sr are found in seafood (up to 25 mg kg-1), grains and 
cereals (up to 18 mg kg-1), whereas meat, poultry, vegetables, milk, fruit and various 
beverages contain lower amounts (0.05-3.5 mg kg-1) [23, 30, 31]. The intake of Sr 
depends on the diet and geographical region. Strontium is a plant growth stimulant, 
but full replacement of Ca by Sr results in reduced growth. The Sr/Ca ratio in plants 
usually correlates with that of their corresponding soil or nutrient solution [32]. In 
the Western countries, a normal diet contains 2-4 mg Sr per day [13], while the 
exposure from the air is in the order of 400 ng per day [20]. Thus, the daily Sr intake 
is negligible compared to the intake of Ca, which normally is about 1 g per day [33]. 
Clearly, if the Sr concentration in the drinking water exceeds a few mg L-1, the water 
becomes the main source of Sr exposure. 
(a) (b) 
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2.5 Limit values 
There is no limit value stated for the amount of Sr in drinking water either in the 
EU directive on drinking water [34] or in WHO guidelines on water quality [35]. The 
Danish Environmental Protection Agency stated a limit of 10 mg L-1 for drinking 
water for human consumption [36]. The United States Environmental Protection 
Agency (USEPA) set a federal limit of 4 mg L-1 and the states of Maine and Florida 
have thresholds of 2.4 and 4.2 mg L-1, respectively. Additionally, USEPA has 
derived a chronic reference dose (RfD), which is an estimate of the daily exposure 
that is likely to be without risk of deleterious effects during a lifetime. RfD for Sr is 
0.6 mg kg-1 day-1, corresponding to an average daily intake of 42 mg Sr for a human 
with a body weight of 70 kg [20].  
2.6 Strontium metabolism 
Several reviews have been published on the biological activity of Sr [13, 37-39]. 
As can be seen from Table 2.2, Sr is a trace metal in the human body. A detailed list 
of Sr concentrations in various organs and tissues can be found in reference [23]. 
Unlike Mg and Ca that are both essential for a number of enzymatic and cellular 
processes, Sr is not considered to be an essential element in human nutrition, as 
absence of Sr in the diet does not cause death. Ca is a major component of bone and 
dentine and kept under strict homeostatic control, i.e. the concentration of Ca in the 
blood is strictly maintained within a very narrow range through accurate feedback 
mechanisms [33]. A similar control of the levels of Sr in the body has not been 
identified.  
Table 2.2 Atomic weight, ionic radii and abundance of Mg, Ca and Sr in the human body [16]. 
Element Atomic weight  M2+ ion radius (Å) [40] Amount (g)*  % of body weight*  
Mg 24.31 0.72 19 0.027 
Ca 40.08 1.00 1000 1.4 
Sr 87.62 1.18 0.32 4.6·10-4 
Ba 137.33 1.35 0.022 3·10-5 
*Composition of a 70-kg “standard man”. 
Many studies, including both whole-body investigations and studies on isolated 
organs, have shown that Sr often acts similarly to Ca, albeit with lower biological 
activity. Hormones whose secretion is elevated or inhibited by presence of Ca are 
also affected by Sr, and Sr can substitute Ca in a number of physiological processes, 
such as muscular contraction and blood clotting. Apparently, any active process that 
transports Ca across biological membranes also transport Sr, but to a lesser degree. 
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These processes, where Sr is in competition with Ca, include intestinal absorption, 
renal excretion, lactation and placental passage. 
Ingested Sr is distributed in plasma, extracellular fluids, soft tissues and the 
skeleton. Because of strontium’s chemical and physical resemblance with Ca, it is a 
natural bone-seeking element, and, like Ca, it accumulates in the skeleton [37]. In 
animals kept on a normal diet, approximately 99% of the absorbed Ca and Sr is 
deposited in bone.  
2.6.1 Uptake and excretion of strontium 
Sr enters the body primarily via the gastrointestinal tract, while a lesser amount may 
be absorbed through the lungs and skin [38]. Absorption has been shown to decrease 
with age in rats, but whether this is also the case with humans is disagreed upon 
between reviewers [13, 38]. Absorption is promoted by fasting and vitamin D [37], 
and inhibited by presence of phosphate, Ca [41, 42] and chelating agents such as 
sodium alginates [43]. Sr uses the same pathways as Ca for uptake and transport 
across the intestinal wall, but the carrier system has greater affinity for Ca [44, 45]. 
Combined with the much lower content of Sr in the diet, this means that Sr 
absorption is inhibited competitively by Ca. It has been suggested that the absorption 
of Sr happens entirely by passive diffusion [46, 47], but carrier-mediated 
mechanisms has also been proposed [45, 48]. Sr can be transferred across the 
intestinal wall against a concentration gradient, albeit with much lower efficiency 
than Ca [44]. It has been suggested that transport of Sr from the intestinal lumen to 
the blood may be entirely passive, while active transport may play a role in 
transferring Sr from the blood into the intestinal lumen. Such an arrangement might 
constitute a sort of homeostatic regulation of blood Sr concentrations at high levels 
[13]. When administered alone, about 25-30% of a Sr dose is absorbed in humans 
[38]. In the presence of Ca, Sr is absorbed to a lesser degree than Ca, with reported 
Sr/Ca absorption ratios of 0.5-0.7 [49, 50]. The discrimination of Sr in favour of Ca 
by the ion channels and calcium carriers may be due to the larger ion radius of Sr 
[13].   
Strontium is excreted primarily through urine, but also thought faeces and sweat 
[38]. Strontium taken orally is primarily excreted in stool, whereas intravenously 
infused Sr is excreted mostly in the urine [51]. Sr excreted in faeces is either non-
absorbed, orally administered Sr, or Sr that has been excreted from the blood to the 
intestine [38]. The renal clearance of Sr is about 3 times higher than for Ca, perhaps 
due to a lower degree of tubular reabsorption in the kidneys [13].  
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2.7 Strontium deficiency 
As mentioned above Sr does not seem to be essential to the human organism, but 
it has been shown to prevent caries in humans [52, 53]. Sr concentrations in water, 
tooth enamel and plaque were inversely related to prevalence of caries, and Sr 
increased dental thickness in rats [54, 55]. Nielsen [13] tentatively hypothesised that 
the therapeutic effect of Sr on osteoporosis could indicate that one feature of 
osteoporosis might be a certain degree of Sr deficiency, but little data is available on 
levels of bone Sr in normal, non-osteoporotic humans. Observations have been 
reported of low levels of Sr in the femur head, which is a frequent site of fractures in 
the elderly [56]. 
2.8 Strontium toxicity 
According to the Unite States Department of Health and Human Services [20], 
no cases of acute toxic effects from Sr overdosing have been reported in man. The 
only Sr compound that is considered harmful to humans is strontium chromate, but 
the toxicity is due to the carcinogenic chromium. However, increased bone Sr 
content has been associated with the presence of osteomalacia (softening of adult 
bone caused by defective mineralisation) in patients undergoing hemodialysis [57]. 
This may be accelerated by Sr contamination of dialysis fluids, which has been seen 
in some developing countries [58, 59]. More than 5% of patients in dialysis 
experience osteomalacia [13]. Additionally, some investigators found that 
intravenous administration of high doses of Sr was associated with an increased renal 
excretion of Ca [51, 60], which may lead to hypocalcaemia (low levels of Ca in the 
blood) [13]. 
2.9 Early studies of Sr as an antiosteoporotic agent 
Although the discovery that strontium interacts with bone was done a least a 
century ago, the development of strontium ranelate as a drug against osteoporosis has 
been accompanied by a rather recent clinical interest in the element. The studies 
reported by Lehnerdt [1] in 1910 may be the first to deal with the influence of 
strontium on bone tissue. The first observations indicating that strontium may be 
useful in the treatment of osteoporosis were published in 1952 by Shorr and Carter 
[2]. They found that moderate doses of strontium lactate (1.75 g Sr per day) 
administered to osteoporotic patients improved the remineralisation of bone as 
observed by an increased deposition of calcium. As a result of this report, McCaslin 
and Janes [61, 62] at the Mayo Clinic (Rochester, MN, U.S) initiated treatment with 
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strontium lactate of a series of osteoporotic patients in the years 1953-1957. A total 
of 72 patients were treated for periods of 3 months to 3 years. Of these 72 patients, 
32 were available for a follow-up study, showing in all treated patients a subjective 
clinical improvement in terms of functionality and relieved pain. Though unable to 
explain the underlying mechanism of action, the observation moved the authors to 
conclude that “the therapeutic value of the drug appears to be established”.  
Despite these promising observations, it was to take almost three decades before 
the potentially beneficial effects of Sr on bone conditions were further investigated. 
Starting in 1981, Skoryna et al. [60, 63, 64] studied the effect of strontium 
administration on serum and tissue concentrations of Sr and Ca, discovering that Sr 
could help remineralise bone lesions originating from metastatic bone cancer. Later 
followed a small-scale clinical study, where administration of small doses of 
strontium carbonate (600-700 mg Sr per day) for six months was found to stimulate 
trabecular bone formation, evaluated by taking biopsies of the iliac crest [65]. These 
studies rekindled the clinical interest in strontium, ultimately leading to the release of 
strontium ranelate. 
It remains a question why it should take almost 30 years before the observations 
reported in the 1950’s received the attention they disserved, but it has been 
speculated that it may in part be due to the reports of rachitogenic effects of high 
doses of strontium. Also, the presence of the radioactive 90Sr in nuclear fallout and 
waste may for many years have associated stable strontium with the radiation 
damages and contamination caused by radiostrontium [13]. 
2.10 Bone physiology 
This section is intended to provide some basic information on the function, 
composition and structure of bone tissue. More detailed information on bone biology 
and disease can be found in references [66-71].  
The skeleton has two primary functions: 
1) a biomechanical, supporting, carrying and protecting the body, 
2) a metabolic, serving as a reservoir for many ions, e.g. Ca and P. 
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Figure 2.2 Hierarchical 
structure of bone, showing the 
seven levels of hierarchy. The 
two main categories of bone 
are 1) cortical (compact) bone 
that is found on the surface of 
all bones and 2) trabecular 
(spongy) bone that fills the 
inside of many bones. 
Compact bone is composed of 
concentric, lamellar structures 
of bone tissue (osteons) that 
surround and protect blood 
vessels occupying the 
Haversian canal. Each 
lamella is composed of fibres 
arranged in geometrical 
patterns. Each of these fibres 
consists of several linked 
collagen fibrils, forming 
together a fibril array. The 
mineralised collagen fibrils 
are the basic building blocks 
of bone. They are composed 
of collagen protein molecules 
(tropocollagen) formed from 
three chains of amino acids 
[67]. Reproduced by permis-
sion of Massachusetts 
Medical Society. 
 
 
Making up the supporting framework of the body, bone tissue must satisfy 
several contradictory needs. Carrying the weight of the body requires stiffness, i.e. 
the ability to resist loading without deforming. At the same time, the bones must 
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posses a certain amount of flexibility, so that they can absorb energy by deforming 
rather than cracking. If the bones are too brittle and inflexible, loading will lead to 
structural failure, initially by development of microcracks and later by complete 
fracture. On the other hand, too much flexibility will cause a bone to bend beyond its 
peak strain, also resulting in fracture. This demand for structural strength must be 
balanced by a requirement for the bones to be light, so that movement is not 
hampered. Different types of bones are fine-tuned to achieve specific functional 
properties. Long bones such as femur and tibia are resistant against bending, short 
bones like vertebrae are resistant to compression but highly flexible, while plate-like 
bones like the skull provide protection for vital organs. The remarkable ability to 
accommodate the opposing demands of stiffness and flexibility, strength and 
lightness, is reflected in the ingenious biomechanical structure of bone tissue [67-69].  
2.10.1 Composition and structure of bone 
Bone tissue consists of bone cells imbedded in a matrix of organic material 
(primarily the fibrous protein type I collagen) stiffened by crystals of an inorganic 
calcium phosphate mineral very similar to hydroxyapatite (Figure 2.2). The crystals 
of bone are plate-shaped with average dimensions of 50 x 25 nm. Together with the 
third major component, water, the organic and inorganic constituents are associated 
in an ordered structure, sometimes referred to as the mineralised collagen fibril [69]. 
2.10.1.1 Hydroxyapatite 
Wopenka and Pasteris [72] produced an in-depth mineralogical review on 
biological apatite. Pure hydroxyapatite (HAp) has a stoichiometric composition of 
Ca5(PO4)3OH, often written as Ca10(PO4)6(OH)2 to denote that there are two formula 
units in one crystallographic unit cell. Using a somewhat simplified view, there a 
four different types of crystallographic positions in the apatite unit cell (Figure 2.3): 
(1) tetrahedral sites for six P5+- ions, each in 4-fold coordination with oxygen, (2) 
Ca[I] sites for four of the Ca2+-ions, (3) Ca[II] sites for the six other Ca2+-ions, 
arranged in such a way that they form an anion channel, and (4) the channel site 
occupied by OH-.  
The apatite structure is highly accommodating to chemical substitutions. The 
body is able to fine-tune the composition of the crystal according to the different 
mechanical requirements of the structure (bone apatite, enamel apatite, dentine 
apatite). A large number of cations (e.g. Mg2+, Fe2+, Zn2+, Sr2+, and Pb2+) can 
substitute Ca2+ in the apatite structure, but because insertion of any foreign ion will 
induce structural changes in the crystal, there is a limit to how much of a given ion 
that can be incorporated. According to Boivin et al. [73], a maximum of 1 out of 10 
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Ca ions can be replaced by Sr via heteroionic substitution in bone apatite. Sr2+ is 
mainly incorporated at the Ca[II] site [74]. 
In contrast, OH- is readily replaced by F-, because the F- ion produces a better fit 
in the channel position than OH-. This is exemplified by the fluoridation of tooth 
enamel via fluorinated dental products, which is advantageous because flourapatite is 
less soluble in acidic solutions than HAp. Carbonate ions can in principle substitute 
both at the OH-site and the PO4-site, but it remains unclear exactly how COଷଶି is 
incorporated. It seems to be generally accepted that, in biological apatite, COଷଶି 
predominantly replaces POସଷି. Bone apatite contains approximately 7% (w/w) 
carbonate and tooth enamel about 3.5% (w/w).  
Even though the mineral associated with bone and teeth is invariably denoted 
“hydroxyapatite” or “carbonated hydroxyapatite” in the medical literature, there is 
now some evidence for a lack of OH-. In one study, Raman spectra of different 
apatites showed clear O-H stretching modes from hydroxyl groups for synthetic HAp 
and teeth enamel, while spectra for mammal cortical bone did not. Contrary to 
common statements, it therefore seems that bone apatites may not contain high 
concentrations of OH- groups, and some may contain none at all [72]. 
Generally, the mechanic properties of the bone structure are largely determined 
by the mineral density [76]. A high mineral content increases the stiffness at the 
 
Figure 2.3 Projection of the (001) plane of the hydroxyapatite structure, showing the tetrahedral 
PO43- ionic groups, Ca2+-ions and OH- channel ions. The parallelogram indicates outline of a unit 
cell. Six of the Ca2+ ions form a six-fold site in which the channel ions reside (OH- in the case of 
hydroxyapatite) [72]. Sr is mainly incorporated at these Ca[II] sites. Reproduced from [75] by 
permission of The Royal Society of Chemistry. 
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expense of flexibility. By testing many different bones from different organisms, 
Currey [77] showed a clear correlation between stiffness and mineral density, bone 
stiffness increasing with increased mineral content.  
2.10.1.2 Collagen 
Whereas hydroxyapatite is the only mineral found in mature bone, more than 200 
different proteins are present, collagen constituting about 90%. A collagen fibril is 
made up of three polypeptide chains of about 1000 amino acids wound together in a 
triple helix (Figure 2.2). Fibrils tend to merge with neighbouring fibrils, forming a 
larger structure called a fibre [69]. 
2.10.1.3 Water 
The third component, water, is located in the gaps between the triple-helix 
molecules, within the fibril, between fibrils and between fibres. The presence of 
water is essential for the mechanical properties of the bone, and the results of 
mechanical measurements differ in dry and wet bone [69]. 
2.10.2 Bone types 
Bone tissue is divided into two main categories: cortical bone and trabecular or 
cancellous bone. Cortical bone is dense and found in varying thickness on the outer 
surface of all bones, whereas trabecular bone is spongy and fills the insides of many 
bones [67].  The analogy to levers and springs formulated by Seeman et al. [68] is 
quite illustrative. Like a lever, long bones, e.g. the femur, must be able to resist 
bending and buckling, prioritising rigidity over flexibility. This property is provided 
by the compact cortical tissue, while lightness is achieved by the marrow cavity. In 
places where stress is mainly compressive, such as in the vertebrae or the femur 
neck, the porous structure of trabecular bone can act like a spring, absorbing energy 
by deformation at the expense of stiffness. 
2.10.3 Modelling and remodelling 
Though easily perceived as a rigid, inert material, bone is in fact a very adaptive 
organ, undergoing constant renewal. During childhood and adolescence, bones are 
formed by a modelling process which allows for concomitant formation of new bone 
at one site and resorption of old bone from another site, in effect allowing the bone 
tissue to shift position and grow in length and thickness. In modelling, osteoblast and 
osteoclast activity is uncoupled and the amount, shape and position of bone tissue 
can change rapidly [71]. 
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The process of remodelling occurs throughout life and becomes the dominant 
process in adulthood. Unlike dentine, bones not only undergo remodelling on the 
surface but also internally [69]. In remodelling, a small amount of old bone is 
removed and then replaced with new bone at the same site. The remodelling has 
three main purposes: 1) to repair microcracks (or indeed fractures) in the skeleton 
caused by the stress of everyday activities, 2) to replace old bone which can loose its 
original elasticity and become brittle, 3) to enable the skeleton to act as a dynamic 
reservoir for calcium and phosphate by releasing and absorbing ions to and from the 
blood. In adults, most of the skeleton is replaced about every 10 years [71].  
The resorption and formation processes are carried out by two types of 
specialised bone cells: osteoclasts and osteoblasts (Figure 2.1). Osteoclasts break 
down old bone tissue, carving long tunnels in the bone. These tunnels are then 
refilled by osteoblasts, leaving only a narrow tunnel and small capillaries to act as 
blood vessels. With time, the osteoblasts get surrounded by the bone tissue they have 
formed and then turn into a third type of cell, osteocytes, which are involved in the 
metabolism of the bone [68]. 
 
Figure 2.4 In bone remodelling, osteoblast activity is coupled to prior osteoclast activity. After 
bone resorption by osteoclasts, osteoblasts start laying down new bone. Some osteoclasts remain 
inside the newly formed bone and are converted to osteocytes, which are connected to each other. 
The resorption process takes place within a matter of weeks, while bone formation takes several 
months. Unless there is remodelling imbalance, net changes in the amount of bone are minimal. 
Figures were produced using Servier Medical Art [78]. 
In healthy adults there is a tight coordination between the activity of osteoblasts and 
osteoclasts, resulting in a fine balance between resorption of old bone and formation 
of new bone [79]. 
2.11 Osteoporosis 
Osteoporosis (Gk. osteon, bone; poros: small hole or passage) is a major 
worldwide health problem, affecting an estimated 75 million people in Europe, USA 
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and Japan [80]. It is a severe, systemic skeletal disease characterised by an imbalance 
between the rates of bone resorption and bone formation, leading to a reduced bone 
mass and deteriorated microarchitecture of bone (Figure 2.5). The decrease in bone 
density and quality results in increased bone fragility and susceptibility to bone 
fractures.  
  
Figure 2.5 Scanning electron micrographs of iliac crest biopsies showing normal bone tissue (a) and 
osteoporotic bone tissue (b). P: Trabecular plate, B: Trabecular bar, Arrow: structural damage.  
Reproduced from [81] by permission of The American Society for Bone and Mineral Research.  
The maximum amount of bone a person achieves in a lifetime, the peak bone 
mass, is normally reached around the age of 20-25 [82]. After the age of 30 the 
quantity of bone starts to decrease because the rate of resorption is no longer 
matched by the rate of formation. The loss of bone is about 0.5% per year in men and 
1% in women. In the years just after the menopause, women may lose up to 6% bone 
mass per year, due to the reduced production of oestrogen [83]. The primary risk 
factors for osteoporosis are advanced age, female gender, family history (genetic 
factors), menopause, low body mass index, poor nutrition and insufficient exercise 
[82]. 
Because of the resulting bone fragility, osteoporosis is associated with an 
increased risk of low-energy fractures, especially in the forearm, vertebrae and the 
femur neck. Low-energy fractures originate from relatively minor trauma, resulting 
from normal activities or low falls, as opposed to high-energy fractures resulting 
from violent incidents such as traffic accidents or high falls. These fractures lead to 
pain, immobility, increased mortality, and loss of normal functioning and quality of 
life. Especially hip fractures contribute substantially to morbidity and mortality in the 
elderly [80].  On average 1 in 3 women over the age of 50 will experience 
(a) (b)
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osteoporotic fractures, as will 1 in 5 men [84-86]. In Denmark, the estimated 
prevalence of osteoporosis in persons aged 50 years or more is 41% among women 
and 18% among men [87]. 
2.11.1 Diagnosis 
Osteoporosis has no specific symptoms and cannot be diagnosed by a 
biochemical laboratory analysis. A diagnosis therefore depends on an assessment of 
skeletal mass, measured as bone mineral density (BMD) [88]. The standard method 
for determination of BMD is dual energy X-ray absorptiometry (DEXA) which is 
described in more detail in Chapter 4. The measured BMD is converted to a T-score, 
which is calculated by taking the difference between a patient’s measured BMD and 
the mean BMD in healthy adults with peak bone mass, matched for gender and 
ethnic group, and expressing the difference relative to the young adult population 
standard deviation (SD) [89, 90]: 
 T‐scoreൌ Measured BMD‐Young adult mean peak BMDSD of young adult population BMD  (1-1) 
A WHO study group has defined a T-score of < -2.5 as osteoporosis in 
postmenopausal women [91]. BMD measurements using DEXA were identified as 
strong predictors of osteoporotic fractures in clinical studies [92, 93], and, in 
practise, a patient with a low-energy fracture of the vertebra or hip is diagnosed with 
osteoporosis by definition [89].  
Table 2.3 WHO definitions of Osteoporosis and Osteopenia based on BMD T-scores [91, 94]. 
Terminology T-score 
Normal T ൒ ‐1.0
Osteopenia (low bone mass) ‐1.0 ൐ T ൐‐2.5
Osteoporosis T ൑ ‐2.5
Established (severe) osteoporosis T ൑ ‐2.5 in the presence of one or more 
low‐energy fractures
 
2.11.2 Current treatment 
The purpose of prevention and treatment of osteoporosis is to reduce the risk of 
fractures [89]. Prevention begins with ensuring an adequate intake of Ca and vitamin 
D, as well as participation in physical activity. Several medicines are approved for 
osteoporosis, traditionally divided into two categories: 1) anti-resorptive (or anti-
catabolic) treatment, which inhibits osteoclastic activity and thereby reduces the rate 
of bone resorption, and 2) anabolic treatment that stimulates bone formation. Most 
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pharmaceuticals are considered to be mainly anti-resorptive. These include 
bisphosphonates (e.g. Alendronate®, Optinate®) and selective estrogen receptor 
modulators (SERM, Evista®). Parathyroid hormone (PTH) and PTH analogues 
(Preotract® and Forsteo®) have anabolic effects on bone. Clinically, strontium 
ranelate (Protelos®) is considered to be mainly anti-resorptive, with a weaker 
anabolic effect. Ca and vitamin D supplements are always recommended as co-
therapy regardless of the primary medicine [82, 89, 95, 96]. 
2.12 Incorporation of strontium into bone 
Strontium has a great affinity for bone and is readily incorporated into bone 
tissue. In an early study, MacDonald et al. [97] observed a rapid increase in bone Sr 
during the first day after oral administration of SrCl2, followed by a much slower rate 
of increase the following 6-8 weeks. The authors suggested that this indicated two 
distinct deposition mechanisms: (1) An initial rapid mechanism, involving 
osteoblastic activity and formation of new bone, whereby Sr2+ is incorporated by 
surface adsorption, ion exchange with Ca2+ and protein binding of Sr2+. This 
mechanism is eventually saturated. (2) A slower mechanism, incorporating Sr into 
the crystal lattice of existing bone mineral. X-ray diffraction studies by the same 
authors also confirmed that Sr is ultimately incorporated into the internal structure of 
the crystal lattice, causing distortions of the unit cell [98]. X-ray crystallographic 
[73] and radioisotope studies [99] later confirmed the idea of two mechanisms for Sr 
incorporation, i.e. a rapid uptake into newly formed bone and a slow ion-exchange 
process in old bone and it is now widely accepted [39]. In a more recent literature 
review, Dahl et al. [39] identified three essential mechanisms for uptake and release 
of bone-seeking elements: 
1) Bone formation, leading to an increase in mineral density, 
2) Resorption, releasing ions into the blood 
3) Surface exchange of ions between the blood and bone can take place 
where bone surfaces are in contact with blood. Diffuse exchange is a slow 
process whereby ions can diffuse through the entire bone volume. These 
exchange processes are considered to be the main mechanisms of trace 
metal uptake in adults. 
Even with large doses over a long period of time, the amount of Sr that is 
incorporated is always very low (a few percent) compared with Ca [39]. The 
discrimination against Sr in the incorporation into hydroxyapatite may be caused by 
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the larger ion radius, which produces a mild distortion of the crystal lattice of 
calcium hydroxyapatite. This may result in a weaker binding of Sr to the crystal [12]. 
After cessation of strontium treatment, the concentration of Sr in bone decreases 
substantially irrespective of the previously administered dose. Sr is eliminated by 
three processes: (1) clearance from the exchangeable bone pool, (2) displacement of 
Sr in hydroxyapatite, presumably by Ca and (3) removal through bone resorption by 
osteoclasts. Sr is better retained in new bone than in old, presumably because the 
heteroionic substitution during bone formation makes Sr more firmly linked to the 
structure than the surface exchange and adsorption processes occurring in old bone. 
Models suggest that the terminal half-life in humans is about 3 years [39].  
2.12.1 Factors influencing the incorporation of strontium in bone 
Dahl et al. also [39] summarised five main factors that influence the amount of 
Sr that is incorporated into bone: dose level (exposure), duration of treatment, 
gender, the concentration of Sr in the plasma and type of bone (Figure 2.6).  
 
Figure 2.6 Factors influencing the incorporation of strontium into bone are dose level (level of 
exposure), duration of exposure, gender, serum Sr and bone remodelling rate. Redrawn from [39]. 
 
2.12.1.1 Dose level 
It has been clearly demonstrated that bone Sr increases with the administered 
dose. Sr in rat femur increased proportionally with doses of 35-140 mg kg-1 day-1 
Sr2+ after 4 and 8 weeks. At higher dose levels (up to 255 mg kg-1 day-1 Sr2+) the 
dose-dependent relative increase was reduced until the bone Sr reached a plateau 
level. The explanation is most likely saturation of the gastrointestinal absorption 
combined with saturation of the incorporation mechanisms as discussed above [39]. 
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2.12.1.2 Duration of treatment 
Together with treatment dose, the duration of treatment plays an important role 
in determining the degree of Sr incorporation. In a 56-days study with rats, the bone 
Sr concentrations doubled from 10 to 25 days of treatment, even though a constant 
level of serum Sr had been reached after 10 days. Bone Sr continued to increase 
slightly from 28 to 56 days of treatment [39]. 
2.12.1.3 Serum strontium 
In rats and monkeys serum Sr often reach a plateau level related to the 
administered dose within 4 weeks. As for bone Sr, the Sr concentration in serum 
increases relatively more at low doses than at high doses, due to saturation of the 
gastrointestinal absorption pathways. Such saturated Sr concentrations were seen to 
correlate positively with bone Sr in monkeys [39]. This relationship might mean that 
a reliable assessment of bone Sr in patients can be performed by taking a blood 
sample rather than a bone biopsy.  
2.12.1.4 Gender 
Rats kept on a normal laboratory chow (1% Ca, 0.02% Sr) showed no 
differences in femur or plasma Sr concentrations. However, oral administration of 
strontium ranelate to rats and monkeys resulted in higher bone and plasma Sr in 
males than in females. The difference may be caused by a gender difference in 
gastrointestinal absorption. A similar gender effect has not been reported in humans 
[39]. 
2.12.1.5 Bone type 
Different skeletal sites incorporate different levels of Sr. The relative proportions 
of cortical and trabecular tissue in a given bone influences the Sr incorporation, 
because the bone turnover and thus the abundance of newly formed bone is higher in 
trabecular bone [39, 100]. Studies with radioisotopes have indicated that at least part 
of the variations in Sr bone uptake is related to the level of regional blood flow [101, 
102]. Strontium concentrations in different skeletal sites (iliac crest and lumbar 
vertebra) were correlated in monkeys, independently of Sr dose [39]. It might 
therefore be possible to asses the Sr content of deeper skeletal sites by bone biopsies 
of the iliac crest in humans. 
2.13 The effect of strontium on bone 
The in vivo effects of Sr depend on the applied dose. High doses may disturb 
calcium metabolism and impair bone mineralisation, while low and moderate doses 
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have beneficial effects on bone. Quantitative limits between high and low doses are 
not completely established, but Marie et al. [37] considered a low dose to be less 
than 350 mg kg-1 day-1 Sr. Based on literature data, Cabrera et al. [38] found that a Sr 
concentration of more than 4 g L-1 in food or drinking water constitutes a high diary 
intake. Morohashi et al. [103] saw a need for a distinction between pharmacological 
and toxic doses of Sr. The authors found that a Sr dose of less than 15 mg per day 
had no adverse effects in rats, while a dose of 75 mg per day markedly suppressed Ca 
metabolism. 
2.13.1 High doses 
The first study indicating that Sr administered in high doses can induce defective 
bone mineralisation was published in 1935 [104]. Several animal studies have later 
shown that a high dietary intake of Sr can cause bone changes similar to those 
observed in rachitic bone, especially if the intake of Ca and vitamin D is low [38]. 
High doses of Sr can disturb Ca metabolism by reducing the intestinal absorption of 
Ca [105, 106] and by inducing hypocalcaemia and hypomineralised bone [48, 107, 
108]. In pigs, a diet of 0.16% Ca and 0.47-0.67% Sr caused incoordination, 
weakness, reduced weight gain and leg paralysis [109].  
One report of Sr related rickets in humans was published by Ozgur et al. [110], 
who investigated the prevalence of rickets in children aged 6-60 months in two 
regions with different soil Sr content in Turkey. Rickets (rachitis) is a bone disorder 
in children similar to osteomalacia in adults. It is characterised by a softening of the 
bones due to a decrease in bone mineralisation. In region I, which had a soil Sr 
concentration of >350 mg g-1, the prevalence of rickets was 31.5%, while region II 
which had a soil Sr concentration of <350 mg g-1, the prevalence was 19.5%. These 
findings are particularly important in areas where nutrition is mainly based on grain 
cereals. The prevalence of osteomalecia in dialysis patients with high serum and 
bone Sr were mentioned previously (section 2.8).  
The mechanism behind these deleterious effects of high Sr doses seems to be a 
combination of competitive inhibition of intestinal Ca absorption and a reduced renal 
synthesis of 1,25-dihydroxy cholecalciferol, which is the hormonally active form of 
vitamin D responsible for increasing the concentration of Ca in the blood [13]. 
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2.13.2 Low doses 
Studies have shown that low doses of strontium administered (as chloride) to rats 
stimulated bone formation and increased trabecular bone volume [107, 111], as well 
as increased the volume of vertebral bone and the number of bone forming sites 
[112]. Later studies showed that strontium ranelate enhanced bone cell replication 
and bone formation in vitro [113]. Bonnelye et al. [114] reported that SrR treatment 
was followed by increased osteoblastic formation and function, as well as decreased 
osteoclastic activity in cultured bone cells. 
Marie et al. [115] reported that SrR prevented trabecular bone loss in oestrogen-
deficient rats by decreasing bone resorption. However, in a recent study, Fuchs et al. 
[116] observed that SrR treatment of oestrogen-deficient rats did neither increase 
bone formation nor inhibit bone resorption. Short-term studies showed that treatment 
with SrR reduced the loss of trabecular bone volume in hind-limb immobilized rats 
[117]. Using X-ray diffraction and Raman microspectrometry, Boivin et al. [73] 
studied the distribution of strontium in monkey bone after administration of 
strontium ranelate. It was found that Sr was dose-dependently incorporated into both 
cortical and trabecular bone, mainly into trabecular and new bone. The study also 
showed that the clearance of Sr is quite high. After withdrawal of SrR, bone Sr 
decreased rapidly and faster in old than in new bone. The authors suggested that this 
observation may be explained by the fact that Sr is mainly incorporated into old bone 
by adsorption and surface exchange, whereas new bone incorporates Sr deeper into 
the crystal lattice by ionic substitution, linking it more firmly to the structure. No 
changes in crystal structure were observed. As an antiosteoporotic drug, the rapid 
clearance distinguishes Sr from bisphosphonates, which, once incorporated, are 
irreversibly bound to bone [13]. Long-term studies in healthy rodents showed a dose-
dependent increase in trabecular bone volume, mineralised bone volume and 
osteoblastic surface, accompanied by a reduction in osteoclastic surface and 
osteoclast number [118].  
In recent studies, SrR has been shown to also have an effect on the 
biomechanical properties of bone. Long-term SrR treatment increased bone strength 
in both vertebra and femur in healthy rats [119], and prevented loss of bone strength 
in oestrogen-deficient rats [120]. In osteoporotic (oestrogen-deficient) rats, six weeks 
of SrR treatment produced an improved healing of bone fractures, measured by 
improved strength and stiffness of healed tibia bones [121]. However, short-term 
studies in chicken treated with SrCO3 did not show any change in breaking strength 
of long bones [122]. 
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2.13.3 Mechanism for strontium activity in bone 
The exact mechanism by which Sr affects bone tissue is unclear at present, but it 
appears that Sr can act through activation of the calcium sensing receptor (CaSR). 
The CaSR is an extracellular receptor which helps maintaining Ca homeostasis in the 
body, making several cells and tissues able to sense and respond to small changes in 
extracellular concentrations of Ca2+. The CaSR controls recruitment and survival of 
bone cells. Via the CaSR, elevations in blood Ca2+ concentrations are countered by 
increased osteoblastic activity and decreased osteoclastic activity, resulting in 
transfer of Ca from the blood to the skeleton [123, 124]. There is mounting evidence 
that Sr2+ acts as an agonist (activator) for the CaSR in bone cells [125-128]. 
However, recent studies have showed that SrR activated replication in osteoblasts 
deprived of the CaSR, indicating that another receptor mediates the effect of SrR on 
osteoblasts. 
2.13.4 Clinical trials with strontium ranelate 
In clinical trials, SrR has been shown to reduce the frequency of vertebral and 
non-vertebral (e.g. hip) fractures in women suffering from osteoporosis. In the first 
phase II trial [129], it was concluded that the minimum dose at which SrR is 
effective in preventing bone loss is 1 g per day (320 mg Sr2+ per day). In the second 
phase II trial [130], a significant and clinically relevant increase in lumbar bone 
BMD and a reduction in the number of patients experiencing vertebral deformities 
were observed after 12 and 24 months of SrR administration. A dose of 2 g day-1 was 
considered to be the best compromise between efficiency and safety. This was the 
first clinical study to demonstrate antiosteoporotic efficiency of SrR. 
Two 5-year phase III trials [131] were conducted with postmenopausal women 
suffering from osteroporosis and with a medical history of at least one prevalent 
fracture. The treatment dose in both studies was 2 g SrR per day. In the first study 
called Spinal osteoporosis therapeutic intervention (SOTI) there was a significant 
reduction in the risk of vertebral fractures with 49% after the first year, 41% after 
three years and 36% after four years compared to placebo. Lumber BMD was 
increased 14% an average after 3 years [132, 133]. The second study, Treatment of 
peripheral osteoporosis study (TROPOS), showed a reduction in the risk of non-
vertebral fractures of 16% after 3 years of treatment. In a subgroup with particularly 
high risk of fractures, a risk reduction of 36% was observed [134]. After 5 years, the 
TROPOS showed that the fracture risks in the treated group were reduced with 15% 
for nonvertebral fractures, 43% for hip fractures and 24% for vertebral fractures 
[135]. After 8 years of treatment the cumulative incidences of vertebral and non-
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vertebral fractures were not significantly different from the incidences in the first 3 
years, but lumber, femoral and hip BMD continued to increase throughout the 8-year 
period. SrR was reported to be safe and well tolerated over the 8-year treatment 
period [136].  
Taken together, the clinical studies show that SrR treatment leads to a significant 
and sustained risk of vertebral and non-vertebral fractures in women suffering from 
osteoporosis.  
2.14 Conclusion 
Strontium is widely distributed in nature, and small amounts of the element are 
usually found whenever calcium is present. The dietary uptake of Sr is much lower 
than the uptake of Ca. In the body, Sr is in competition with Ca, as the two elements 
share the same routes and mechanisms for absorption and transportation. All 
transport processes has a higher affinity for Ca, and the biological activity of Sr is 
lower than that of Ca for all Ca-activated processes. Sr is not counted as an essential 
element, but at the same time the organism is able to tolerate quite high contents of 
Sr in the diet.  
Sr has an effect on bone on both the molecular and cellular levels. It is a bone-
seeking element and 99% of the Sr in the body is found in the skeleton. The amount 
of Sr incorporated in bone following Sr administration depends mainly on dose level, 
gender, type of bone and duration of treatment. Sr is incorporated into bone by ion 
exchange, both at the crystal surface and during formation of new bone. As a 
pharmaceutical agent, Sr has been shown to have a positive effect on bone tissue by 
concomitantly stimulating bone formation and reducing bone resorption, thereby 
providing a sustained skeletal benefit. Low and moderate doses of Sr have been 
shown to increase bone volume and osteoblastic activity while reducing osteoclastic 
activity. In rats, Sr prevented osteoporotic bone loss, increased mineralised bone 
volume and improved the biomechanical properties of bone. Conversely, high doses 
of Sr cause rachitis and hypocalcaemia due to competitive inhibition of Ca uptake. 
The mechanism behind strontium’s effect on bone tissue is not fully understood, but 
it may involve activation of the calcium sensing receptor. 
Phase III clinical trials have shown that treatment with strontium ranelate 
significantly reduces the risk of vertebral and hip fractures in osteoporotic women.  
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3.1 Introduction 
Sr measurements in biological fluids have long been used for assessment of Ca 
metabolism and pharmacokinetics [137]. The interest for determination of Sr in 
calcified tissues increased with the discovery of strontium’s potential as an 
antiosteoporotic agent, and Sr isotope analysis of prehistoric bone can provide 
information about the migration patterns of ancient populations [138]. In forensic 
science, the fact that sea water contains much higher Sr concentrations than human 
blood has been used to establish sea drowning. When drowning occurs, Sr enters the 
body via the alveolocapillary membrane in the lungs, resulting in an increase of 
blood Sr [139, 140]. 
Earlier, atomic absorption spectrometry was the technique of choice for 
elemental analysis in clinical laboratories, but today, inductively coupled plasma 
atomic emission spectrometry and mass spectrometry are becoming increasingly 
popular because of their lower detection limits, wider dynamic ranges and multi-
element capabilities [141]. This chapter provides an overview of the most common – 
as well as few less common – analytical techniques for determination of Sr in 
biological matrices. Sample preparation and the applications of metrology and 
reference materials for Sr quantification are discussed, and applied techniques and 
sample preparation procedures for analysis of bone, teeth, hair, whole blood, serum, 
plasma, marrow and urine are summarised in Table 3.1, p 37. 
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3.2 FAAS 
Flame atomic absorption spectrometry (FAAS) has been used for determination 
of Sr in foodstuffs [142], teeth [143] and bone [56, 144-146]. Sr has its most 
sensitive resonance line at 460.7 nm. Air-acetylene and N2O-acetylene flames 
provide similar sensitivities and detection limits, though the latter is usually 
recommended due to better accuracy. An air-acetylene flame is subject to strong 
interferences from Al, Fe, Mg, Si, Ca, PO34-, SO42-, NaCl and various acids (H3PO4 > 
H2SO4 > HCl > HNO3), but the extent of interference is strongly dependent on flame 
stoichiometry, burner position and presence of releasing agents. Addition of 0.2-1% 
lanthanum, e.g. as LaCl3, may reduce interference, but matrix matching with respect 
to acid concentration is strongly recommended. Even in the high-temperature N2O-
acetylene flame, interference from Ca and PO34- remains a problem and a complete 
matrix-matching may be necessary [143]. Ionisation interference is observed in both 
flames; in a N2O-acetylene flame Sr is approx. 80% ionised, while approx. 10% is 
ionised in the cooler air-acetylene flame. In both cases the ionisation can be 
suppressed by adding 0.1-0.2% K+ as KCl [147-149]. Sanz-Medel et al. [150] found 
that the observed sensitivity using flame atomic emission spectrometry (FAES) was 
about four times higher than the sensitivity found using FAAS.  
3.3 ETAAS 
Electrothermal atomic absorption spectrometry (ETAAS) was used for 
quantification of Sr in bone [151], teeth [152], whole blood [145], plasma [137, 153], 
serum [151], urine [145, 151, 153], brain tissue [154] and saliva [155]. Following 
acidic sample digestion, typical analytical electrothermal protocols include drying at 
90-250°C, pyrolysis at 1200-1500°C and atomisation at 2400-2700°C. The 
atomisation efficiency is relatively low due to formation of carbides, cyanides and 
halides [148]. Halide interference can be countered by using diluted HNO3 as a 
matrix modifier [156] or by masking Sr with EDTA [157]. H2SO4, H3PO4 and HClO3 
cause interference and should be avoided in the sample preparation [148]. D’haese et 
al. [151] reported that addition of the surfactant Triton X-100® to dissolved bone 
samples improved the reproducibility, perhaps due to a more uniform sample 
deposition into the graphite furnace.  
3.4 ICP­AES 
Inductively coupled plasma atomic emission spectrometry (ICP-AES) is a very 
popular technique for determination of Sr and has been used for analysis of bone 
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[158, 159], lung [160], soft human tissues [161], urine, plasma, serum and dialysis 
fluids [162, 163]. Sanz-Medel et al. [150] compared FAAS, FAES and ICP-AES for 
determination of Sr in biological samples. The authors concluded that ICP-AES was 
the more suitable technique, owing to a better limit of detection (two orders of 
magnitude lower than N2O-acetylene FAES), a linear range spanning five orders of 
magnitude, good precision (0.3%) and virtual absence of spectral interferences. The 
presence of 200 mg L-1 Ca and P had no significant influence on the emission of 2 
mg L-1 Sr. In contrast, Shiraishi et al. [159] reported that accurate determination of Sr 
in bone (sample concentrations approx. 0.1 mg L-1 Sr) required matrix-matching of 
the standards due to significant spectral interferences, primarily from calcium and, to 
a minor extent, phosphate. 
3.5 ICP­MS 
Inductively coupled plasma mass spectrometry (ICP-MS) has been applied for 
quantification of Sr in bone and teeth [164-166], bone marrow [167] and serum [168-
170], and for measuring isotope ratios in archaeological bone [171, 172]. The 
fundamental difference between ICP-AES and ICP-MS is that the ICP is used to 
generate photons in ICP-AES as opposed to positively charged ions in ICP-MS. For 
both techniques, plasma effects of 1000-1300 W are most frequently applied. In most 
ICP-MS studies, an internal standard (IS) is added to the calibration standards and 
samples in order to correct for non-spectroscopic interferences and instrumental drift. 
89Y, 103Rh and 115In have been used with success for determination of Sr [164, 167, 
169, 170].  
Determining Sr and other trace metals in teeth and bone, Outridge et al. [165] 
reported that a hydroxyapatite matrix gave rise to significant signal suppression of 
several isotopes and that Sr determination without an IS suffered from very poor 
precision (about 40%) and poor accuracy. Roberts et al. [164] used 115In for Sr 
determination in bone but did not report any observations of interference on the Sr 
signal. Analysing serum and saline matrices, Gerotto et al. [173] found no significant 
spectral interferences affecting the Sr measurements in serum. Using cluster-analysis 
to evaluate 103Rh, 89Y and 128Te as IS, the authors concluded that 89Y provided the 
best correction for signal suppression induced by 0.5% NaCl. Prohaska et al. [138] 
used ICP-MS and laser ablation (LA) ICP-MS for measurement of 87Sr/86Sr ratios in 
prehistoric human teeth and bones. The LA-ICP-MS method was used for isotope 
measurements of transversal bone cross sections, resulting in a precision of 0.1-0.2%. 
The authors found that interference from 87Rb necessitated an effective separation of 
Rb and Sr, either by a Sr specific resin or by a mathematical correction.  
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In a recent study, De Muynck and Vanheacke [166] used ICP-MS in 
combination with a dynamic reaction/collision cell (DRC) for determination of P, Ca 
and Sr in bone. NH3 was used as a reactant gas and the flow rate was optimised 
based on the ratio between signals from the analytes and interfering ions. Addition of 
NH3 improved the signal-to-noise ratios with a factor of about 200 for 42Ca and a 
factor of 10 for 86Sr and 88Sr. The reactant gas reduces interferences via charge 
transfer between the neutral NH3 and interfering ions (e.g. Ar+, ArCa+ and Ca2+). For 
instance, a positively charged Ar+ ion formed in the plasma will react with (more 
precisely, accept an electron from) NH3, forming Ar and NH3+. P has a slightly 
higher first ionisation energy than does NH3, making it thermodynamically 
favourable to form NH3+ and P, which would be expected to remove P+ from the 
reaction cell. However, it was demonstrated that P could be determined under the 
same conditions as for Ca and Sr. 103Rh was used as IS for Sr and 51V for Ca and P. 
3.6 Other analytical techniques for determination of Sr 
Neutron activation analysis (NAA) has been used for Sr determination in bone 
[174-176], serum and packed blood cells [177, 178]. NNA is well suited for analysis 
of bone samples, as it can be performed directly on solid samples, which reduces the 
sample preparation. However, the additional production of radioactivity in the 
samples, the relatively slow sample throughput and the limited availability of reactor 
facilities constitute considerable drawbacks of the technique [179]. X-ray 
fluorescence (XRF) has been used for analysis of bone and teeth [180-183]. In the 
context of clinical analysis, the major advantage of XRF is that measurements can be 
carried out in vivo, saving the patient the discomfort and pain of undergoing a bone 
biopsy. The main disadvantage is a relatively large uncertainty [183]. Other non-
invasive methods for determination of trace elements in bone include proton induced 
X-ray emission (PIXI) [184] and dual-photon absorptiometry (DPA) [185]. 
3.7 Sample preparation 
Table 3.1 presents an overview of different sample preparation procedures for 
biological samples found in the literature. The table is not exhaustive but shows the 
variety of procedures available. Generally, for techniques requiring liquid samples, 
solid tissues such as hair, teeth, bone and soft tissues are dissolved in concentrated 
mineral acids at high temperatures. HNO3 or HNO3/HCl is often used for calcified 
tissues, though in one case HF was recommended for total digestion of a bone 
reference material [186]. To decrease preparation time, the digestion mixture is 
heated, either at atmospheric pressure by means of a hot plate or a microwave oven, 
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or at elevated pressures in an autoclave or a closed-vessel microwave oven. The high 
pressure raises the boiling point of the acids and therefore substantially increases the 
dissolution rate of the organic matrix components [187]. Some investigators 
evaporated the digests to dryness on a hot plate, followed by redissolution in diluted 
nitric acid.  
Bone samples are frequently cleaned of adhering blood, lean tissue and fat in 
order to avoid analyte contributions from these tissues. Typically, the cleaning is 
carried out mechanically with a scalpel and chemically by means of oxidants and 
solvents, e.g. hydrogen peroxide, ether, ethanol, formic acid or water. The clean 
samples are dried before weighing, in order to eliminate a mass contribution from 
water. Some investigators avoided these preparation steps by using dry ashing for 
removal of organic material and moisture. The bone and adhering tissue were ashed 
at temperatures of 450-800°C for up to 10 hours, and the inorganic bone ash was 
subsequently dissolved by acid digestion (cf. Table 3.1).  
Microwave assisted or autoclave acid digestion has also been applied for 
preparation of whole blood, urine, plasma and serum. In ICP-MS, the major reasons 
to digest liquid samples are to avoid matrix-induced signal suppression and 
deteriorated, unstable performance caused by deposition of organic material on the 
nebuliser, injector tubes and cones. Digestion reduces the content of organic material 
and total dissolved solids, thereby reducing or eliminating the tendency to clogging 
[168, 188]. A major drawback of this approach is the high acid concentration in the 
digested sample. To avoid problems with nebulisation and corrosion inside the 
instrument, the digests must be diluted with about a factor of 10 before analysis. One 
alternative is to use UV photolysis to break down organic material, thus avoiding the 
use of concentrated mineral acids. UV digestion has been used for urine, serum and 
whole blood, and has been found to be preferable to conventional acid digestion 
[189, 190].  
Several investigators have reported that satisfactory results could be obtained 
merely by diluting the liquid sample with water, dilute HNO3 and/or Triton X-100® 
[191, 192], or an alkaline solution with EDTA for stabilisation [193]. Direct sample 
dilution of course reduces the time required for sample preparation compared to any 
digestion procedure. The advantage of diluting with an acid is that preparation of 
matching standards (i.e. standards made with the same acid) is more straightforward 
and that the standard solutions prepared are more stable [194]. Indeed, in most 
studies external standard solutions were made up in diluted HNO3, but quantification 
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by standard addition [193] and matrix-matched standards have also been reported 
[166, 173]. 
3.8 Metrology  
3.8.1 Uncertainty budgets 
Few clinical studies, and indeed few studies on Sr, using spectrometric 
equipment for quantification refer to the metrological guidelines presented in the 
Guide to the expression of uncertainty in measurement (GUM) [195] or the 
Eurachem/CITAC guide Quantifying Uncertainty in Analytical Measurement 
(QUAM) [196]. The evaluation of analytical performance is almost invariably given 
as reproducibility/repeatability rather than a metrological uncertainty. We applied 
and discussed the concepts of GUM and QUAM in the 4-week dog study presented 
in Appendix II. One of the few other examples was published by Prohaska et al. who 
determined Sr isotope ratios in archaeological bones [138]. The authors stated that all 
uncertainty calculations were performed according to the Eurachem guidelines and 
explicitly declared that no outlier rejection was performed on the data. Bettinelli et 
al. [197] and Breda et al. [198] included measurement uncertainty in the validation 
of ICP-MS methods for determination of Pt in plasma, serum and urine. Bettinelli et 
al. found an instrumental limit of detection (LOD) of 2 ng L-1, while the minimum 
quantifiable concentration in urine based on the calibration uncertainty was set to be 
three orders of magnitude higher at 2 µg L-1.  
Patriarca et al. [199] presented a worked example of an uncertainty budget for 
determination of Pb in blood using ETAAS. Combining contributions from 
calibration, repeatability and sampling, the authors arrived at a concentration-
dependent combined uncertainty of up to 10%. The paper gave rise to some 
correspondence [200, 201] and an erratum [202] concerning the inclusion of bias 
data into the uncertainty calculations. As noted by Taylor et al. [203], the dispute as 
well as the low number of reported applications illustrate that more than a decade 
after the publication of the first edition of the Eurachem guide, the practical 
preparation and application of uncertainty budgets are far from well established for 
clinical analysis.  
3.8.2 Reference materials 
Reference material (RM) is a generic term for materials that can be used for 
calibration, validation and quality control of analytical methods. In particular the 
accuracy of an analytical procedure is generally demonstrated by the quantification 
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of relevant analytes in a reference material with a matrix and analyte concentrations 
matching those of the samples. The term certified reference material (CRM) is 
reserved for materials for which an unbroken chain of traceability has been 
established, and for which certified values are expressed with accompanying 
uncertainties at a stated confidence level.  Many CRMs are produced by national 
metrological laboratories, following guidelines established by ISO. Major suppliers 
of commercial reference materials include IRMM (Belgium), LGC (United 
Kingdom), Biorad (CA, United States), NIST (MD, United States) and Sero 
(Norway). The United States National Institute for Standards and Technology (NIST) 
has registered the trademark SRM® (Standard Reference Material) for its CRMs, 
while the European Institute for Reference Materials and Measurements (IRMM) 
uses the trademark ERM® (European Reference Material) for CRMs produced in 
partnership with European organisations [141].  
3.8.3 Applied reference materials in this project 
During this project, three different reference materials were applied: NIST 1400 
Bone Ash, NIST 1486 Bone Meal and Sero Seronorm Trace Elements Serum. The 
SRMs obtained from NIST were regarded as very suitable for the project, as they 
provided certified values for all the elements of interest (Sr, Ca, Mg and P) in 
matrices matching real samples. It was assumed that bone and dentine are so 
comparatively close in composition that a bone CRM could be used for validation of 
analysis of teeth as well.  
In contrast, serum CRMs containing all the relevant analytes were not 
commercially available. In fluid reference materials such as blood, urine and serum, 
usually only a few elements are certified (e.g. Ca, Mg and Li in IRMM’s BCR-304). 
Three of the most widely used reference materials, Sero’s Seronorm Trace Elements 
Whole Blood, Serum and Urine, provide concentrations of more than 70 elements, 
but none of these values are certified. The conventional procedure for establishing 
certified analyte concentrations is to allow several laboratories to analyse the 
material, using different techniques, in order to obtain reliable consensus values. 
Conversely, most of the analytes in the Sero materials have been determined by a 
single laboratory only. In the documents accompanying the sample vials, the 
manufacturer states element concentrations as “analytical data”, but the 
concentration of each analyte is listed by the analytical technique that was applied, 
resulting in up to three different reference concentrations for each element. 
Following the example set by Krachler et al. [191] the values provided by Sero are 
therefore referred to as “reported” rather than “certified” in this report.   
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3.9 Choice of technique 
Three of the described techniques, FAAS, ETAAS and ICP-MS were available 
for this project. The primary aim was to quantify trace-level concentrations of Sr in 
bone, teeth and body fluids, and the secondary aim was to determine the 
macronutrients Mg, Ca and P, which are found in much higher concentrations 
(medium – high mg g-1 and mg L-1). Keeping in mind that biological Sr 
concentrations are of the orders of 10-100 µg L-1for serum and 50-200 µg g-1 for 
bone, it is clear from Table 3.1 that of the available techniques, only ETAAS and 
ICP-MS provide adequate limits of detection. FAAS has LODs in the low-medium 
µg L-1 range [204], whereas, with ETAAS, LODs are typically below 1 µg L-1, 
corresponding to the low-medium ng g-1 range in solid tissues. ICP-MS provides the 
lowest LODs, with values ranging from about 1 µg L-1 to below 10 ng L-1, 
corresponding to values below 1 ng g-1 in solids. Though Ca and Mg do exist in 
concentrations high enough to be measured by FAAS, these elements suffer from 
phosphate interferences [149]. Even though ETAAS provides an adequate LOD for 
Sr quantification, the technique has the major drawback of only being able to 
determine one element per analysis. Thus, as the large number of samples made 
analysis time an important factor, ICP-MS was chosen primarily for its multi-
element capability and wide dynamic range. 
It is worth noting here that the LODs given in Table 3.1 are not necessarily 
directly comparable, as the methods, by which they were obtained, are not explained 
in all cases. LODs are customarily given as three times the standard deviation (3) of 
a series of blank measurements, but whether this blank was made from ultrapure 
water, a diluted acid, a digested blank sample or a matrix matched blank is often not 
stated. LODs given on a mass basis (e.g. g µg-1) for solids may either be based on 3 
of a sample with a very low analyte concentration compared with the LOD, or on 3 
of a blank, whilst taking into account the maximum amount of solid sample that can 
be conveniently weighed and transferred to the digestion vessel.  
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CHAPTER FOUR 
Introduction to experimental 
techniques: ICP­MS, DEXA and 
biomechanical testing 
4.1 Introduction 
This chapter gives an introduction to three of the analytical techniques that have 
been used during this study: inductively coupled mass spectrometry (ICP-MS), dual 
energy X-ray absorptiometry (DEXA), and mechanical testing. The ICP-MS 
apparatus was available at our laboratory, whereas the DEXA scanner and the 
mechanical testing machine was located at the Department of Endocrinology at 
Hvidovre Hospital and kindly put at our disposal by Dr. Jens-Erik B. Jensen.  
4.2 Inductively coupled mass spectrometry 
Since the first paper on ICP-MS was published by Houk et al. in 1980 [208], the 
technique has been applied for elemental and isotopic analysis at the trace and ultra-
trace level in a variety of fields such as chemistry, geology, pharmacology as well as 
the clinical, forensic, nuclear, environmental and food sciences. The number of 
papers published each year on ICP-MS continues to grow, and the amount of 
available literature still merits regular publications of review papers, summarising 
recent fundamental studies, method developments and applications [192, 209-213]. 
In this project, ICP-MS was used for determination of Sr and other key bone 
elements in bone, teeth, bone marrow and serum. This section aims at giving a reader 
unfamiliar with the technique some background knowledge of the instrumental 
components and parameters. Emphasis is put on matters with a direct relevance for 
the following chapters. Further information can be obtained from the literature 
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updates mentioned above or some of the several comprehensive reviews that have 
been published on the technique, including introductory tutorials [204, 214-216] and 
extensive treatises on the fundamentals, applications and theory [217-219]. 
The basic instrumental design of the applied ELAN 6000 ICP-MS is shown in 
Figure 4.1. Briefly explained, an aqueous sample is pumped into a nebuliser, where it 
is converted to an aerosol and transported to the argon plasma. The plasma is 
generated by ionised argon coupled to a radio-frequency (RF) electromagnetic field, 
and it is used to atomise and ionise the sample components. Via the interface and the 
ion optics, the ions are then directed into the quadrupole mass filter, which separates 
the ions of interest from the ion beam and allow them to reach the detector.  
Figure 4.1 Basic instrumental components of an ELAN 6000 ICP-MS. See text for details. 
4.2.1 Sample introduction 
The main function of the sample introduction system is to convert the liquid 
sample into an aerosol. In the current project, two types of pneumatic nebulisers were 
applied: cross-flow and concentric microflow (Figure 4.2). Both designs use the 
mechanical forces of a gas flow to break up the liquid sample into a fine mist of 
droplets. In the cross-flow design, the argon gas is directed perpendicularly to the 
sample flow, while, in the concentric nebuliser, the gas is running in parallel to the 
sample capillary. Generally, the concentric design is more stable and produces an 
aerosol with smaller droplets than the cross-flow design. As the name suggests, the 
microflow nebuliser is able to handle very low sample flow rates. A useable aerosol 
can be produced at sample flows down to 20 µL min-1, where a cross-flow type of 
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nebuliser typically requires a flow in the range of 0.4-1.0 mL min-1. The main 
disadvantage of the microflow nebuliser is that it is more prone to clogging because 
of the narrower liquid capillary and shorter distance between liquid and gas injectors. 
The cross-flow nebuliser requires a peristaltic pump to propel the sample, whereas 
the concentric nebuliser is self-aspirating, relying on the fast flow of argon gas to 
suck up the sample (the venturi effect).  
 
 
   
Figure 4.2 Schematics of a cross-flow nebuliser (left) and a concentric nebuliser (right). 
The ICP is not very efficient at dissociating large droplets and therefore the 
aerosol cannot be injected directly into the plasma. Instead, the aerosol is introduced 
into a spray chamber, which has two purposes: 1) to smooth out pulses from the 
peristaltic pump, if one is used, and 2) to only allow the smaller droplets (< 10 µm) 
to pass through. In this work, the two most common types of spray chambers were 
applied: a Scott double-pass and a cyclonic spray chamber (Figure 4.3).  
 
 
Figure 4.3 A double-pass spray chamber with a cross-flow nebuliser (left) and a cyclonic spray 
chamber with a concentric nebuliser (right).  
Designed with two concentric tubes, the double-pass spray chamber discriminates the 
droplets by directing the spray into the central tube, where the larger droplets 
impinge on the inner wall and exit by gravity through a drain tube. The smaller 
droplets are forced back to the outer tube and on to the sample injector. In the 
Argon  
Liquid sample flow Liquid sample flow 
Argon  
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cyclonic spray chamber, the sample aerosol is introduced tangentially into the 
circular chamber, causing the larger droplets to collide with the wall and fall out the 
drain, while the smaller droplets are carried with the gas into the plasma. Cyclonic 
spray chambers are generally considered more efficient at separating the smaller 
droplets, while double-pass chambers are regarded as being more rugged for routine 
analysis [204, 219]. 
4.2.2 The plasma  
The plasma torch consists of three concentric tubes, respectively carrying the 
plasma gas (15 L min-1), auxiliary gas (0.8 L min-1) and nebuliser gas (0.9-1.2 L 
min-1) together with the sample aerosol. The torch is surrounded by a copper load 
coil connected to a radio frequency (RF) generator (Figure 4.4), which is used to 
create an intense electromagnetic field at the top end of the torch. The plasma is 
formed by the plasma gas, which flows tangentially into the torch through the 
outermost tube. The middle tube carries an auxiliary gas, which pushes the plasma 
away from the sample injector to prevent it from melting. The plasma is ignited by 
generating a high-voltage spark, which produces free electrons in the argon gas. The 
electrons are accelerated by the RF field at a power of 700-1600 W, causing 
collisions and further ionisation of the argon gas, sustaining the plasma at a 
temperature of 6.000-10.000 K. The sample injector introduces the sample aerosol 
into the plasma, where it is dried, vaporised, atomised and ionised as it passes 
through to the interface [204].  
Beside the singly charged M+ ions that are used for quantification of the sample 
components, many other ion species are formed in the plasma. Oxides of atomic ions 
are the most significant, but, depending on the plasma/nebuliser gas and the matrix 
components, also argides, nitrides, chlorides, hydrides and sulphides can be produced 
[220]. Additionally, elements with low second ionisation potentials, such as Ba and 
Sr, may form significant levels of doubly charged atomic ions, M2+. Oxides form 
mainly due to the presence of water in the sample aerosol and oxygen in the ambient 
air and will therefore be produced regardless of the nature of the sample. They are a 
result of incomplete oxide dissociation in the plasma and recombination in the 
plasma-vacuum interface. Interferences caused by oxides are typically found at 16, 
36 and 48 amu above the parent ion, corresponding to MO+, MO2
+ or MO3
+ [221].  
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Figure 4.4 Photograph of a plasma torch, RF coil and sample injector mounted in an ICP-MS 
instrument. The sample aerosol is introduced into the plasma through the sample injector.  
In one of the early, fundamental studies on operational ICP variables and signal 
optimisation, Horlick et al. [222] indentified RF power and nebuliser gas flow as key 
parameters, while Vaughan et al. [223] also found the sampling depth – the position 
of the RF coil and torch relative to the tip of the sampling cone (see section 4.2.3) – 
to play a significant role. The three parameters interact extensively, which means that 
any one sampling depth and RF power setting has a corresponding optimum 
nebuliser gas flow. If the RF power is changed, the gas flow must also be altered in 
order to achieve maximum signal.  
 
Figure 4.5 Effect on levels of oxides and doubly charged ions when changing RF power and 
nebuliser gas flow. 
Generally, a high RF power causes a high degree of oxide dissociation, resulting 
in low levels of oxide species. The high plasma temperature, however, also causes an 
increase in formation of doubly charged ions. Conversely, if the flow of argon 
through the nebuliser is increased, the plasma gets relatively cooler, causing the level 
of oxides to increase, while the level of doubly charged ions decreases (Figure 4.5) 
[224]. However, opposite trends have also been observed [225], emphasising that the 
exact effects of the RF power and gas flow on ion intensities depend on the particular 
Sample injector 
Plasma gas 
Outer tube 
RF coil
Auxiliary gas 
Middle tube 
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instrument, sample matrix and analyte. In any case, optimising the ICP parameters is 
a matter of finding the best compromise between these three effects. 
4.2.3 Interface and ion optics 
The role of the interface region is to bring the ions from atmospheric pressure in 
the plasma to the high vacuum (< 0.01 Pa) in the mass spectrometer. The interface 
consists of two metallic (nickel or platinum) cones kept at 200-400 Pa. From the 
plasma, the ions pass into the first cone, called the sampler cone, which has an orifice 
of 0.8-1.2 mm i.d. After the sampler cone, the ions travel a short distance and pass 
through the second cone, called the skimmer cone, which is pointier than the sampler 
cone and has a smaller orifice of 0.4-0.8 mm i.d. When they emerge from the 
skimmer cone, the ions are directed towards the mass spectrometer by an 
electrostatically controlled cylinder lens, called the ion optics. To reduce background 
noise and keep the mass spectrometer clean, non-ionic species, such as photons, 
particulates and neutral sample components, are prevented to reach the detector by a 
stop disk placed behind the skimmer cone [204]. The applied lens voltage can be 
adjusted and optimised, primarily depending on the mass of the desired analyte, but 
also on the condition of the lens. During operation, neutral sample components may 
slowly collect on the lens, reducing its ability to deflect the ion beam [214].  
4.2.4 Quadrupole mass filter 
The mass filter is the heart of the ICP-MS system. It separates the ions arriving 
from the ion optics according to their mass/charge (m/z) ratio. A photograph of a 
quadrupole system from an ELAN 5000 ICP-MS is shown in Figure 4.6. The 
quadrupole consists of four metal rods on which can be placed both a direct current 
(DC) field and an alternating current of radio frequency. By appropriate selection of 
the RF/DC-ratio, ions with a specific m/z ratio can be steered through the middle of 
the rods and on to the detector, while ions with different m/z ratios will pass through 
the spaces between the rods and be ejected from the quadrupole.  
The mass discrimination can basically be conducted in two different ways, 
depending on the objective of the analysis. One approach is performing a continuous 
scan across the mass range of interest, a method well suited for obtaining peak shape 
information and complete mass spectrums. Figure 4.7 presents an example of a mass 
spectrum of dissolved dog bone.  
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Figure 4.6 Photograph of the quadrupole system of a Perkin-Elmer ELAN 5000 ICP-MS showing the 
ion lenses, the rods of the quadrupole mass filter and the dynode detector. 
 
Figure 4.7 Section of a mass spectrum of dissolved dog bone, showing mass/charge (m/z) peaks of 
the four stable strontium isotopes.  
The other approach is peak hopping, where the quadrupole is driven to discrete 
RF/DC-settings matching the m/z values of the analytes. At each mass peak, the 
electronics are allowed to settle and dwell for a certain period of time while the 
measurements are recorded (Figure 4.8). This approach has been used exclusively 
throughout this work, as it results in lower detection limits and faster analysis times.  
Outlet to mechanical roughing pump 
Ion optics 
Quadrupole mass filter 
Detector 
Outlets to turbo pumps  
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Figure 4.8 Illustration of the measurement protocol for the quadrupole in peak-hopping mode. 
Modified from reference [204]. 
While the scan and settling times depend on the instrument, the dwell time can 
be chosen for each mass as a compromise between precision and sensitivity on the 
one side and sample frequency on the other. A longer dwell time increases the total 
amount of ions registered by the detector, which improves the sensitivity and 
reliability at the expense of increased analysis time and higher sample consumption. 
4.2.5 Detection 
The ELAN 6000 ICP-MS is equipped with a dual stage dynode electron 
multiplier with 22 discrete dynodes (partly visible in Figure 4.6). The detector is 
placed off-axis to the quadrupole in order to minimise noise from stray radiation and 
neutral species. When the ions emerge from the quadrupole they are attracted to the 
first, negatively charged dynode, causing secondary electrons to be liberated. These 
electrons are accelerated to the second dynode where they generate more free 
electrons. This process is repeated at each dynode, until the final pulse of electrons is 
captured at the multiplier collector (anode) and registered by a counting circuitry 
[204]. The total gain of the electron multiplier can be defined as the average number 
of electrons arriving at the collector for each incoming ion [218]. 
In the samples analysed in this work, Sr was found in concentrations varying 
from the low µg L-1 range to more than 10 mg L-1, and macronutrients such as Mg 
and Ca exist in even higher concentrations (10-100 mg L-1). This difference of more 
than four orders of magnitude either requires several dilutions of each sample in 
order to bring each analyte to an appropriate concentration, or, more conveniently, a 
correspondingly wide dynamic range of the analytical method. With the dynode 
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detector, an extended dynamic range can be achieved by taking advantage of the 
detector’s ability to provide two types of signals simultaneously [214, 218, 226]: 
1) Conventional pulse signal suitable for detection of ion counts at ultra trace to 
trace concentrations. The gain is typically in the range of 106-108. A 
protection circuit cuts off pulse responses above 2·106 counts per second 
(cps). 
2) Analogue current signal for determination of higher concentrations with 
responses in the range of 105-109cps. The analogue signal is measured at the 
midpoint dynode and the sensitivity is much lower than that of the pulse 
mode. The gain can be defined as the ratio between the output and the input 
ion current, and it is in the range of 104-106. The detector is completely cut 
off at signals exceeding 2·109 cps. 
In the response range where the two stages overlap, the output current of the 
analogue detector stage can be normalised to the response of the pulse stage, 
providing a conversion factor that can be used to express all responses as pulse 
counts pr. second (Figure 4.9). In theory, this cross-calibration produces a linear 
response with a constant slope throughout both response regions. However, evidence 
for a significant nonlinearity between the two stages has been reported [227, 228]. 
 
 
Figure 4.9 Cross calibration of the two detector stages by measuring concentrations that give both a 
pulse count and an analogue response. The resulting conversion factor is used to express all signals as 
ion counts pr. second.  
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When operating in dual-detector mode, ion intensities exceeding 2·106 cps are 
processed through the analogue circuitry at the midpoint dynode. Signals with fewer 
ions are amplified through all 22 dynodes and measured as a pulse signal.  
4.3 Dual energy X­ray absorptiometry 
DEXA scanners were introduced in 1987, and since then DEXA has become the 
method of choice for non-invasive evaluation of bone mineral status in clinical 
practise [90]. It is recommended by several guidelines for diagnosing 
postmenopausal osteoporosis [229-231], and, as described in Chapter 2, BMD T-
scores obtained from DEXA scans of spine, femur and hip are recommended by 
WHO to classify normal, osteopenic and osteoporotic bone. 
4.3.1 Principle of operation 
As the name suggests, DEXA scanners evaluate BMD by measuring the 
transmission of two X-ray beams with different, known photon energies through the 
subject of interest. Across a broad range of photon energies, the X-ray transmission 
can be decomposed into the equivalent areal densities of any two reference materials. 
In the case of bone densitometry, the two materials are bone mineral 
(hydroxyapatite) and soft tissue, as the analysed bone will normally be surrounded by 
tissues such as skin, fat, muscles, tendons and bone marrow. The decomposition is 
limited to two materials because there are only two types of attenuation processes 
involved: Compton scattering and the photoelectric effect. The magnitude of these 
processes depend on photon energy and atomic mass, and because the Ca and P 
atoms in bone have higher masses (40 and 31) than the C, N and O atoms (masses 
12, 14 and 16) in the soft tissue, DEXA can be used to distinguish between bone and 
soft tissue [90]. By using the mass attenuation coefficients for bone and soft tissue at 
the given photon energies, the attenuated intensities can be written as [232, 233] 
 ܫ ൌ ܫ଴exp൫െߤ௦௢௙௧݉௦௢௙௧ െ ߤ௕௢௡௘݉௕௢௡௘൯ (4-1) 
 ܫԢ ൌ ܫԢ଴exp ൫െߤԢ௦௢௙௧݉௦௢௙௧ െ ߤԢ௕௢௡௘݉௕௢௡௘൯ (4-2) 
where I and I0 are the unattenuated and attenuated photon intensities, µ [cm2 g-1] the 
mass attenuation coefficients and m the masses of the two types of tissue [g cm-2].  ᇱ 
denotes the same quantities at the second photon energy. The intensities and 
attenuation coefficients can be measured directly, leaving only msoft and mbone, which 
can be determined by solving the above equations. As each data point represents a 
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fixed area, a scan is processed by using the attenuation measurements to create a 
pixel-by-pixel map of BMD over the entire scanned region. The reported BMD value 
of the region is calculated as the mean BMD over all the pixels identified as bone. 
The total projected bone area is determined by first using a detection algorithm to 
find the bone edges and then summing the pixels within the edges [233]. The bone 
mineral content (BMC) in grams is found by multiplying the mean BMD by the 
projected bone area: 
 ܤܯܥ ൌ ܤܯܦ · ܣݎ݁ܽ (4-3) 
Examples of DEXA scan images are shown in Chapter 8. 
4.3.2 Calibration and quality control 
A DEXA scanner performs self-calibration at start-up. In addition, it is necessary 
to carry out an independent quality control in order to monitor instrumental drift. 
This is usually done by a daily scan of a so-called phantom, typically a known 
amount of mineral shaped as vertebrae, imbedded in a plastic material with an X-ray 
transmittance matching that of soft tissue. This does not only provide a daily check 
of the self-calibration, but, by recording a large number of phantom scans, it also 
allows for monitoring the long-term performance of the instrument [233, 234].  
4.3.3 Precision and accuracy 
The precision of a given DEXA scanner affects the ability to monitor a patient’s 
response to treatment, while the accuracy affects the diagnosis of osteoporosis 
through the calculated T-score [235]. Usually, the precision of the DEXA 
measurement itself is approximately 1.5%. A poorer precision may be observed if the 
subject is placed incorrectly or is moving slightly during the scan. A precision of 
<2% for the spine and <4% for the hip is accepted in clinical practise. Bearing in 
mind that the expected age-related bone loss is about 1% per year, and the effect of 
anti-resorptive treatment is 1-3% per year, it is clear that, for the purpose of 
monitoring bone status, there is no point in repeating scans with less than 2-3 year 
intervals [234]. 
The accuracy of DEXA is challenged primarily by two issues. Firstly, the 
obtained scan is a 2 dimensional projection image of a 3 dimensional subject, leading 
to a result expressed as an areal density (g cm-2) rather than a volumetric density (g 
cm-3). In other words, BMD is a measure of the average thickness of bone tissue 
measured along the direction of the X-ray flux [236]. Because of the missing depth 
value in the calculation of the mineral density, the resulting BMD value is affected 
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by bone size as well as the true 3D volumetric density and orientation of the bone 
tissue.  
The second issue is the two-component limitation. As can be seen from 
Equations (4-3) and (4-2) above, accurate density determinations depend on correct 
estimates of the attenuation coefficients of the two reference materials, µsoft and µbone. 
Soft tissue, however, is not a well-defined homogeneous material. For the purpose of 
X-ray transmission, soft tissue consists of at least two types of tissue: lean muscle 
tissue and fat. Fat is largely composed of methylene units, (CH2)n, while lean tissue 
attenuates X-rays similarly to water (H2O).  The difference of the X-ray attenuation 
of the two types of tissue is therefore equivalent to the mass difference between C 
and O. Since adipose tissue is heterogeneously distributed in the body, the 
composition of the soft tissue overlaying a given bone may not be known exactly, 
and this introduces a potential error in the BMD estimate. Adding further to the soft 
tissue complexity, the marrow inside the bone is a mixture of red and yellow 
marrow, each with different attenuation coefficients. Thus, soft tissues may be 
constituted of three or four absorptiometrically different components, all influencing 
the magnitude of the X-ray attenuation. In clinical practise, this effect means that the 
result of e.g. a spine scan may suffer from significant error because of the large 
thickness of soft tissue in the abdomen [90, 236].  
The composition of extraosseous soft tissue can be estimated by measuring the 
attenuation of the beams at sample sites that do not contain any significant bone 
tissue [237]. Tissue regions that are adjacent to bone provide a reference area of 
comparable thickness and composition, from which a line-by-line correction is 
applied to the bone region BMD [233]. A DEXA scan will therefore not only provide 
information about the bone mass but also an estimate of the soft tissue composition 
of the region of interest [238]. Still, the only reliable way of quantifying the soft-
tissue error is through cadaver studies, which often suffer from large statistical error 
due to a small number of subjects. Such studies have shown that the patient-to-
patient accuracy is 5-7% [90, 235]. However, Bolotin et al. [236, 239] reported 
errors in accuracy exceeding 20% in a study where various phantoms and cadaveric 
lumber vertebra were analysed. These observations caused the authors to question 
the reliability of DEXA as a means for patient-specific inferences concerning 
osteoporotic/ostepenic categorisation and predictions of fracture risks, and to call for 
prudence and circumspection in assessments of treatment effects of particular drugs, 
diets or exercise therapies.  
Finally, it is important to note that scanners from different manufacturers 
(Norland, Lunar, Hologic) have different reference values, leading to significantly 
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different BMD results. BMD values obtained on Hologic scanners are 10% lower on 
average than values obtained from Norland and Lunar scanners. Hence, a reliable 
monitoring of a patient’s BMD requires that the same instrument be used for all 
examinations. When an old instrument is replaced with a new, a thorough cross-
calibration between the two instruments is required in order to make past and future 
results comparable [234].  
4.3.4 Correction for bone Sr content 
BMD measurements of patients and animals treated with Sr presents another 
accuracy problem. In the calculations of the bone mass, the instrument assumes that 
the bone mineral consists of regular hydroxyapatite. Presence of any element with a 
mass higher than that of Ca in the bone mineral will interfere with the mass 
determination, because it significantly alters the attenuation coefficient of the bone. 
Because of its higher mass, Sr attenuates X-rays more than does Ca, and presence of 
Sr in more than trace concentrations will therefore lead to an overestimation of BMD 
and BMC. Testing several DEXA scanners from different manufactures, Nielsen et 
al. [240] found an average of 10% overestimation of BMD for 1 mol/mol% Sr. In a 
recent study, Liao et al. [241] found that the overestimation was different for 
scanners from different manufacturers. Consequently, interpretation of DEXA 
measurements in patients treated with strontium ranelate should therefore be 
exercised with great care [242, 243]. The Danish Institute for Rational 
Pharmacotherapy recommends that the increase in BMD (in %) after initiation of 
strontium ranelate treatment be divided by two as a rule of thumb [95].  
4.4 Mechanical testing 
Biomechanical testing of bones provides information about the mechanical 
integrity of the bone structure [244]. The biomechanical testing of the bone samples 
was conducted using a material testing machine (Figure 4.10). Bending tests were 
used for dog femur, and compression tests were used for vertebra biopsies. The load 
was applied by a twin-mounted crosshead, travelling between two columns. The 
applied force was measured by an exchangeable load cell and the displacement was 
measured as the distance travelled by the crosshead.  
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Figure 4.10 Photographs of the material testing machine used for mechanical strength measurements 
of bone. The picture on the right hand side shows compression testing of a dog vertebra biopsy. The 
load is measured by the black, square load-cell.
 
 
Figure 4.11 Load-displacement bending curve. The biomechanical properties of the bone were 
described by the load at failure (N), deformation at failure (mm), energy to failure (J) and stiffness (N 
mm-1). Figure redrawn from [245]. 
Data was collected on-line at a sampling rate of 50 Hz, resulting in a load-
displacement curve (Figure 4.11). From this curve the following biomechanical 
values could be calculated [244, 245]: 
- the maximum load (load at fracture; breaking force) 
- the deformation at osteoid collapse (displacement at fracture), representing 
reciprocal brittleness 
- the energy absorption at fracture (area under the curve in N mm or J) 
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- the maximum stiffness (slope of the linear part of the load-displacement 
curve in N mm-1), representing the elastic deformation. 
Experimental details and a recorded load-displacement curve from a three-point 
bending test of a dog femur are presented in Chapter 8. 
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CHAPTER FIVE 
Method development for determination 
of Sr, Mg, P and Ca in serum 
 
5.1 Introduction 
This chapter focuses on optimisation and validation of a procedure for 
determination of Sr and other key bone elements (Mg, P and Ca) in serum using ICP-
MS. Serum samples were obtained from two animal studies, investigating 
strontium’s influence on bone properties. The aim of the first study was to 
investigate the effect of strontium on healed bone fractures in normal rats after 3 and 
8 weeks of healing, while the second study examined the effect of strontium and 
parathyroid hormone (PTH) on immobilised-induced bone loss. At the end of both 
studies, blood samples were obtained in order to monitor the effect of the treatment 
on the concentration of Sr in serum. The administration of strontium and the 
mechanical and morphological investigations were carried out by Dr. Annemarie 
Brüel and co-workers at Aarhus University [8]. 
5.2 Experimental  
5.2.1 Animals and treatment 
The experiments were performed in compliance with the guiding principles in 
the “Care and Use of Laboratory Animals”, and they were approved by the Danish 
Animal Experiments Inspectorate. The measurements were blinded so that no 
information about dose and group distributions was given to our laboratory until the 
results of the analysis were reported back to the study coordinator.  
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5.2.1.1 Strontium’s effect on fracture healing 
The experiment is described in detail in reference [8]. Briefly, 84 female Wistar 
rats (Taconic, Lille Skensved, Denmark), 12 weeks old, were divided into four 
groups in such a manner that group means and standard deviations of body weight 
were matched as closely as possible. The animals were anaesthetised, and a closed 
fracture was produced at the right tibia by three-point bending. Groups 1 and 2 were 
allowed three weeks of healing, while groups 3 and 4 were allowed eight weeks of 
healing. Strontium ranelate (SrR) was administered to groups 2 and 4 in doses of 900 
mg/kg/day (288 mg/kg/day Sr2+) by mixing SrR with the rat feed. At the end of the 
study blood samples were obtained, serum was isolated and stored at -80°C and later 
at -18°C for subsequent analysis.  
5.2.1.2 Effect of strontium and PTH on bone loss 
72 female Wistar rats, 12 weeks old, were divided into six groups (no treatment, 
vehicle only, Botox, Botox + PTH, Botox + Sr + PTH, Botox + Sr) and treated for 
four weeks. As above, the Sr dose was 900 mg/kg/day and blood samples were 
extracted at the end of the study, except for the animals in the untreated group, which 
were killed at the start of the study. 
5.2.2 Equipment and reagents for ICP­MS analysis 
All glassware was cleaned overnight in 5% alkaline detergent (Extran MA 01, 
Merck), rinsed with ultra-pure water (18.2 M·cm, Millipore), soaked in 10% (v/v) 
nitric acid (puriss p.a., Sigma-Aldrich) for 24 hours and again rinsed thoroughly with 
ultra-pure water. The measurements were performed using a Perkin-Elmer ELAN 
6000 ICP-MS equipped with an ESI Apex Q (Elemental Scientific) sample inlet 
system. Instrument handling and data collection were performed using the software 
supplied with the instrument (ELAN v. 3.3 Patch 6), while the data processing for 
calibration and analysis was carried out by exporting the raw data to external 
software (Microsoft Excel®, Origin® and Minitab®). The applied settings of the ICP-
MS and the Apex system are given in Table 5.1. At the beginning of each working 
day, before conducting measurements, the ICP-MS and the Apex were allowed to 
stabilise for 30 min, and the analytical performance was checked using a standard 
solution containing 10 µg L-1 Be, Mg, Ca, Rh, In, Ba, Ce and Pb.  
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Table 5.1 Settings on the ELAN 6000 ICP-MS and apex sample inlet system 
after full optimisation. 
RF power 1000 W 
Nebuliser argon flow 1.13 L min-1 
Secondary argon flow 0-50 mL min-1 
Sample flow 260 µL min-1 
Working pressure 1.8·10-3 Pa 
Background pressure 2.4·10-4 Pa 
Torch box temperature 40-43°C 
Lens voltage 10.2 V 
Detector mode Dual 
Pulse detector voltage 1500 V 
Analogue detector voltage -2587.5 V 
Sweeps pr. reading 15 
Scan mode Peak hopping 
Readings pr. replicate 1 
No. of replicates 5 
Dwell time pr. mass 100 ms 
Measured isotopes  24Mg, 25Mg, 26Mg 
31P 
42Ca, 43Ca 
84Sr, 86Sr, 87Sr, 88Sr 
103Rh (internal standard) 
 
5.2.2.1 Apex sample inlet system 
Due to the low natural concentration of strontium in serum, the analyses required 
a lower limit of detection than could be obtained using a standard cross-flow 
nebuliser. Furthermore, only a limited amount of serum (down to 150 µL for some 
animals) was available, resulting in a final sample volume after dilution of less than 2 
mL, which would be insufficient for a reliable analysis using a cross-flow nebuliser. 
The combined problem of a low analyte concentration and a small sample volume 
was accommodated by applying the more advanced ESI Apex Q sample inlet system. 
By means of a concentric perfluoroalkoxy nebuliser (ES-2040 PFA-ST), the sample 
is self-aspirated, converted into an aerosol and transported to a quartz cyclonic spray-
chamber heated to 140°C. For sample flow rates of 20-700 µL min-1, the flow is 
controlled by the inner diameter of the sample tube; higher flow rates can be 
obtained with the aid of a peristaltic pump. From the spray-chamber, the aerosol is 
led through a first condenser loop cooled by air at room temperature to a second 
Peltier-cooled condenser kept at 2°C (Figure 5.1). At the second condenser, N2 can 
be added to the sample aerosol, and additional Ar can be added at the end of the 
condenser before the aerosol is led to the plasma.  
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Figure 5.1 Photograph of the apex sample inlet system connected to the ELAN 6000 ICP-MS (a) and 
a schematic of the spray-chamber (SC) and condensers (b). 
5.2.2.2 Standards 
Standards were prepared in 0.1 M NHO3 (Merck, Suprapur) by dilution of a 
multi-element stock standard solution (PlasmaCAL, SCP Science). A total of 17 
standards were used, with concentrations ranging from 0.5 µg L-1 to 10 mg L-1. An 
internal standard of 5 µg L-1 Rh (Fluka) was added to all standards and samples. 
5.2.2.3 Sample pre­treatment 
Nitrile gloves were worn at all times when handling undigested samples 
containing biological tissue. By the end of each day, work bench and tools were 
cleaned thoroughly with ethanol and water. After thawing at room temperature, 100-
200 µL serum from each animal was transferred to a quartz tube, IS was added and 
the samples were diluted 1+11.5 with 0.1 M HNO3 (Suprapur, Merck).  
5.2.2.4 Quality control 
The accuracy of the analytical procedure was assessed by repeatedly analysing a 
serum reference material (Seronorm Trace Elements Serum, Level 2, SERO AS). 
The lyophilised serum was reconstituted with 3.00 mL ultra-pure water according to 
the manufacturer’s instructions. 30 min after the reconstitution, sample aliquots of 
200 µL were transferred to a quartz tube and prepared as described above. 
5.3 Results and discussion 
5.3.1 Instrument optimisation 
Before measuring the serum samples, a number of instrumental parameters were 
optimised with the aid of built-in procedures in the instrument software [214]. The 
optimisation included: RF power, nebuliser gas flow, lens voltage, the quadrupole 
mass filter and the detector voltage. Previous studies have used different criteria for 
(a) (b)
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ICP-MS optimisation: best relative precision [246], highest sensitivity [224, 247, 
248] and minimum matrix-induced interference [249-251]. The plasma conditions in 
particular can be adjusted with one of two objectives in mind: maximum sensitivity 
or good robustness. The term “robust conditions” in ICP context was introduced by 
Mermet and co-workers [252-254] for ICP-atomic emission spectroscopy and refers 
to the capability of the plasma to handle changes in matrix composition (acid 
concentration, interferents, etc.) without producing a change in the analytical signal. 
Earlier, Fernandez et al. [255] had demonstrated that low nebuliser gas flow and high 
RF power in ICP-MS produce a plasma that can accept changes to matrix acid 
concentration without changing plasma characteristics such as temperature and 
spatial conditions. In general, the two objectives lead to very different settings. 
Robust conditions are characterised by a reduced nebuliser gas flow and a low 
sample flow rate [256], conditions which are quite opposite to those required for 
maximum sensitivity. Hence, the purpose of the optimisation must be defined clearly 
from the onset. The plasma conditions used in this study were chosen mainly for 
optimum analyte sensitivity. 
Strictly speaking, the procedure described below cannot be called a true 
optimisation, since this would involve the use of a statistically founded experimental 
setup such as Simplex optimisation [257, 258] or factorial designs [259]. However, 
these approaches require a single response function, i.e. they focus on optimisation of 
a single parameter, while, in the present study, several parameters had to be taken 
into account. Hence, the outcome of a single-response optimisation would likely 
have to be modified, in order to accommodate the remaining parameters. Considering 
the nature of the samples and the purpose of the analysis, the sensitivity and 
precision of  the Sr response were given highest priority in the optimisation, but the 
other analyte responses, background noise and sample consumption were also 
included in the evaluation. It was therefore considered most practical to find the 
optimum setting for one parameter at a time and then iterate through the parameters 
until a set of satisfactory compromise values was reached (Table 5.1). Because of 
day-to-day variability, minor daily or weekly adjustments of the settings were 
necessary, in order to keep the instrument running consistently at peak performance.  
5.3.1.1 Plasma parameters 
As described in section 4.2.2, the sampling depth, nebuliser gas flow and RF 
power interact profoundly, making this stage of the method development susceptible 
to the inherent problems of the one-variable-at-a-time approach [260]. However, 
with the instrument used in this work, the tolerance of the sampling depth was quite 
low, requiring the torch to be positioned exactly right before the plasma could be 
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ignited. Once this position was established, it was left unchanged throughout the 
analysis, in effect fixing one of the optimisation factors. The remaining adjustments 
of nebuliser gas flow and RF power were a matter of reaching the best compromise 
between a high sensitivity and low degree of formation of oxides and doubly charged 
ions. Both parameters had a considerable impact on the ion intensity. Figure 5.2 
shows the effect of RF power on the intensity of the isotopes determined in serum. 
Increasing the RF power from 700 to 1000 W gave a substantial increase in the 
response from Mg, P, Sr and Rh. At power settings above 1000 W, only slight signal 
increases were observed, and above 1150 W Sr and Rh intensities started decreasing. 
Only the response from Ca showed a steady increase up to 1500 W. Using 
conventional nebulisers, determination of Sr in the literature has been conducted with 
RF power settings ranging from 1000 to 1400 W. In comparison, the major part of 
the increase in ion intensity seen in Figure 5.2 occurs already in the range of 700-950 
W. This may be a result of the dry aerosol produced by the desolvation process in the 
Apex inlet system (see section 5.3.5). With less solvent in the spray injected into the 
plasma, less energy is needed for evaporation and ionisation of the sample. Similar 
observations were reported by Pozebon et al. [248], who, also using an Apex-Q inlet 
system, found no significant increase in ion intensities of 10 different elements at RF 
power above 850 W. On the other hand, D’Ilio et al. [261] applied an RF power of 
1500 W for determinations of 17 trace elements, using an Apex-IR inlet system and a 
dynamic reaction cell. 
Increasing the RF power causes the levels of doubly charged ions to increase, 
because of the elevated temperature in the plasma. Sr has a much lower second 
ionisation potential (11.03 eV) than Rh (16.76 eV), and it would therefore be 
expected that the intensity of Sr would start decreasing at lower power settings than 
the intensity of Rh, but the two elements responded very similarly to the change in 
RF power. The formation of M2+ ions is commonly monitored using the ratio of 
Ba2+/Ba+, because of the very low second ionisation energy of the element (10.00 
eV). Based on previous studies [256], a maximum level of 3% Ba2+/Ba+ was 
accepted in this work. At the optimum nebuliser gas flow, an RF power of 1000 W 
resulted in a Ba2+/Ba+ ratio of 2.5% (Table 5.5, p 77). Since higher power settings 
had no obvious benefits, the serum measurements were conducted at an RF power of 
1000 W. It is interesting to note that, even though the aim here was maximum 
sensitivity, this power setting is identical to one recommended by Tromp et al. [256] 
for obtaining a robust plasma. The authors reported that while a higher RF power in 
some cases marginally reduced the matrix interferences, it was not enough to 
recommend operating at an RF power above 1000 W. 
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Figure 5.2 Influence of RF power on the response from the elements determined in serum (24Mg, 88Sr, 
103Rh: 10 µg L-1; 31P, 42Ca: 100 µg L-1).  Nebuliser gas flow rate: 1.13 L min-1.  
  
Figure 5.3 Effect of nebuliser gas flow on the signal intensity (10 µg L-1 88Sr) and formation of oxides 
(CeO/Ce). The best compromise was found at 1.13 L min-1. RF power was 1000 W.  
As a result of using the Apex nebuliser with free aspiration, the sample uptake 
rate increases with the nebuliser gas flow. It is therefore expected that the ion 
intensity increases correspondingly. Figure 5.3 shows that the signal is indeed 
enhanced by a factor of 3 when the gas flow is increased from 0.7 to 1.15 L min-1. At 
gas flows above 1.15 L min-1 a plateau is reached. This observation is somewhat in 
contrast to previous reports [262, 263], where the Apex-Q system was used for 
determination of 226Ra and 236U/238U with nebuliser flow rates no higher than 0.99 L 
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min-1. Pozebon et al. [248] reported that the maximum response across a broad mass 
range was seen already at a nebuliser gas flow of 0.9 L min-1. Conversely, Epov et al. 
[264] determined Pu using a gas flow of 1.15 min L-1.  
Clearly, the varying operational conditions found in the literature are partly due 
to the differences in mass and ionisation potential of the determined elements, but, 
nevertheless, the discrepancy is quite substantial. The most likely explanation seems 
to be the complex interactions between the plasma parameters. The sampling depth 
and the nebuliser gas flow both have an impact on the position of the plasma’s 
ionisation zone, which deliver the analyte ions to the sampler cone. Instruments of 
different makes and models may have different sampling depths and 
plasma/auxiliary gas flow rates, which would result in different optimum nebuliser 
flow rates and power settings. However, the instrument used by Pozebon et al. was a 
Perkin-Elmer ELAN 6100, which is in many respects similar to the ELAN 6000 used 
in this work. The control of the sample flow rate is another factor adding to the 
complexity of the optimisation. When the nebuliser is used in self-aspiration mode, 
the sample flow is mainly controlled by the inner diameter of the sample tubing, but 
also by the nebuliser gas flow. Changing the nebuliser gas flow therefore not only 
affects the ion intensity via the plasma conditions but also through the amount of 
injected sample.  
The oxide formation was investigated by analysing a sample containing 10 µg 
L-1 Ce, an element often used for this purpose because of its characteristic tendency 
to form CeO+ [221]. The CeO+/Ce+ ratio was monitored as a function of the nebuliser 
gas flow as shown in Figure 5.3. As a result of the solvent removal performed by the 
Apex, the oxide formation was kept at a very low level (<1%). Still, the figure 
reveals a steep increase in formation of CeO+ at gas flows above 1.13 L min-1, and 
therefore this value was chosen as the best compromise setting. The effect of the 
secondary argon flow on the ion intensities was less systematic than the nebuliser gas 
flow. The setting giving the highest Sr signals varied between 0 and 50 mL min-1 
from day to day.  
5.3.1.2 Lens voltage 
The voltage of the ion lens determines the transmission of ions from the interface 
to the quadrupole. The optimum lens voltage depends on the mass of the isotope of 
interest and on the condition of the lens. The ion lenses on the ELAN 6000 can be 
operated in two different modes: 
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1) Static ion lens voltage optimised for a particular isotope. When measuring 
several elements across a mass range, a suitable compromise setting based on 
a medium mass is used.  
2) Variable lens voltage, in which case the lens voltage is changed automatically 
in concert with the quadrupole mass filter for each measured isotope during 
the analysis. This mode provides an optimum lens voltage for the entire mass 
range. 
Appling a variable lens voltage requires an optimisation procedure, during which the 
lens voltage is changed while isotopes covering the mass range of interest are 
measured. Be, Co and In are often recommended because they are monoisotopic, 
they typically have well-defined lens voltage maxima and they span sufficiently well 
the entire mass range (masses of 9, 59 and 115 amu, respectively) [214]. The 
optimisation showed that the optimum lens voltage increased with increasing analyte 
mass, going from 9.1 V for Be to 11.8 V for In. At a first glance, this feature seemed 
to be a very compelling option for a sensitive determination of Mg at mass 23 
through to Sr at mass 88. Compared to a static lens voltage optimised for 
determination of Sr, sensitivities for Mg, P and Ca improved by 19%, 8% and 13%, 
respectively. Unfortunately, this was accompanied by a poorer precision (up to 50% 
higher RSD) for all measured isotopes. The reason for this loss of signal stability is 
unclear, but it may indicate that either the settling time of the lens was longer than 
that of the quadrupole, or that lens and quadrupole were not completely coordinated 
when scanning through the mass range.  
 
Figure 5.4 Effect of lens voltage on the signal intensity (10 µg L-1 88Sr). The optimum setting was 
found to be 10.2 V. 
Given that maximum sensitivity for Ca, Mg and P would not be required due to their 
high natural concentrations, the minor increase in sensitivity could not justify the loss 
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of precision. It was therefore decided to optimise the lens voltage for determination 
of Sr (Figure 5.4), which had the highest sensitivity at 10.2 V. 
5.3.1.3 Quadrupole mass filter tuning 
When the mass filter is set in the peak-hop mode, only a single mass/charge ratio 
is measured for each isotope (cf. Figure 4.8, p 48). Consequently, for the best 
sensitivity to be achieved, the mass filter electronics must be properly calibrated or 
tuned, so that the quadrupole settles exactly on the maximum of the analytes’ mass 
peaks. The instrument was tuned across the mass range by using spectral peaks of 
3He (present as an impurity in the Ar gas), 9Be, 24Mg, 103Rh and 208Pb. The tuning 
was repeated until all mass peaks were positioned within 0.05 amu of their true 
value. Spectral peaks for Mg, Rh and Pb are shown in Figure 5.5. 
 
Figure 5.5 Spectral peaks of Mg, Rh and Pb obtained after tuning of the quadrupole mass filter. The 
horizontal lines mark the intensity at 10% of the peak maximum, which is where the resolution (peak 
width) is measured. 
5.3.1.4 Detector voltage and dual­detector calibration 
The optimum detector voltage depends primarily on the age of the detector. As 
the detector ages, its saturation point shifts towards higher values. Operating the 
detector at low voltages decrease the sensitivity, while voltages at or above the 
saturation point increase the noise level and reduce the lifetime of the detector [214]. 
The pulse detector stage was considered to be close to the saturation point when a 
further voltage increase of 50 V yielded less than 5% increase in the response. This 
approach arrived at 1500 V as an appropriate pulse voltage (Figure 5.6). In practise, 
the pulse stage was optimised both before and after the analogue stage adjustment, as 
the settings of the two detector stages may influence each other. 
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Figure 5.6 Response curve from the final pulse detector stage optimisation (10 µg L-1Rh). The 
detector pulse voltage was subsequently set to 1500 V.  
The voltage of the analogue detector stage was adjusted by defining a maximum 
signal that could be measured by the detector. Converting from the analogue signal 
current to ion counts, the threshold was set to 1·109 cps and the detector gain was 
adjusted accordingly by measuring a test solution of 200 µg L-1 Mg. The resulting 
gain and voltage were 1.2·104 and -2587.5 V, respectively.  
Figure 5.7 Examples of cross calibrations between the detector’s analogue and pulse modes, 
providing an expanded dynamic range for each isotope. The lower right-hand graph shows how the 
conversion factors (the slopes of the individual calibrations) depend on the isotope masses. 
After the final pulse stage adjustment, a cross calibration was performed between 
the two detector stages (Figure 5.7). As pointed out by Mestek and Koplik [226], it is 
important that such a calibration be carried out for each analyte, rather than merely 
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using a few isotopes to represent the entire mass range. Since the detector gain varies 
with isotope mass, the relationship between the analogue and pulse stages is also 
mass dependent and must be determined individually for each isotope, in order to 
obtain the best precision. With the aid of the ELAN software, the calibration was 
conducted by applying a single multielement solution of relatively high 
concentration (approx. 200 µg L-1 of 39 elements). The calibration points shown in 
Figure 5.7 were obtained by making 20 scans of each mass at different lens 
potentials. By varying the voltage of the lens, the ion transmission is reduced, in 
effect creating a dilution of the ion beam. The slopes of the all the cross-calibrations 
represent the conversion factor between the two detector stages for each mass.  The 
lower right-hand graph in Figure 5.7 shows the mass dependence of the conversion 
factor. The pulse mode is approximately 10 times more sensitive than the analogue 
mode for most isotopes.  
5.3.1.5 Daily performance check 
In order to continuously asses the performance of the apparatus, a test solution 
was measured before the first standard, recording sensitivity, background intensity, 
precision and levels of oxides and doubly charged ions (Figure 5.8).  
 
 
 
 
 
Figure 5.8 Excerpt from a daily performance report. Reports were obtained every day before the 
analysis was commenced. Sensitivity, background, precision, oxides and doubly charged ions were 
monitored as indictors of the instruments’ performance.  
Since undigested samples were analysed, it was particularly important to ensure that 
the instrument had been cleaned properly between two sample sets. Poor sensitivity 
was an indicator of reduced sample flow or clogged cones, while reduced precision 
Determination of Sr, Mg, P and Ca in serum  69 
 
 
often was a result of nebulisation problems or unstable plasma, caused by a dirty 
torch. 
5.3.2 Spectral interferences and selection of target isotopes 
The elemental composition of serum is well-documented (Table 5.2). Ca, P and 
Mg are major elements, found in the mg L-1 concentration range, while Sr is a trace 
element normally found in the low µg L-1 range. The natural molar ratios are about 
1.9:1, 2.7:1 and 7500:1 for Ca/P, Ca/Mg and Ca/Sr, respectively.  For animals treated 
with strontium, concentrations of more than 15 mg L-1 have been reported [39]. 
Table 5.2 Concentration ranges of Mg, P, Ca and Sr in human serum [170, 265-268]. 
 (mg L-1)   (µg L-1) 
Mg P Ca  Sr 
17-23 23-51 80-106  4-47 
Table 5.3 p. 71 shows ionisation energies, naturally occurring isotopes and 
potentially interfering ions of all measured elements. Mg, Ca and Sr have several 
isotopes, with both high (24Mg, 40Ca, 88Sr), medium (25Mg, 26Mg, 86Sr, 87Sr) and low 
(42Ca, 43Ca, 44Ca, 46Ca, 48Ca, 84Sr) abundance. Considering the natural concentration 
ratios between these elements, it was expected that an analytical protocol 
determining the low-abundant isotopes of Mg and Ca together with the high- and 
medium-abundant Sr isotopes would lead to ion intensities that fell within the 
dynamic range of the instrument. For the potentially very high Sr concentrations in 
the treated animal groups, the least abundant 84Sr could be exploited. The high 
concentration of phosphorous would have to be determined through 31P, the only 
exiting P isotope. However, as the first ionisation energy of P is much higher than 
that of the other measured elements, P is ionised to a much lesser degree in the ICP, 
resulting in a lower sensitivity.  
De Muynck and Vanheacke [166] compiled a very comprehensive list of 
potential interfering ions for ICP-MS determination of Ca, P and Sr (Table 5.3). 
Some interfering ions can be corrected for mathematically by entering so-called 
elemental equations in the instrument software. The principle of this method is to 
monitor the interfering isotope at the analyte mass by measuring a different, ideally 
interference-free, isotope of the same element at an alternative mass, and then use the 
ratio of the natural abundances to correct the analytical result. For instance, the 
interference of 84Kr on 84Sr is corrected by simultaneously monitoring the combined 
ion intensity of 84Kr + 84Sr and the intensity of 83Kr. The ELAN software supplied 
with the instrument suggests relevant equations for each measured isotope.  
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All the isotopes of interest suffer from spectral interferences. Most notably, the 
most abundant Ca isotope, 40Ca, is unavailable for analysis by standard Ar-ICP due 
to severe spectral interference from the vast concentration of 40Ar+ in the ion beam. 
The overlap cannot be resolved even by a high resolution instrument [166], but the 
Ar interference can be removed by applying a dynamic reaction cell with NH3 as the 
reactant gas [269]. Of the five remaining Ca isotopes, 44Ca, 46Ca and 48Ca were not 
considered suitable for analysis. 46Ca has a very low abundance, while the P-based 
interferences on 48Ca+ and the interference of C Oଶା 16 12  on 44Ca are both potentially 
very significant. The interference from 26Mg16O+ on 42Ca was expected to be less 
pronounced, since 26Mg is only medium abundant. The two measured Ca isotopes, 
42Ca and 43Ca, are both susceptible to interferences from doubly charged Sr2+ ions. In 
serum taken from untreated animals, this interference would be negligible due to the 
large Ca/Sr concentration ratio and the low amount of M2+ formed in the ICP 
(M2+/M+ < 3%, see p. 62). However, the serum Ca/Sr ratio in animals treated with Sr 
is potentially raised to the order of 20:1, thus increasing the possibility for Sr 
interference. The effect was expected to be very low for 42Ca, due to the low 
abundance of 84Sr.  
High concentrations of C, Ca and Na have been reported to interfere with 
determination of Mg in low concentrations due to spectral interferences from 
Ca2൅ 48 , Na൅ 23 (tailing), Na H൅ 1 23  and C 12 N 14  [270], but in view of the high 
concentration of serum Mg, no significant interference was expected. This was 
confirmed by the method validation, where a good agreement between the three Mg 
isotopes was observed. 
Several investigators have used ICP-MS for determination of P and P-
compounds [271-274], even though the single phosphorous isotope, 31P, suffers from 
serious interference from carbon- and nitrogen based polyatomic species. In general, 
the presence of C has been reported to enhance the signal of elements with ionisation 
potentials of 9-11 eV [275], an observation that was later confirmed specifically for 
P [276]. NO+ and NOH+ are of course especially problematic if nitric acid is used for 
dilutions of samples and standards. The interferences can be overcome by using a 
high resolution instrument [277, 278] or a reaction cell [279-281]. Alternatively, the 
molecular ion PO+ has been used for quantification of P at m/z 47 [276, 282], but 
since other interferences exist at this mass ( N 15 O2൅ 16 , N 14 O 16 O ൅ 17 , N 14 O 16 H21  ൅), this 
approach was not pursued in the present study.  
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Table 5.3 First and second ionisation energies, natural isotope abundances [16] and some potentially 
interfering ions [166, 270, 276, 283-285] for Mg, Ca, P, Sr and Rh. 
Element Ionisation energy (eV) Isotope 
Abundance 
(%) Potentially interfering ions 
Magnesium I: 7.646 
II: 15.035 
24Mg 
 
78.99 
 
C2൅12 , NaଵH൅23 , Na൅23 ሺtailingሻ, Li ଵ଼O ൅ 6 , Liଵ଻O൅7 , Ca2൅48 , Ti 2൅48  
25Mg
 
10.00 
 
CଵଷC൅12 , C2112 H൅, Be ଵ଺O ൅9 , Mg 1H ൅ 24 , Liଵ଼O൅7 , Ti2൅50  
26Mg 11.01 CଵସN൅12 , C2൅13 , CଵଷC H 1  ൅12 , Mg 1H ൅ 25 , 
Phosphorous I: 10.487 
II: 19.769 
31P 100 N O H1 ൅1614 , N O൅1615 , N O൅ 17 14 , 
C O H1 ൅1812 , C O H1 3൅1612 , Si 1H ൅ 30  
Calcium I: 6.113 
II: 11.872 
40Ca 96.94 Ar൅40 , K൅40 , Mg16O൅24 , Ar H 1 2൅ ଷ଼  
, K1H൅39 , 
42Ca 
 
0.647 
 
Mg16O൅26 , N3൅14 , O C N 14  ൅ 1216 , Ar H 1 2൅ ସ଴ , Ca H1 2൅ସ଴ , Sr2൅84  
43Ca 
 
0.135 
 
Al16O൅27 , Mg17O൅26 , N31 14 H ൅, C O N15 ൅1612 , C O N 14  ൅1613 , C O N 14  ൅ 17 12 , 
Ar H1 2൅ସ଴ , Ca H1 ൅ସଶ ,  Sr 2൅ 86  
44Ca 
 
2.086 
 
Si16O൅26 , C O2൅1612 , N216O ൅14  , Si 28 O 16  ൅, Ca H1 ൅ସସ , C O N15 ൅1613 , C O N 14  ൅ 17 13 , 
C O N15 ൅1712  
46Ca 0.004 Ti൅46 , Si28 O18 ൅, N O2൅ 1614 , N216O ൅ 15 , C O2൅1712 , C O N15 ൅1813 , Zr2൅ 92  
48Ca 0.187 Ti൅48 , P31 O16 H൅1 , P31 O ൅ 17 , N218O ൅ 15 , C O2൅1812 , Zr2൅96 , Ar36 C ൅ 12 , S 32 O ൅ 16  
Strontium 
 
 
I: 5.695 
II: 11.030 
84Sr 0.56 Kr84 ൅, Ar Ca൅4836 , Ar Ca ൅ 4638 , Ar Ca൅ 44 40 , Ar Ti ൅ 48 36 , Ar Ti ൅ 46 38 , Ca Ca ൅ 44 40 , Ca2൅ 42 , Zn O൅1866 , Zn O൅1767 , Zn O ൅ 16 68  , Er 168 ൅, 
Yb168 2൅ 
86Sr 9.86 Kr86 ൅, Ar Ca൅4838 , Ar Ca ൅ 4640 , Ar Ti൅ 50 36 , 
Ar Ti ൅ 48 38 , Ar Ti ൅ 46 40 , Ar Cr ൅ 50 36 , 
Ca Ca ൅ 46 40 , Ca Ca ൅ 44 42 , Ca2൅ 43 , Zn O ൅ 18 68 , Zn O൅1670 , Ga O൅1769 , Ge O ൅ 16 70 , Yb 172 2൅, 
Lu172 2൅ 
87Sr 7.00 Rb87 ൅, Ar Ti൅4938 , Ar Ti ൅ 4740 , Ar V ൅ 51 36 , 
Ca Ca ൅ 44 43 , Zn O ൅ 17 70 , Ga O ൅ 18 69 , 
Ga O൅1671 , Ge O൅1770 , Yb 174 2൅, Hf 174 2൅, 
Lu174 2൅ 
88Sr 82.58 Ar Ca൅4840 , Ar Ti൅5038 , Ar Ti ൅ 48 40 , 
Ar V ൅ 50 38 , Ar 50Cr൅ 38 , Ca Ca ൅ 48 40 , 
Zn O൅1870  , Ga O൅1771 , Ge O ൅ 18 70 , 
Ge O൅1672 , Yb176 2൅, Hf 176 2൅, Lu 176 2൅,  
Rhodium I: 7.459 
II: 18.08 
103Rh 100 Ar63Cu൅40 , Ar65Cu൅38 , Ar 67Zn൅ 36 , 
Ar40 2 Na൅23 , Sr16O൅87 , Rb 16O൅ 87 , 
Rb18O൅85 , Pb2൅206  
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As the main element in this investigation, all four Sr isotopes were applied in the 
analysis. The least abundant isotope, 84Sr, was included in anticipation of the 
elevated serum Sr concentrations present in the treated animal groups, where the high 
Sr sensitivity might result in ion counts above the range of the detector. The Sr 
isotopes are all potentially affected by spectral overlap from ArCa+ molecular ions 
and/or Ca dimers, especially since Ca and Ar are both present in high concentrations 
in the ICP. Nevertheless, determination of Sr in Ca-rich matrices has not been 
reported to suffer from such interferences. In fact, it has been argued that elements 
with masses above 82 are essentially free of serious spectral interference from 
polyatomic species [286]. Of the interfering ions listed in Table 5.3, corrections were 
only made for spectral interference from singly charged monoatomic ions (Kr and 
Rb). All serum analyses showed excellent agreement between the three most 
abundant Sr isotopes. In the samples with low Sr contents, ion intensities for 84Sr 
were often too low for a reliable quantification, whereas, in the Sr-treated groups, all 
four isotopes were in agreement within the measurement uncertainty. This confirmed 
that no serious spectral interferences for Sr were present. 
The monoisotopic internal standard 103Rh is subject to interference from 87Sr160+ 
as well as several Ar-based species. Using an ELAN 6000 with a cross-flow 
nebuliser for analysis of environmental materials, Djingova et al. [285] found that a 
correction of 0.003% · [Sr] was necessary to achieve a good accuracy for 
determination of Rh. In the present study, however, the sample desolvation reduced 
the extent of oxide formation tenfold compared with a cross-flow nebuliser (Table 
5.5, p 77). Therefore, the SrO+ interference was assumed to be negligible and no 
correction was performed. 
Based on the considerations above, it was decided to measure the isotopes 24Mg, 
25Mg, 26Mg, 31P, 42Ca, 43Ca, 84Sr, 86Sr, 87Sr and 88Sr. Taking advantage of the 
expanded dynamic range of the dual detector mode, it was expected that this protocol 
would enable simultaneous determinations of all the analytes within their potential 
concentration ranges.  
5.3.3 Non­spectral interference and internal standardisation 
The serum matrix induced a severe suppression (>50%) of the analytical 
responses for all measured isotopes (Figure 5.9). The presence of biological 
constituents such as salts, proteins and lipids in the serum may suppress the signal 
through different mechanisms. Firstly, it may be a simple sample transport effect 
brought on by the sample components’ impact on the flow dynamics and surface 
properties of the sample. A change in these properties would alter the formation of 
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aerosol droplets in the nebuliser and the droplet selection in the spray-chamber. The 
sample uptake rate may also be affected if the diluted serum has a different viscosity 
than the pure standards. Secondly, the signal suppression may be induced by a shift 
in the ionisation equilibrium [287] in the ICP. The ions in the plasma exist in 
equilibrium with their corresponding atoms:  
 ܯ ֕ ܯା ൅ ݁ି (5-1) 
 
The serum matrix contains high amounts of easily ionisable matrix elements (e.g. Li, 
Na, and K) that may give rise to a high density of free electrons. The mass-action 
effect of these electrons might shift equation (5-1) towards the left, thus suppressing 
the formation of analyte ions. Finally, some of the plasma energy is used to vaporise 
and atomise the heavy biological components in the samples, which in effect cool 
down the plasma, leaving less energy for the ionisation of the analyte atoms.  
 
Figure 5.9 Signal increase after addition of 5 µg L-1 Sr and Rh to 0.1 M HNO3 and diluted serum 
(1+11.5). The Sr and Rh responses were suppressed by 50 and 52 %, respectively. 
The matrix interference made it absolutely essential to apply a suitable internal 
standard (IS) to correct the measured ion intensities of the analytes. Studies by 
Vanhaecke et al. [288] indicated that an IS with a mass close to that of the analyte is 
to be preferred for all elements, and both 89Y, 103Rh and 115In have previously been 
used with success for determination of Sr (cf. section 3.5). In our laboratory, Rh is 
measured on a regular basis as a part of the instrument optimisation and daily 
performance checks. Consequently, extensive documentation concerning precision, 
sensitivity, long-term drift and day-to-day variability of Rh measurements was 
available, making it a good candidate for monitoring the analyses of standards and 
samples throughout the study. Rh was tested as IS during the initial method 
development and was found to provide a satisfactory correction of the Sr response.  
 The analyte signals were normalised by dividing the ion intensity of each 
analyte with that of the internal standard according to the general expression [169] 
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ܫ஺
ܫூௌ ܥூௌ ൌ ܽ ൅ ܾܥ஺ (5-2)  
where a is the intercept and b the slope of the calibration function, IA is the analyte 
intensity in cps, IIS the intensity in cps for the internal standard, CIS the internal 
standard concentration in µg L-1, CA is the concentration of the analyte in µg L-1. 
Since the IS concentration was identical for all standards and samples, CIS could be 
omitted in the calculations.  
103Rh has also been used as IS for determinations of Mg and Ca [173, 289], 
though, admittedly, Rh is unlikely to be the best choice for these analytes due to the 
relatively large differences in mass and ionisation potential. Other investigators have 
used 59Co as IS for determination of Mg, 35Cl and 51V for P, while 45Sc and 51V have 
been used for Ca [166, 290-292], but, as the main focus of this investigation was on 
Sr, no other IS than Rh was tested. This may have contributed to the large 
measurement uncertainty for these elements, as well as the poor accuracy of the P 
determination (cf. section 5.3.9).  
5.3.4 Digestion vs. dilution 
As described in Chapter 3, the primary motivation for digesting biological 
liquids is to avoid matrix-induced signal suppression, as well as clogging of the 
nebuliser, injector tubes and cones. This is especially true for a nebuliser with a 
concentric design, which is more prone to clogging because of the very fine liquid 
capillary. The perhaps most widespread method for preparation of serum samples is 
microwave assisted acid-digestion [168, 188]. However, considering the large 
number of samples (>150) to be analysed in this project, digestion would be very 
time consuming. Moreover, as the minimum solvent volume required for the 
laboratory’s microwave digestion system is 7 mL, the small amount of serum 
available from each animal would risk being diluted below the limit of 
quantification. With this in mind, the more straightforward “dilute and shoot” 
approach was tested. A serum sample with a Sr concentration close to that of the 
animal control groups was divided into 8 subsamples, one half of which was diluted 
and the other one digested (500 µL serum was digested with HNO3, HCl and H2O2 
by a similar procedure to the one used for digestion of bone marrow in Appendix 
II).The analytical results obtained by the two methods (Table 5.4) were not 
significantly different, and consequently it was decided to avoid the labour-intensive 
digestion procedure. 
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Table 5.4 Results (mean ± SD) of analysis of several sub-samples taken from the same serum 
sample after microwave assisted acid digestion and dilution. 
 Result (µg L-1 Sr) p (student t-test) 
Diluted serum (n = 4) 42.4 ± 3.7  
Digested serum (n = 4) 38.8 ± 5.2 0.31 
 
The major drawback of this approach was a severe clogging of the line going 
from the Apex to the ICP-MS as shown in Figure 5.10a. After analysis of even a 
moderate number of samples, salts and organic sample material built up on the inner 
tube wall and eventually blocked the tube completely, at which point the plasma had 
to be stopped and the sample line disconnected and cleaned. Furthermore, sample 
material deposited on the inner wall of the plasma torch (Figure 5.10a). As a result, 
plasma ignition was hampered and ultimately the torch had to be replaced.  
Figure 5.10 Photographs of the Apex aerosol tube (a) and the ICP-MS quartz nebuliser (a) after 
analysis of undigested serum samples illustrate the disadvantage of merely diluting the samples as 
opposed to performing a full digestion. Organic sample material is deposited on the inner tube wall, 
hindering and eventually blocking the sample flow.  
The clogging of the aerosol line could to some extent be prevented by aspirating a 
solution of HNO3 in high concentration (>5 M) between each sample, but even so, no 
more than 15-20 samples could be analysed before the sensitivity started to 
deteriorate. Similar, albeit less pronounced, effects was reported by Krahcler et al. 
[191], who used ICP-MS for determination of trace elements in serum, urine and 
even whole blood, which is a matrix much richer in organic material than serum. A 
dilution of 1+19 was necessary to achieve a good long-term stability (>24 h) for all 
three types of liquids, but a 1+9 dilution was reported very effective for serum and 
urine alone. Using ICP sector field mass spectrometry, Rodushkin et al. [293] 
reported that a 1+9 dilution of serum and urine allowed the instruments to remain 
stable for 6 h, corresponding to 30-35 clinical samples. de Boer et al. [194] used a 
special Hewlett-Packard V-groove nebuliser and a 2.4 mm torch injector tube to 
(a) (b) 
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avoid blockage. These instrumental features allowed for 600-1000 blood samples to 
be measured without blocking the nebuliser. The somewhat lower tolerance to 
clogging seen in the present study must be attributed to the Apex inlet system. 
Contrary to preceding expectations, the clogging did not occur in the narrow 
capillary of the nebuliser, but rather at the aerosol outlet of the Apex. This suggests 
that a conventional cyclonic spray-chamber without a desolvation unit might have 
been more robust to clogging. Clearly, further dilution of the serum would allow 
more samples to be analysed without clogging, but the low Sr concentrations in 
serum from untreated animals set a limit to the extent of dilution.  
5.3.5 Apex inlet system 
Apex-Q sample inlet systems have previously been used for ICP-MS analysis of 
trace elements in acid-digested blood [261] diluted serum [188] and biological 
tissues [248]. The two main functions of the system are  
1) to limit the amount of liquid entering the plasma, which reduces solvent-
induced spectral interferences such as oxides, hydrides and argon/solvent-
based polyatomic species. This is achieved by first heating the aerosol in the 
spray-chamber, which promotes solvent evaporation and analyte transport, 
and subsequently by cooling and condensing the evaporated solvent, thus 
creating a dry aerosol, 
2) to increase sensitivity by adding N2 to the sample aerosol.  
Besides minimising solvent-based interferences, the low amount of solvent reaching 
the plasma reduces the energy needed to vaporize the solvent, which allows more 
energy to be available for ionisation of the analyte ions. Finally, controlling the 
temperature of the spray chamber can help minimising signal drift caused by changes 
in the ambient temperature [204, 219]. Addition of N2 to argon-ICP has been studied 
extensively and has been shown to reduce formation of oxides [294] and other 
polyatomic species [295-297], while both enhancement [294, 298] and suppression 
[299] of the analyte sensitivity have been reported. Addition of N2 fundamentally 
changes the physical and electrical properties of the plasma, but the mechanism by 
which N2 affects the analyte sensitivity is uncertain. At a temperature of 7000 K, the 
thermal conductivity of N2 is 32 times that of Ar, which may facilitate a greater heat 
transfer to the central channel of the plasma, causing a higher degree of ionization 
[300]. This view is supported by the measurements of the Ba2+/Ba+ ratios shown in 
Table 5.5. The desolvation system operating without N2 yields a Ba2+/Ba+ level 
similar to a cross-flow nebuliser. Adding N2 to the sample aerosol more than doubles 
the ratio, indicating that the gas facilitates ionisation. Contradicting this view, Lam 
Determination of Sr, Mg, P and Ca in serum  77 
 
 
and Horlick [294] found no clear correlation between ionisation potential and signal 
enhancement after addition of N2, which would have been expected if the mixed gas 
effect were related to the energy of the ionisation zone. This may be investigated 
further by looking at the degree of ionisation in the plasma. Using the Saha [301] 
equation, Houk [302] calculated the degree of ionisation in an ICP expressed as 
M+/(M++M) for 79 elements and found a ratio of > 90% for both Mg, Sr, Rh and In. 
Table 5.5 shows that adding N2 to the Apex aerosol increased the sensitivity 44-
111% for these elements. With more than 90% of the elements already ionised, it 
would clearly be impossible to achieve the observed sensitivity enhancement solely 
by further ionisation of the elements, which also speaks against an energetic 
explanation of the N2 effect.  
Table 5.5 Comparison of sensitivities and formation of oxides and doubly-charged ions using a cross-
flow nebuliser and the Apex inlet system. The sensitivities have been corrected for the difference in 
sample flow (cross-flow: 480 µL min-1, Apex: 260 µL min-1). Instrument settings were optimised for 
determination of Sr.  
 Sensitivity (counts fg-1)  3-limit of detection (µg L-1) 
Nebuliser Cross-flow Apex, no N2 Apex with N2  Cross-flow Apex with N2 
24Mg 0.54 3.5 5.1  0.11 0.025 
31P 0.043 0.12 0.24  1.8 1.14 
42Ca 0.063 0.42 0.44  7.1 3.33 
88Sr 4.2 27 42  0.009 0.005 
103Rh 3.5 18 37  0.002 0.0007 
115In 4.1 19 38  0.002 0.001 
138Ba 3.7 16 28  0.004 0.002 
140Ce 4.0 16 31  0.003 0.002 
208Pb 4.0 10 21  0.008 0.005 
CeO/Ce 2.8% 0.33% 0.26%  - - 
Ba2+/Ba+ 1.2% 1.1% 2.5%  - - 
Compared with the most common injector combination of a cross-flow nebuliser 
and a double-pass spray chamber, the Apex provides a considerable increase in 
sensitivity for all analysed elements except Ca (Table 5.5). Being the target element 
of the optimisation, Sr sensitivity increased by a factor of 14, but large enhancements 
were also seen for both lighter (Mg, 8 x increase) and heavier (Rh 10 and Pb 5 x 
increase) elements. The improvement is due to the high efficiency of the concentric 
nebuliser and cyclonic spray chamber combined with the solvent removal and 
addition of N2 in the Apex. Concomitantly, the CeO/Ce ratio was reduced with one 
order of magnitude, showing that the desolvation provided a marked decrease in the 
oxide levels. Finally, the microflow nebuliser allowed for much lower sample 
consumption (260 µL min-1) than the cross-flow nebuliser (480 µL min-1). 
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As discussed above, a possible disadvantage of the Apex is a more pronounced 
tendency to clogging, leading to a lower tolerance to heavy matrices. In addition, the 
efficient removal of the sample solvent enables more sample material to reach that 
plasma, which may amplify the signal suppression caused by the matrix. 
5.3.6 Sample containers 
Controlling and minimising blank contributions in trace and ultra-trace analysis 
of clinical samples is at least as important as maximising instrument sensitivity 
[303]. Different containers made from plastic, borosilicate glass (Duran) and quartz 
were tested as vessels for dilution and storage of the serum samples. The blank levels 
for both plastic and borosilicate containers showed a very large vessel-to-vessel 
variance with up to 60 times higher blank responses for Sr than found using quartz 
vessels. The highest observed contaminations were in the order of 0.5 µg L-1, a level 
which would have had a serious impact on the means and standard deviations of the 
final results, particularly in the untreated groups. To keep the blank values 
consistently at a minimum, 70 quartz vessels were custom made for the analysis. The 
calibration standards were produced using volumetric flasks made from Duran. Only 
flasks showing consistent, low background levels were applied. 
5.3.7 Dynamic range 
The purpose of operating in dual detector mode is to increase the linear range of 
the ICP-MS, thus reducing the need for sample dilution. In principle, the cross-
calibration of the two detector stages should enable a single linear calibration 
function to cover concentrations in both the pulse and the analogue regions. 
However, Campbell and Burns [227] reported nonlinearity of the detector response 
when applying the dual-detector mode on an ELAN 6000. Despite a satisfactory 
linear correlation in the cross-calibration (similar to the ones shown in Figure 5.7, p 
67), the slopes of the calibration curves for the two stages were found to be different. 
Confirmed by other investigators [228], this nonlinearity leads to bias if a single 
calibration function is fitted to both response ranges. To investigate if a similar 
behaviour could be identified with the instrument used in the present work, 
calibration functions were calculated for Mg, P, and Sr for both the combined and 
separate detector stages (Table 5.6). The results showed that the slopes for the two 
regions did in fact differ significantly with the analogue stage giving systematically 
higher slopes than the pulse stage. This trend is in agreement with previous findings 
[227, 228]. As a consequence, separate calibration functions were calculated for the 
two regions. Isotopes with signal intensities below 2·106 cps were quantified using 
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the pulse mode calibration, while higher signal intensities were processed using the 
analogue mode calibration. 
Table 5.6 Sensitivities for pulse, analogue and dual stages for the ELAN 6000. 
 Slope ± standard deviation (L · µg-1) P/A-
ratio  Dual mode Pulse mode  Analogue mode  
24Mg (46.8±0.1) ·10-3 (45.1±0.3)·10-3 (46.9±0.3) ·10-3 0.96 
31P (21.9±0.1)·10-4 (20.7±0.3)·10-4 (21.8±0.1) ·10-4 0.95 
42Ca (47.1±0.1) ·10-4 (39.2±0.1) ·10-4 (48.6±0.8)·10-4 0.81 
86Sr (28.2±0.1) ·10-3 (23.9±0.2) ·10-3 (28.3±0.2) ·10-3 0.84 
88Sr (26.2±0.2) ·10-2 (21.48±0.07) ·10-2 (26.3±0.3) ·10-2 0.82 
 
Without the application of an internal standard, the response showed a 
pronounced curvature at high analyte concentrations, starting above 500 µg L-1 
(Figure 5.11). This was observed for all isotopes, irrespective of the ion intensity or 
the detector mode. The curve shape bears resemblance to a signal approaching 
detector saturation, but, since the curving is independent of the ion count, it cannot 
be attributed to the detector. Rather, it must be taken as an indication of a lower 
efficiency in the generation and transmission of ions by the ICP and the ion lens at 
high analyte concentrations.  
Figure 5.11 Calibration with respect to 88Sr and 44Ca up to 10,000 µg L-1 using the analogue detector 
mode. The ion intensity () shows a pronounced curvature starting above 500 µg L-1. Correcting the 
88Sr response using 5 µg L-1 Rh as IS () results in a good linearity in the whole concentration range. 
The curvature was seen for all isotopes irrespective of the ion intensity.  
The explanation may be linked to the nature of the calibration standards. In addition 
to the analytes, the multi-element solution used for preparation of the standards 
contained similar concentrations of heavier elements such as Pb and Cd. Early 
investigations [304] showed that the magnitude of signal suppression increased with 
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the masses of elements concomitantly present in the sample. It was later suggested 
that the primary cause of this interference is the so-called space charge effect [305], 
which causes the heavier matrix elements to dominate the ion beam and deflect the 
lighter elements, in effect defocusing the beam and reducing ion transmission [306, 
307]. It was observed that the suppression depended on the absolute concentrations 
of the analyte and matrix ions as well as their concentration ratios [304]. It has also 
been suggested that the distribution of analyte ions in the presence of concomitant 
matrix ions is affected by ambipolar diffusion in the ICP [304, 308]. Shifts in 
ionisation equilibria may also play a role, as discussed in section 5.3.3. As a final 
note, some investigators [309, 310] found that signal suppression cannot be 
explained by a single mechanism, but must be due to a combination of several 
causes. 
In the present work, the curvature could be corrected by normalising the 
intensities with the internal Rh standard, and a good linearity could be obtained 
throughout the whole concentration range. This shows that whatever the cause of the 
suppression may be, it affects equally the analytes in the mg L-1 range and the 
internal standard at 5 µg L-1. 
5.3.8 Ruggedness 
From the discussion in section 5.3.1 it is clear that all the optimisation 
parameters need to be carefully controlled during operation, as they greatly affect the 
analytical signal. Other factors influencing the performance of the instrument include 
the background pressure (1.7-2.4·10-4 Pa) and working pressure (1.5-2.1·10-3 Pa) of 
the mass spectrometer as well as the torch box temperature (39-43°C). Such factors 
are determined by the instrumental design and the laboratory’s facilities (ambient 
temperature, cooling water, ventilation etc.) and cannot be readily adjusted by the 
operator. The values were noted daily in the instruments logbook together with the 
results of the performance check described in section 5.3.1.5.  
The main factor affecting the analytical performance was deposition of sample 
material on the tubing. During analysis, the extent of clogging was monitored by 
recording the response of the internal standard. The first serum sample to be analysed 
typically gave a Rh response of approximately 3·105 cps. As more samples were 
measured, the response decreased due to the reduced aerosol flow. The 
measurements were stopped when the signal fell below approx. 1·105 cps. Sample 
depositions on cones and torch caused a need for these components to be removed 
and cleaned regularly.  
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Figure 5.12 The Rh signal from the internal standard (mean ± SD) was monitored during the 
measurements. The intensity decreases as the aerosol flow is reduced due to clogging of the tubing.  
5.3.9 Quality control 
The precision was <2.5% for all isotopes when measured in the standards and 
<5% in the diluted serum. Sr and Rh measurements tended to exhibit better precision 
than those of the lighter isotopes, but the trend was not consistent in all samples. 
The accuracy of the analytical procedure was evaluated by analysing a Seronorm 
serum reference material acquired from Sero, Norway. Despite its shortcomings, this 
material was the best of its kind commercially available. As discussed in Chapter 3, 
the manufacturer states up to three different reference intervals for each analyte 
concentration, and none of the analytical values are certified. In this context, it is 
worth mentioning that several investigators have reported analytical results for Mo 
and Se that differed significantly from the reported values in the serum material [191, 
311, 312]. However, to this author’s knowledge, no discrepancies regarding P, Mg, 
Ca and Sr have been reported.  
The Seronorm reference material was analysed at regular intervals and it was 
always included at least once when a series of serum samples was measured. Table 
5.7 presents a summary of the measured concentrations. Excellent agreement 
between measured and reported values was found for Sr.  
Table 5.7 Measured (mean ± SD) and reported (95% confidence interval) values for the serum 
reference material Seronorm Trace Elements Serum, Level 2. 
 Sr (µg L-1) Sr (mg L-1) Mg (mg L-1) P (mg L-1) Ca (mg L-1) 
Found 134 ± 11 1.08 ± 0.078 31.5 ± 8.6 108 ± 31 120 ± 22 
Reported 130 ± 5* 1.01† 27.3-32.2 39-44 108-126 
*Mean ± SD, †Prepared by adding Sr to the Seronorm material 
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It should be noted that the strontium concentration in the certified reference sample 
was about 4 times higher than the lowest concentration found in a sample. Therefore, 
the accuracy of these analyses may not be properly evaluated by using the reference 
material. The measured concentrations were, however, at least three orders of 
magnitude above the LOD and 5 times higher than the lower limit of analysis (cf. 
Chapter 6) for which reason the validation was expected to be adequate.  
The mean values of Mg and Ca were also within the reported reference interval, 
whereas the concentration of P was considerably overestimated as compared with the 
reported value. The reason for poor accuracy in the P determination was not 
investigated further, but it is most likely a result of N- and C-based spectral 
interferences (cf. Table 5.3, p 71), arising from the organic material in the serum 
samples. Likewise, the relatively large standard deviation observed for Mg is 
probably also a result of spectral interferences disturbing mass peak resolution at the 
low masses. A control chart showing all individual Sr results is presented in Chapter 
6, p 92.  
5.3.10 Analysis of rat serum 
5.3.10.1 Strontium 
The results of the analysis are presented in the tables below. The Sr 
concentrations found in the control groups were generally in good agreement with 
previously reported natural Sr levels in serum [112, 313, 314]. As expected [118], 
treatment with SrR caused a dramatic increase in serum Sr concentrations. In both 
studies, serum Sr levels in the Sr treated groups increased with approximately two 
orders of magnitude compared with the control groups.  
Table 5.8 Animals, treatment and serum Sr (mean ±SD) in the fracture study [8].  
 Group 1 Group 2 Group 3 Group 4 
No. of animals 21 18 19 18 
Fracture healing 3 weeks  3 weeks 8 weeks 8 weeks 
SrR treatment No Yes No Yes 
Serum Sr (µg L-1) 92 ± 101 (10.37 ± 0.89)·103 45 ± 16  (8.99 ± 0.77)·103 
Serum Mg (mg L-1) 31.1 ± 6.3 28.9 ± 5.6 29.2 ± 7.2 30.1 ± 4.9 
Serum P (mg L-1) 184 ± 43 160 ± 60 176 ± 55 134 ± 33 
Serum Ca (mg L-1) 99.6 ± 10.2 98.9 ± 8.9 101.3 ±11.2 98.7 ± 16.3 
Perhaps a bit surprisingly, the group mean of Group 2 in the fracture study was 
significantly higher than that of Group 4, even though Group 4 was treated for a 
longer period of time. This indicates that the transport of Sr from the intestine to the 
blood has reached saturation already after 3 weeks. Tentatively, it may also suggest 
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that the longer treatment time induced a more efficient transport of Sr from the blood 
to the intestinal lumen, supporting the idea put forth by Nielsen [13] that active 
transport of Sr to the lumen may act as a mechanism for homeostatic control of Sr at 
high Sr blood levels.  
The large relative standard deviations observed in Group 1 in the fracture study 
and Groups 2 and 4 in the Botox study are results of one or more sample values that 
were significantly different to the other samples in the respective groups. In the 
fracture study, three samples in Group 1 contained significantly higher Sr 
concentrations (317-388 µg L-1 Sr) than the remaining samples (44-77 µg L-1 Sr). In 
the Botox study, Group 2 contained one value that was abnormal (424 µg L-1 Sr) 
compared to the rest of the group (42-76 µg L-1 Sr), while three samples (0.35-3.2 
mg L-1 Sr) in Group 4 contained significantly different concentrations (remaining 
range 49-103 µg L-1 Sr). Since none of these groups were treated with Sr, it was 
much unexpected to find such high serum concentrations. The reason remains 
unclear, but it may be a result of cross-contamination during the sampling or 
preparation steps. However, as no errors or irregularities could be identified by 
consulting the study journals, the abnormal results could not be marked as outliers 
and they are therefore included in the group means and SDs. 
Table 5.9 Animals, treatment and serum Sr (mean ±SD) in the Botox study. 
 Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 
No. of 
animals 
12 12 12 12 12 12 
Treatment None Vehicle Botox Botox 
PTH 
 
Botox 
Strontium 
PTH 
Botox 
Strontium 
Treatment 
time 0 days 4 weeks 4 weeks 4 weeks 4 weeks 4 weeks 
Killed Study start Study end Study end Study end Study end Study end 
Serum Sr 
(µg L-1) 43.5±5.2 84±109 48.5±6.7 (0.57±1.1)·10
3 (9.4±1.0)·103 (7.85±0.49)·103 
 
5.3.10.2 Magnesium, Calcium and Phosphorous 
Mg, Ca and P were determined in the fracture study only (Table 5.8). In 
agreement with previous studies on strontium treatment in rats, no significant 
differences in serum concentrations of the three elements were observed between the 
groups. The observed Ca concentrations were in excellent agreement with values 
previously reported in rats, while the Mg concentrations were approx. 25% lower 
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[112, 313, 314]. However, the observed Mg levels were in very good agreement with 
rat serum Mg measured by another technique in the study presented in Chapter 7.  
The measured P concentrations were much higher than what has been reported 
earlier, owing to the poor accuracy of the P determination. No statistical difference in 
serum P was found between the groups. Omdahl et al. [48] reported consistently 
lower serum phosphate in rats kept on a Sr-rich diet compared with rats kept on a 
low-Sr diet, while Schrooten et al. observed no significant differences in serum 
phosphorous between rats treated with Sr and a control group [314]. In the present 
study, the poor accuracy and large group SDs make it difficult to make any reliable 
biological inference about the treatment effect on serum P.  
5.4 Conclusion 
A procedure for determination of Mg, P, Ca and Sr in serum using ICP-MS has 
been established and optimised. Rh was found to be a suitable internal standard for 
all analytes. By running the instrument in dual detector mode, a linear response range 
of more than four orders of magnitude was obtained. To enable determination of the 
natural trace-levels of Sr, a sample introduction system with a concentric nebuliser 
and a desolvation unit was applied. The inlet system reduced the generation of oxides 
in the ICP and increased the sensitivity for Sr by a factor of 14 compared with a 
conventional cross-flow nebuliser. The sample preparation was based on direct 
dilution with diluted nitric acid, omitting sample digestion. This approach 
considerably reduced the time required for sample preparation, but the high content 
of organic material in the samples gave rise to a severe clogging of the sample inlet 
tube. Good accuracy was obtained for Mg, Ca and Sr, whereas serum P was grossly 
overestimated, probably due to spectral interferences from organic serum 
components. It must be concluded that the analytical procedure was very well suited 
for determination of Ca and Sr, adequate for determination of Mg, but unsuited for 
determination of P. The analysed serum samples from two studies in rats showed that 
treatment with strontium ranelate for 3, 4 and 8 weeks increased the concentration of 
Sr in serum about two orders of magnitude, while concentrations of Mg, P and Ca 
were maintained.  
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6 Uncertainty calculations and sampling 
 
CHAPTER SIX 
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6.1 Introduction 
This chapter presents a discussion of measurement uncertainty calculations 
associated with the ICP-MS analysis of Sr. Before the samples from the first animal 
study (4-week dog) were analysed, a complete uncertainty budget was constructed 
for the analytical procedure. The assessment of the uncertainties associated with the 
ICP-MS measurements was used for evaluating whether the methods were fit for the 
analytical purpose. In order to reach reliable clinical conclusions regarding the 
treatment effects of strontium on the tested animals, it was essential that the 
measurement uncertainty was considerably lower than the expected biological 
variations related to the treatment. In addition, the sampling procedure that was used 
for taking samples from bones from test animals is also discussed.   
6.2 Uncertainty budget 
The uncertainty budget was produced in accordance with the guidelines 
presented in the Guide to the expression of uncertainty in measurement (GUM) [195] 
and the Eurachem/CITAC guide Quantifying Uncertainty in Analytical measurement 
(QUAM) [196]. The sample preparation procedure and the magnitude of the 
uncertainty contributions from weighing, dilutions, measurement and traceability are 
presented in Appendix II. It was concluded that the uncertainty originating from the 
ICP-MS analysis was by far the most dominating contribution to the total 
uncertainty, while the repeatability and tolerance of the equipment used for preparing 
the sample solutions were negligible in comparison. Similar conclusions were 
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reached for the two long-term animal studies (26-week rat and 52-week dog), even 
though the samples from these studies were analysed using a more recent apparatus 
(ELAN 6000 ICP-MS) than the one used for the 4-week dog study (ELAN 5000). 
Hence, the uncertainty of the sample preparation will not be discussed further in this 
chapter. 
6.3 Measurement uncertainty of the ICP­MS analysis 
6.3.1 Regression equations 
Being the dominating uncertainty contribution, it was particularly important that 
the uncertainty of the ICP-MS measurements was properly evaluated. This section 
presents the most important equations used for the calculations. The remaining 
regression equations are summarised in Appendix III. 
In order to avoid complex, non-linear regression calculations, it was firstly 
ensured that the relation between the normalised response and the analyte 
concentration was well described by a linear function. Contrary to common practise, 
evaluation of linearity was not based on the magnitude of the correlation coefficient 
(r2), but rather performed by testing for a random sign distribution of the regression 
residuals (Wald-Wolfowitz runs test [315]). Once linearity was established, the 
calibration data was fitted to the function  
 
ܫௌ௥
ܫோ௛ ൌ ߙܥௌ௥ ൅ ߚ (6-1) 
where CSr is the concentration of Sr, and ISr and IRh are the intensities of Sr and Rh, 
respectively.  (slope) and  (intercept) denotes the regression coefficients. Figure 
6.1 shows a calibration curve and the corresponding regression residuals obtained 
from five replicate measurements at each standard concentration. Inspection of the 
residuals revealed clear heteroscedasticity, which in theory require application of 
weighted least-squares regression (WLSR). In ordinary least-squares regression 
(OLSR) all calibration points are given equal weight in the calculations, which is 
technically incorrect if they do not have equal variance [230].  
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Figure 6.1 Calibration line (WLSR) and residuals for 86Sr for the concentration range 0.5-200 µg L-1 
(pulse mode). Five replicates were measured at each concentration.  
The idea behind weighing is to attach most importance to data that is known with 
the highest statistical precision. However, it is rarely straightforward to assign proper 
weights to the individual calibration points. For any least-squares fit, the most 
statistically precise parameter estimates are obtained only if the data are weighed 
inversely as the true response variance (wi = i-2). Unfortunately, 2 is never truly 
known for real data. It is well established that merely using the variance of repeated 
measurements to assign weights is not adequate, and the estimation of the variance 
function is therefore very important [316, 317]. Many different weights have been 
applied for different analytical applications. For a calibration function, y = ax + b, 
weights such as x-0.5, x-1, x-2, y-0.5, y-1 and y-2 have been suggested [318]. In this 
project, the variance was assumed to follow the empirical equation suggested in the 
CITAC/Eurachem guide [196]: 
 ݑଶ ൬ܫௌ௥ܫோ௛൰ ൌ ݏ଴
ଶ ൅ ൬ܫௌ௥ܫோ௛ · ݏଵ൰
ଶ
 (6-2) 
This equation satisfies the residual pattern seen in Figure 6.1, where the variance is 
practically constant at the low response limit and proportional to u(ISr/IRh) at the high 
response limit. The response variance was measured for each standard concentration, 
and the data was fitted to equation (6-2) using the Solver function in Microsoft 
Excel®. The weights were then calculated by 
 ݓ݅ ൌ
1
ݑ2݅ · ෍
1
݉ · ݑ2݅݅
 (6-3) 
88    
 
 
where u = u(ISr/IRh) from equation (6-2) and m is the number of calibration standards. 
In equation (6-3) the weights are scaled such that the sum of the weights equal the 
number of calibration standards: ∑ ݓ௜ ൌ ݉௜ . 
Clearly, the calculations involved in WLSR are far more complex than those 
required for OLSR. Even so, it has been our experience there is no or very little 
practical difference between the calibrations functions obtained by OLSR and WLSR 
when working with ICP-MS (cf. Table 2, Appendix II). This is supported by the 
regression equations calculated from the data in Figure 6.1. Table 6.1 shows that the 
regression parameters were similar within their respective uncertainties. Based on 
these observations, it can be debated whether it was worthwhile going through the 
time-consuming WLSR routine. However, it was thought to be necessary for 
obtaining a complete and theoretically sound treatment of the calibration data. 
Table 6.1 Parameter estimates for calibration functions determined by ordinary least squares 
regression (OLSR) and weighted least squares regression (WLSR) for 86Sr. 
Regression method  Calibration function
OLSR 
ூೄೝ
ூೃ೓ ൌ 0.02255ሺേ0.000047ሻ · ܥௌ௥ ൅ 0.0035ሺേ0.0031ሻ 
WLSR 
ூೄೝ
ூೃ೓ ൌ 0.02275ሺേ0.00015ሻ · ܥௌ௥ ൅ 0.00081ሺേ0.00058ሻ 
 
After calculation of a (weighted or unweighted) calibration function, the 
concentration of Sr in a sample can be found by rearranging equation (6-1): 
 ܥௌ௥ ൌ
ூೄೝூೃ೓ െ ߚ
ߙ  (6-4) 
The uncertainty estimate of the predicted concentration can be calculated by 
propagating the uncertainties associated with the quantities in equation (6-4), 
resulting in [195, 319] 
where u(ISr/IRh) is the uncertainty of the normalised sample response, u() and u() 
are the uncertainties of the regression coefficients and r(,) is the coefficient of 
correlation between  and  given by [320] 
 ݑሺܥௌ௥ሻ ൌ
1
ߙ ඥݑሺܫௌ௥ ܫோ௛⁄ ሻଶ ൅ ݑሺߚሻଶ ൅ ሺݑሺߙሻ · ܥௌ௥ሻଶ ൅ 2ܥ௦௥ݑሺߙሻݑሺߚሻݎሺߙ, ߚሻ (6-5) 
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 ݎሺߙ, ߚሻ ൌ െ
1
√݉ ·
∑ ܥௌ௥,௜௜
ට∑ ܥௌ௥,௜ଶ௜
 (6-6) 
The above equations were applied for evaluation of the measurement uncertainty as 
described in the following sections. 
6.3.2 Single­day calibrations 
Throughout this project, a suitable reference material (RM) was always included 
in the ICP-MS analysis of samples from test animals. Prior to analysis, the 
performance of the instrument was optimised and validated as described in Chapter 
5. As described above, the calibration of the instrument, and the calculations of 
sample concentrations and associated uncertainties, were performed in accordance 
with conventional recommendations [196, 230, 315, 321]. However, it was soon 
observed that the uncertainty estimates calculated from the linear regressions (either 
weighted or unweighted) did not correspond well with our observations. This can be 
illustrated by looking at results from analysis of the Seronorm Serum RM at four 
different days (Table 6.2). The first result was perfectly in agreement with the 
reported value of the RM, while the next two were respectively below and above the 
reported range. The second measurement was close to the upper limit of the reported 
range, but because of the low uncertainty (1.9%), the result was not within the 
reported concentration range, and thus significantly different from the reference 
value. The fourth result was, within the uncertainty, again in agreement with the 
reference value. Furthermore, the table reveals a large difference in the uncertainty 
estimates of the four measurements, ranging from 1.9 – 8.3% relative uncertainty. 
This is unfortunate, as identical samples with identical levels of analyte would be 
expected to give very similar uncertainty estimates. The calibration of the ICP-MS 
and the application of an internal standard were expected to correct appropriately for 
day-to-day variations in the instrumental response, but, as judged from Table 6.2 this 
seems not be the case. 
Table 6.2 Results from analysis of Seronorm Trace Elements Serum 
RM. WLSR was applied for the calibration. 
Repetition  
(separate days) 
Result ± expanded uncertainty 
(coverage factor, k = 2) 
1 131 ± 11 
2 145 ± 3 
3 106 ± 4 
4 143 ± 7 
Reference value (± 2SD) 130 ± 10 
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After seeing these results, the ICP-MS and the sample introduction system were 
thoroughly checked for clogging, unstable sample flow and other factors that might 
have disturbed the measurements. In addition, performance checks for precision, 
sensitivity, oxides, etc. were conducted regularly, and the response of the internal 
standard was monitored continually during the measurements. We could identify no 
errors or signs of reduced instrumental performance. Hence, it was found that the 
measurements had not been compromised, and consequently we could not justify 
rejection of any results as outliers. We therefore concluded that the measurement 
uncertainty was underestimated. 
6.3.3 Pooled calibrations 
In view of the above observations, we abandoned the uncertainty estimates based 
on single-day calibrations and applied instead an alternative method of pooled 
calibrations, which has previously proven useful for a variety of analytical 
techniques at our laboratory: ICP-MS [10], ETAAS [322], UV/Vis spectroscopy 
[323], gas chromatography-MS [324, 325] and ion chromatography [326]. In an 
attempt to explain and predict the spread of the sample results by exploiting the long-
term variation in the calibration data, all of the calibrations and RM data were 
collected and pooled into one single dataset. The determination of 86Sr in the 
Seronorm serum RM is used again as an example. 86Sr was chosen because the 
abundance of this isotope allows for measurement in a reasonably wide concentration 
range (up to 200 µg L-1) without producing intensities that saturate the pulse stage of 
the detector. The high abundance of the most abundant isotope, 88Sr, resulted in pulse 
stage saturation already at 15 µg L-1.   
The serum RM was analysed through a period of approximately four weeks. 
During this time a total of 13 sets of calibration data were recorded. The graph 
shown in Figure 6.2 was produced by collecting all this calibration data and 
calculating a single calibration function using ordinary least-squares regression. An 
estimate of the predicted uncertainty of the Sr determination was then calculated 
from this calibration line, using equation (6-5). In this case, u(ISr/IRh) for the sample 
was estimated from the pooled calibrations using equation (1-4). This led to a 
standard uncertainty estimate of ±10.5 µg L-1 Sr for the serum RM analysis. It should 
be noted that the pooled calibration can only be used for uncertainty calculations and 
not for determining the concentration of the RM.  
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Figure 6.2 Pooled calibration data recorded during a period of four weeks. A single calibration 
function was calculated from all the data. The Sr intensities were normalised using an internal 
standard  of 5 µg L-1 Rh. 
The uncertainty estimate was evaluated by comparing it with the SD of the 
results from the individual serum measurements: 
 ܵܦሺܥௌ௥ሻ ൌ ඩ෍
ሺሾܥௌ௥ሿ௜ െ ܥௌ௥തതതതሻଶ
݊ െ 1
௡
௜ୀଵ
 (6-7) 
where CSr is the Sr concentration found by each individual analysis. The SD of the 
individual determinations was determined as ±11.2 µg L-1 Sr.  
The results of the RM analyses are summarised in Table 6.3, showing excellent 
correspondence between the uncertainty estimate calculated from the pooled 
calibrations and the observed SD of the 20 individual determinations. Conversely, 
the uncertainties calculated from the single-day calibrations were often 
underestimated compared with the observed variation. Figure 6.3 presents a control 
chart showing the individual results and uncertainties together with the reported 
concentration range of the RM. The mean of the 20 measurements was 134 µg L-1, 
which is within 1 SD of the reference value. The chart shows that three of the results 
are in disagreement with the reported concentration, when the individual 
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uncertainties were applied. However, as no experimental or instrumental errors had 
been identified, it was considered incorrect to reject these results. Instead, pooled 
data were applied to obtain a better estimate of the measurement uncertainty. 
Table 6.3 Results, standard uncertainties (SU), standard deviations (SD) and relative 
uncertainty/deviation (RSU/RSD) for determination of Sr in Seronorm Serum RM. 
 Result (µg L-1)  RSU/RSD (%) 
Range of individual determinations 
(result ± SU) 
106.1 – 152.4 (±3.2) – (±10.1)  2.0 – 7.1 
Combined individual determinations 
(mean ± SD) 
133.7 ±11.2  8.4 
Pooled calibrations (SU) - ± 10.5  7.8 
Reported concentration 130 5  3.8 
 
 
Figure 6.3 Control chart of 20 determinations of Sr in a serum CRM. Error bars show expanded 
uncertainty (k =2). Blue lines indicate the reported concentration (solid) and 2 standard deviations. 
The mean and SD of all the repetitions were determined as 133.7 ± 11.2 
The mean value of the 20 Sr measurements was in very good agreement with the 
reported value, demonstrating that the accuracy of the analysis was satisfactory. The 
determinations of Ca and Mg also showed good accuracy and a good correspondence 
between the predicted and observed variation (Table 6.4). As described in Chapter 5, 
the determination of serum P suffered from very poor accuracy due to an unidentified 
interference. 
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For the analysis of calcified tissues described in the following chapters, a bone 
meal reference material was used for quality control. As with the serum RM, the 
observed SD of the analytical results was seen to be larger than the uncertainties that 
were predicted by applying single-day calibrations in the uncertainty budget. The 
method of pooled calibrations was therefore also applied for measurements of this 
RM; the results are summarised in Table 6.4. Generally, the SDs of the individual 
bone meal measurements were slightly lower than predicted by the pooled calibration 
data, but the correspondence was found to be very good for the purpose of the 
analysis. For both serum and bone, the determinations of Mg, P and Ca showed 
considerably higher SDs than the Sr determinations. This is due to the higher 
occurrence of interferences at the low masses (cf. Table 5.3, p 71).  
Table 6.4 Analytical results, standard uncertainties (SU), standard deviations (SD) and 
certified/reported values for the reference materials Seronorm Serum and NIST bone meal. 
Seronorm Trace Elements Serum Sr (µg L-1) Mg (mg L-1) P (mg L-1) Ca (mg L-1) 
Individual determinations (mean ± SD) 134 ± 11 31.5 ± 8.6 108 ± 31 120 ± 22 
Pooled calibrations (± SU) ± 11 ± 9.0 ± 13 ± 20 
Reported value / range 
(mean ± SD / 95% conf. int.) 
130 ± 5 27.3 – 32.2 39 – 44 108 – 126 
NIST 1486 Bone meal Sr (µg g-1) Mg (mg g-1) P (mg g-1) Ca (mg g-1) 
Individual determinations (mean ± SD) 269 ± 14 4.58 ± 0.30 122.8 ± 9.3 265 ±  27 
Pooled calibrations (± SU) ± 19  ± 0.61    ± 13 ±  40 
Certified value 
(mean ± expanded uncertainty) 
264 ± 7 4.66 ± 0.17 123.0 ± 1.9 265.8  ±  2.4 
 
Figure 6.4 shows a control chart of 63 determinations of Sr in the bone SRM. 
The average of the analyses was within the expanded uncertainty of the certified 
value, and it was concluded that the measured concentration was in agreement with 
the certified value. Similar conclusions were reached for Mg, P and Ca the in the 
bone SRM (Table 6.4).  
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Figure 6.4 Control chart of 63 determinations of Sr in NIST Bone meal. Blue lines indicate the 
reported concentration (solid) and the expanded uncertainty (dashed) of the SRM. The red lines 
indicate the mean (solid) and 2SD (dashed) of all the determinations.  
Based on these findings it was concluded that the pooled calibration data 
provided a reliable and realistic uncertainty estimate of the analysis. Consequently, 
this method was used for determining the measurement uncertainty for ICP-MS 
analysis of serum, bone and tooth samples.  
6.3.4 LLA 
Pooling all calibration data allows for calculation of the lower limit of analysis 
(LLA) [322, 323]. The LLA value is defined as the lowest concentration that can be 
determined from the pooled calibrations with an uncertainty of less than 50%. The 
LLA is given by 
 LLA ൌ 1ߙ ඨ
ݏ௕௟௔௡௞ ൅ ݏఉ
2  (6-8) 
where sblank is the SD of a series of blank measurements, s the SD of the intercept of 
the pooled calibration function and  is the slope. The LLAs for the most abundant 
analyte isotopes are shown in Table 6.5. For comparison, the limit of quantification 
(LOQ) was also calculated using the common 10·sblank formula. The LLA exceeds 
considerably the LOQ for all analytes, in particular for Sr and Mg, where a 
difference of respectively three and one orders of magnitude is seen. This shows that 
using the instrumental LOQ as a basis for deciding the lowest quantifiable 
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concentration may lead to very large measurement uncertainties at concentrations 
below the LLA. According to the pooled calibrations, analysis is not feasible at Sr 
concentrations below 0.69 µg L-1, strongly contradicting the manufacturer’s 
specifications (ELAN 6000 without Apex: LOD < 1 ng L-1 Sr).  
Table 6.5 LLA and LOQ (10) for the Apex-ICP-MS analysis.  
 Concentration (µg L-1) 
 88Sr 24Mg 31P 44Ca 
LLA 0.69 0.88 18 26 
LOQ 0.02 0.08 4 11 
 
As the variance of the instrumental response depends on the analyte 
concentration (cf. Figure 6.1), it is worthwhile investigating how the relative 
measurement uncertainty changes with the concentration. Figure 6.5 shows that the 
uncertainty generally decreases with increasing concentration, attaining values of 
<10% at concentrations above 5 µg L-1. As a consequence, it may be suggested that 
samples should not be diluted to a Sr concentration below 5 µg L-1, if the uncertainty 
associated with the ICP-MS analysis is desired to be less than 10%. 
 
Figure 6.5 Relative uncertainty estimate calculated by equation (6-5) vs. the Sr concentration. 
6.4 Sampling 
6.4.1 Theory of sampling 
Generally, the purpose of taking samples is to collect a smaller, manageable 
portion of the material of interest, which can then be used to describe the original 
material. Hence, the sample should be representative of the material. Procedures and 
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theoretical background for obtaining representative samples are included in the 
Theory of Sampling (TOS), which was introduced and developed by Gy [327]. 
Detailed explanations about the fundamental aspects of TOS are beyond the scope of 
this text but can be found in the literature [327-330]. It will merely be mentioned 
that, in TOS terms, a correct sampling procedure means that all constituent elements 
of the original material have an even, non-zero, probability of being selected. This is 
called the Fundamental Sampling Principle (FSP), which can never be compromised 
if a representative sample is to be obtained. The need for developing a correct 
sampling procedure for this project arose as the results from the first animal study 
showed that Sr was very heterogeneously distributed in the bones (cf. Appendix II). 
The variance associated with sampling (TOS: sampling error) is caused by the 
existence of heterogeneity, and representativity is therefore closely linked to 
heterogeneity. 
6.4.2 Sampling for bone and teeth analysis 
After the 4-week dog study, mid-sections of the femurs were sent to our laboratory 
for analysis (Figure 6.6). These bones were too large to be digested whole, and 
sampling was therefore required. A cleaned bone was submerged in liquid nitrogen 
for an hour, placed in a plastic bag and fractured with a hammer. The bone pieces 
were then dried at 110°C for five hours. The dried fragments were spread out on a 
piece of weigh-paper and a suitable amount of bone was collected by taking out 
pieces at random with a pair of tweezers. These bone pieces were then weighed and 
digested.  
 
Figure 6.6 Photos of the cleaned mid-shaft of a femur (left), the large bone pieces from fractionating 
the femur with a hammer (middle) and the small bone pieces after 2 min of grinding (right). Notice 
the large size difference of the bone pieces in the middle picture.  
Because of the large size difference between the bone pieces (Figure 6.6), all bone 
material did not have equal probability of being selected, the probability being close 
to zero for the smallest bone pieces. This was a violation of the FSP. By taking 
several subsamples from the same femur, it was confirmed that the variance of the Sr 
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concentration in these samples was much too large to be explained exclusively by the 
analytical uncertainty (Figure 6.7).  
 
Figure 6.7 Analytical results from repeated sampling of a femur from an animal treated with 3000 mg 
kg-1 day-1 SrM for 4-weeks. The charts illustrate the sample heterogeneity after fractionation using a 
hammer (a) and an analytical mill (b). Error bars show the expanded uncertainty according to the 
uncertainty budget. 
Consequently, it was concluded that the applied sampling procedure was not 
representative and had to be improved. With the principles of TOS in mind, it was 
necessary to 1) reduce the heterogeneity of the primary sample (the whole femur) 
before taking subsamples and 2) to observe the FSP. This was achieved by applying 
an analytical mill to reduce the grain size of the bone pieces. The sampling procedure 
was therefore changed to include 2 min of grinding of the bone pieces. After the 
grinding, the mill was left to stand for a few minutes, in order to allow the finer 
particles to settle. The bone powder was then carefully poured out in a thin line on a 
weigh-paper, in effect making all the bone material accessible for sampling. 
Increment samples were taken by passing a folded piece of thin paper through the 
line, while making sure that each increment covered the whole cross-section of the 
material. In TOS, such a design is known as 1-dimensional sampling. The increments 
were collected, weighed and transferred to the digestion vessel, thus creating a 
representative composite sample. 
6.5 Conclusion 
This chapter has demonstrated that the measurement uncertainty associated with 
determination of Sr using ICP-MS was often underestimated when applying WLSR 
to calibration data obtained on a single day. To account for the observed variation in 
the analytical results, calibration data from many different days were pooled into one 
data set. The uncertainties predicted by these combined calibrations were in very 
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good agreement with the observed variation in the RM results. This new principle of 
processing calibration data successfully provided a satisfactory estimate of the 
measurement uncertainty related to the ICP-MS analysis, ensuring reliable 
determinations of the analytes of interest. The analytical procedure showed excellent 
accuracy for all analytes in the bone CRM and for Sr, Mg and Ca in the serum RM.  
Substantial differences between the LOQ and LLA were observed, and it was 
suggested that the LLA is a useful parameter for estimating the lowest concentration 
at which a sample can be reliably measured. Thus, analysis between the LOQ and the 
LLA cannot be expected to provide reliable results. 
Exploiting the concepts of TOS, a new sampling procedure reduced the sampling 
error related to the collection of subsamples from bone and teeth. This was 
accomplished by decreasing the heterogeneity of the sample through a substantial 
reduction in the average particle size, and through a thorough mixing of the sample 
material. Additionally, the FSP was observed by ensuring that all sample material 
was equally accessible for sampling. 
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Influence of strontium on mineral 
composition in rats after 26 weeks of 
treatment with strontium malonate 
 
7.1 Introduction 
This chapter presents a 26-week study on the effects of strontium malonate 
(SrM) treatment on teeth, bone and serum in rats. Concentrations of Sr, Mg, Ca and P 
in incisors and femur were determined using ICP-MS, and bone mineral density 
(BMD) of femur and vertebrae was measured using DEXA. The ICP-MS analyses 
were performed in collaboration with Søren R. Sørensen [10], MSc. The BMD 
measurements were performed by Dr. Jens-Erik Beck Jensen, MD, at Hvidovre 
Hospital. 
As described in Chapter 2, the incorporation of Sr happens faster in newly 
formed mineralised tissue than in old. In humans, there is an almost complete 
absence of remodelling of the dentine matrix, and the propensity for incorporation Sr 
is therefore very small in adult humans. The situation is different in rodents, as 
rodent incisors are open-rooted and continue to erupt and grow throughout life [331, 
332]. It was therefore expected that rat incisors would be suitable indicators for 
SrM’s ability to make Sr available for incorporation in calcified tissues. Femur bone 
was chosen for comparison because the mid-shaft of the femur is purely cortical and 
therefore has a relatively low turnover rate. 
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7.2 Experimental 
7.2.1 Animals 
7.2.1.1 Study design 
The experiment was performed in 80 male and 80 female SPF Wistar rats of the 
strain HanTac:WH (GALAS) from Taconic M&B A/S, Ejby, Denmark. The in-life 
part of the study was conducted at LAB Scantox, Ejby, Denmark under GLP 
conditions. At the start of the acclimatisation period, the rats were approximately 5 - 
6 weeks old. An additional 20 animals (10 of each sex) were available until 
completion of the acclimatisation period for replacement purposes. An 
acclimatisation period of 22 days was allowed in order to reject animals in poor 
condition or at the extremes of the weight range and to allow animals to adjust to the 
housing conditions and recover from any adverse effects induced by the transport. 
On the day of arrival, the animals were allocated randomly to 4 treatment groups and 
a group of extra animals, using a randomisation scheme. Prior to commencement of 
treatment, 11 animals were re-allocated in order to reduce possible differences in 
average body weight between the groups [333]. 
Table 7.1 Design of 26-week study of strontium malonate treatment in rats. 
Group SrM dose (mg kg-1 day-1) 
SrM dose 
formulation 
(mg mL-1) 
No of animals 
Males Females 
1 0 0 20 20 
2 100 20 20 20 
3 300 60 20 20 
4 1000 200 20 20 
 
7.2.1.2 Treatment 
The vehicle for preparation of the dose formulation was 0.5% carboxymethyl 
cellulose (0.5% CMC). The vehicle was prepared with de-ionized water for all 
treatment groups. The dose formulations were prepared by suspending SrM in the 
vehicle. The animals in Group 1 (control) were treated with vehicle (0.5% CMC). 
The animals in Groups 2, 3 and 4 were treated respectively with 100, 300 and 1000 
mg strontium malonate per kg body weight per day, corresponding to 46, 138 and 
460 mg kg-1day-1 Sr2+. All animals were weighed upon arrival, on the day of re-
allocation, on the first day of treatment (Day 1) and weekly thereafter. The daily dose 
was given by oral gavage according to the most recent body weight data, and the 
dose volume was 5 ml per kg body weight [333].  
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7.2.1.3 Diet and drinking water 
A complete pelleted rodent diet "Altromin 1314" (for growing animals) was 
available ad libitum until Day 49 of the dosing period. On Day 50 and throughout the 
remaining part of the study, the animals were offered ad libitum “Altromin 1324” 
(for adult animals). Altromin was supplied by Chr. Petersen, Ringsted, Denmark. 
The animals had free access to bottles with domestic quality drinking water acidified 
with hydrochloric acid to pH 2.5 in order to prevent microbial growth. Analyses for 
relevant possible contaminants were performed regularly on the drinking water prior 
to acidification [333]. 
7.2.1.4 Collection of blood samples 
In week 26 blood samples were taken from all animals (approx. 750 µl) for 
clinical pathology assessment. Blood samples were drawn from the orbital venous 
plexus during CO2/O2 anaesthesia. The samples were analysed for Mg, Ca, P and 
bone specific alkaline phosphatase (BSAP) on a Hitachi 902 automated clinical 
chemistry analyser by a commercial accredited laboratory. Two additional sets of 
blood samples for determination of strontium in serum were collected halfway 
through the study (week 13) and at the end of the study (week 26). 2 and 24 hours 
after Sr administration, 0.5-0.6 ml blood from orbital venous plexus was taken from 
96 animals during CO2/O2 anaesthesia. After 30-60 minutes the collected blood was 
centrifuged (10 minutes, 1270 G, 20°C) and the serum stored at -18°C. The serum 
samples were analysed by a commercial accredited laboratory [333]. 
7.2.1.5 Collection of bone and teeth samples 
A piece of the lumbar vertebral column (L2-L4), the left femur, and a tooth (front 
incisor) was removed from each animal. The tissue samples were stored in suitable 
plastic containers at -18°C until analysis. Incisors from all animals as well as 24 
femurs (3 males and 3 females from each group) were analysed for concentrations of 
Mg, P, Ca and Sr. 
7.2.2 Densitometry 
 Bone densitometry measurements were performed on cleaned and dried femur 
and vertebra samples, using a Lunar PIXImus DEXA scanner designed especially for 
small samples. The femur samples were scanned once each for quantitative 
measurements of bone mineral content and density. 
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7.2.3 ICP­MS analysis of bone and teeth 
7.2.3.1 Equipment and reagents 
The chemicals used were of at least p.a. grade. The samples were digested with 
65% nitric acid (Merck Suprapur), 30% hydrochloric acid (Merck Suprapur) and 
35% hydrogen peroxide (Riedel de Haën p.a.) in an Anton-Paar Multiwave 3000 
microwave oven. Ultra-pure water (18.2 M·cm, Milli-Q Plus, Millipore) was used 
throughout. All applied glassware was cleaned in 4 M HNO3 at 80°C for 40 min in 
an automatic acid washer (Miele). Measurements were performed using a Perkin-
Elmer ELAN 6000 ICP-MS equipped with a cross-flow nebuliser. The parameter 
settings are presented in Table 7.2. Instrument control and data collection were 
performed using the software supplied with the instrument (ELAN v. 3.3 Patch 6), 
while the data processing for calibration and analysis was carried out by exporting 
the raw data to external software (Microsoft Excel®, Origin® and Minitab®). The 
ICP-MS was allowed to stabilise for 30 min before analysis was commenced. The 
analytical performance (sensitivity, precision, oxides and doubly-charged ions) was 
checked using a standard solution containing 10 µg L-1 Be, Mg, Ca, Rh, In, Ba, Ce 
and Pb.  
Table 7.2 Settings on the ELAN 6000 ICP-MS. 
RF power 1000 W 
Nebuliser argon flow 0.95-1.0  L min-1 
Sample flow 0.480 mL min-1 
Working pressure 1.8·10-3 Pa 
Background pressure 2.4·10-4 Pa 
Torch box temperature 40-43 °C 
Lens voltage 7.5-8.75 V 
Pulse detector voltage 1500 
Detector mode Pulse 
Sweeps pr. reading 10 
Scan mode Peak hopping 
Readings pr. replicate 1 
No. of replicates 3 
Dwell time pr. mass 100 ms 
Measured isotopes  24Mg, 25Mg, 26Mg 
31P 
42Ca, 43Ca 
84Sr, 86Sr, 87Sr, 88Sr 
103Rh (internal standard) 
 
7.2.3.2 Standards 
Standards were prepared in 0.1 M NHO3 (Merck, Suprapur) by dilution of two 
multi-element stock standard solutions (1000 mg L-1 Sr PlasmaCAL, SCP Science; 
P/N 4000 ICP-MS ICS solution A, CPI International). A total of 20 standards 
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containing concentrations of 1 µg L-1 to 5 mg L-1 of all analytes were used. 10 µg L-1 
Rh (Fluka) was added to all standards and samples for internal standardisation. 
7.2.3.3 Cleaning procedure 
Nitrile gloves were worn at all times when handling undigested biological 
samples. Tools and lab bench were cleaned with ethanol and water at the end of each 
working day. The tooth and bone samples were stored at -18°C until analysis. The 
first step in the preparation was to heat the samples for 4-5 min in a standard 
domestic microwave oven at a low power (270W). This eased the following removal 
of soft tissue, which was carried out using a stainless steal scalpel. The samples were 
then submerged in 35% H2O2 (Riedel de Haën, p.a.) for 10 min, and washed with 
ethanol and copious amounts of ultra-pure water. Any remaining lean tissue, 
periosteum, cartilage or marrow was removed with a scalpel and water, and the 
incisors were separated from the jaw (Figure 7.1). The samples were dried at 110 °C 
for 2 hours and cooled to room temperature in a dessicator before being weighed 
(Mettler AE 260 DeltaRange) and transferred to a quartz vessel (Figure 7.2a) for 
digestion.  
  
Figure 7.1 Photographs of femur, lumbar vertebral column (L2-L4) and tooth from 26-week rat before 
(a) and after (b) the cleaning procedure. 
 
7.2.3.4 Digestion 
The samples were dissolved by microwave assisted high-pressure acid digestion. 
A rotor with eight quartz vessels (Figure 7.2b) was used, each vessel containing a 
sample weighing 22-130 mg (incisors) or 120-300 mg (femurs). The digestion 
procedure is presented in Table 7.3. 
(a) (b) 
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Figure 7.2 Anton-Paar quartz vessels with Teflon cap and digested bone samples (a) and 
rotor for 8 vessels (b).  
 
Table 7.3 Procedure and chemicals used for digestion of incisor and femur from 26-week rat. 
Step Duration (min) Power (W) Chemicals Volume per vessel (mL) 
1 (ramp) 10 0  1200 65 % HNO3 5 
2 (digestion) 10 1200 35% H2O2 3 
3 (cooling) 20 0 30% HCl 0.5 
 
7.2.3.5 Quality control 
The accuracy of the analytical procedure was validated by using the standard 
reference material NIST SRM 1486 Bone Meal. The material was dried and digested 
using the procedure described above. The material provides certified values for all 
elements of interest to this study. 
7.2.4 Statistics 
Data was processed to give mean values and standard deviations for groups and 
gender. Each continuous variable was tested for homogeneity of variance using 
Bartlett's test. If the variance was accepted as homogeneous, analysis of variance 
(ANOVA) was carried out for the variable. If the ANOVA detected any significant 
differences, possible inter-group differences were assessed with Dunnett's test 
(comparing treated groups with a control group). Sr data for both serum and 
mineralised tissues was invariably heteroscedastic, and the data was therefore log-
transformed before analysis. Comparison of regression slopes (OLSR) was 
performed using analysis of covariance (ANCOVA). If the variance was 
heterogeneous, each variable was tested for normality by the Shapiro-Wilk test. In 
(a) (b) 
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case of normal distribution, possible inter-group differences were identified with 
Student's t-test. Otherwise the possible inter-group differences were assessed by 
Kruskal-Wallis's test. If any significant inter-group differences were detected, the 
subsequent identification of the groups was carried out with Wilcoxon Rank-Sum 
test. For all tests, the level of significance was defined as p < 0.05. Calculations were 
performed using Minitab®, Microsoft Excel® and Origin®. 
7.3 Results and discussion 
7.3.1 Cleaning procedure 
The initial sampling from the terminated animals was fairly crude, leaving 
adhering skin, muscles, fat, marrow, etc. on the bones. The purpose of cleaning the 
samples before analysis was to ensure that the analytical results only reflected the 
analytes present in the mineralised tissue and not in the surrounding soft tissues. In 
addition, each incisor had to be separated from the jaw in order to avoid 
contamination from the jawbone. Because of the high number of samples, the 
cleaning step was by far the most time-consuming step in the analytical procedure, 
but it was essential for the purpose of the analysis. Once the samples were cleaned 
and dried, they could be digested directly without sub-sampling; due to their limited 
size, whole samples could easily be contained in the digestion vessels. 
The validation of the analytical method was performed on bone powder, which 
had already been cleaned and homogenised by the manufacturer. Consequently, the 
effect of the initial heating, as well as the cleaning with H2O2 and ethanol, was not 
covered by the validation. There is, however, no reason to presume that these steps 
introduced significant contamination or loss of analytes. Using a similar procedure, 
Roberts et al. [164] found that the loss of sample in the washing solutions from 
cleaning of bones with H2O2 and ethanol were only of minor importance. 
7.3.2 Digestion 
The applied digestion procedure has previously been applied for digestion of 
teeth and femurs from dogs (cf. Appendix II). It was developed using the trial-and-
error method and validated using a certified bone material. During the method 
development, it was observed that inclusion of HCl and H2O2 tended to give slightly 
better recoveries than HNO3 alone. Digestions without HCl sometimes resulted in 
cloudy digestion solutions. Similar observations were reported by Oitridge et al. 
[165], who found that use of a mixture (3:1) of HNO3 and HCl provided a more 
complete dissolution of bone tissue than a pure HNO3 solution. H2O2 was added in 
106  Chapter 7 
 
 
order to improve oxidation of organic matter. Moreover, inclusion of H2O2 resulted 
in solutions virtually free from nitrous fumes, which eased the subsequent handling.  
In the microwave oven, the temperature and pressure in the digestion vessels was 
monitored continually during the digestion (Figure 7.3). The maximum pressure of 
80 bar was reached after about 20 minutes of digestion. At this point, the power was 
reduced as to maintain the maximum pressure for the remainder of the digestion 
program. During this time, the temperature continued to rise and reached its 
maximum level after about 25 minutes. Since NIST suggests that bone powder be 
digested using HF [186], such a procedure was also tested. This did not result in 
better recoveries than those obtained with HNO3/HCl/H2O2, and, in view of the 
safety issues of working with HF, the application of HF for digestion of bones was 
therefore abandoned.  
 
 
Figure 7.3 Graphs showing temperature, pressure and power during digestion of 8 bone samples. The 
temperature was measured in each individual vessel by an IR sensor, while the pressure was measured 
as the combined pressure in all vessels.  
7.3.3 ICP­MS analysis 
The procedures used to establish optimum values for RF power, gas flow, lens 
voltage, quadrupole tuning and detector voltage were similar to those described in 
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Chapter 5. From an analytical point of view, the major differences between the two 
studies can be summarised in the following points: 
1) The digested bone samples contained higher concentrations of Sr than the 
diluted serum samples and were also available in ample volumes. This 
allowed for a conventional cross-flow nebuliser to be used for sample 
introduction instead of the Apex desolvation system. 
2) Contrary to the serum samples, all bone and teeth samples were of necessity 
digested, and therefore all organic macromolecules were completely 
dissolved. Hence, the problems of tube clogging experienced with the serum 
samples were non-existent in this study. 
3) Another consequence of the sample digestion was an absence of any 
noticeable non-spectral interferences in this study. Therefore, it was not 
strictly necessary to include an internal standard for correction of the analyte 
signals. During the method development, it was observed that application of 
Rh as IS increased the measurement uncertainty for determinations of Ca, 
Mg and P, without providing a notable improvement of the accuracy of the 
CRM analysis. Hence, Rh was used as internal standard for determination of 
Sr only.  
4) The ICP-MS was operated exclusively in pulse mode in this study, whereas 
the serum samples were measured in dual mode. 
7.3.3.1 Quality control 
The NIST reference material was analysed at regular intervals and was always 
included when a series of samples was measured (cf. Chapter 6). Table 7.4 presents a 
summary of the measured and certified concentrations. There was very good 
agreement for all analytes.  
Table 7.4 Measured (mean ± SD) and reported (expanded uncertainty) values for the serum reference 
material NIST SRM 1486 Bone Meal. 
 Sr (µg L-1) Mg (mg L-1) P (mg L-1) Ca (mg L-1) 
Found (mean) 269 ± 14 4.58 ± 0.30 122.8 ± 9.3 265 ±  27 
Certified value 264 ± 7 4.66 ± 0.17 123.0 ± 1.9 265.8  ±  2.4 
Recovery 102% 98.2% 99.8% 99.7 
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7.3.4 Serum 
Serum was sampled in study weeks 13 and 26. Samples were taken at 2 and 24 
hours after oral administration, as these times were expected to represent respectively 
the highest and lowest concentrations of circulating strontium. The mean values of 
each group are shown in Figure 7.4. Serum Sr increased substantially in each of the 
treated groups, demonstrating that strontium administered orally as strontium 
malonate was highly available for absorption into the blood. 
  
Figure 7.4 Mean serum Sr concentrations (error bars show SD) 2 and 24 hours after administration of 
Sr malonate for males () and females (). The trend lines indicate linear response to the SrM dose for 
Groups 1-3 after 2 h and all groups after 24 h).  Pooled data for samples taken after 13 and 26 weeks. 
 
The strontium concentration was analysed in a linear model with dose groups, 
gender, week and time of day as effects. In order to obtain a homogeneous variance, 
the serum data was log-transformed before analysis. The data analysis showed that 
dose group, gender, time and study week were all significant (p  0.001 for all 
effects), with interactions between time and dose group, as well as between time and 
gender. The analysis was therefore performed separately by time and gender. In the 
control group, overall means and SDs of 71 ± 10 for males and 72 ± 18 for females 
showed no significant differences between the genders. In order to evaluate whether 
the absorption of strontium in the blood was linearly related to the administered dose 
of strontium malonate, the following linear model was formulated: 
 ܥௌ௥ ൌ ߙ · ݀݋ݏ݁ఉ (7-1) 
CSr is the concentration of Sr in the serum, dose is the administered dose of SrM, and 
 and  are model parameters. If  = 1, i.e.  is not significantly different from 1, the 
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relationship between dose and serum Sr is linear. By taking the natural logarithm of 
both sides of the equation, we obtain 
 lnሺܥௌ௥ሻ ൌ lnሺߙሻ ൅ ߚ · lnሺ݀݋ݏ݁ሻ (7-2) 
Hence, a test for dose linearity can be performed as a test of the hypothesis H0:  = 1 
against the alternative hypothesis H1:   1. Linearity was concluded if H0 was 
accepted. The analysis showed that 24 hours after administration, dose linearity was 
accepted ( = 1.02, p = 0.64) for all treated groups. It was therefore concluded that 
circulating serum Sr concentrations were proportional to the administered dose at the 
time of expected minimum Sr concentrations (just before the next dose 
administration). In contrast, 2 hours after administration, linearity had to be rejected 
( = 0.86, p = 0.001). Figure 7.4 shows that the lack of linearity is caused by the 
highest dose group, whose serum Sr did not increase proportionally to the dose. This 
may be an indication that the absorption of strontium at dose levels above 300 mg kg-
1 day-1 was limited by saturation of the gastrointestinal tract.  
The bioavailability was found to be higher for males than for females, in 
accordance with previous reports [39]. In the treated groups, the males showed a 
significantly higher serum Sr response than females after 24 hours (OLSR slopes: 
males 28.0 ± 2.2, females 15.1 ± 0.7, p < 0.001, ANCOVA). This observation is in 
contrast to observations in 4-week dog, where Sr administered as SrM had higher 
bioavailability in females (cf. Appendix II), showing that the test organism can have 
a profound influence on the clinical conclusions. 
Finally, it was observed that the average of all treated groups were 10% lower at 
week 26 than at week 13, demonstrating that steady-state conditions had been 
obtained for serum Sr. It is unclear why the serum Sr levels were lower by the end of 
the study than at week 13, but since the serum was taken from different animals at 
the two time-points, it may be a result of biological variation between individual 
animals. It is worth noting that a similar trend was observed in the fracture study 
described in Chapter 5, where the average serum Sr of the group treated for 3 weeks 
were higher than for the group treated for 8 weeks (Table 5.8, p 82). However, 
because of the different time-scale of the two studies, a direct comparison may not be 
feasible. 
The serum was also analysed for Mg, P, Ca and bone specific alkaline 
phosphatise (BSAP) at the end of the study (Figure 7.5). The concentrations of 
phosphorous showed opposite trends for the two genders. Serum P was significantly 
increased for males in Group 3 and 4, while a minor (non-significant) decrease with 
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dose was observed in the females. Decrease in serum P in mice following short-term 
Sr treatment has previously been reported [334]. The Mg concentrations were 
unaffected by the treatment, while Ca concentrations were significantly decreased in 
the highest dose group for both genders. These observations are in agreement with 
those of Skoryna and Fuskova [60], who found that after 12 weeks of Sr 
supplementation (up to 0.34% SrCl2 in the drinking water), no changes in serum Ca 
and Mg were observed in rats.  
 
Figure 7.5 Serum levels (mean ±SD) of P, Mg, Ca and bone specific alkaline phosphatase (BSAP) for 
males () and females () The unit µkat L-1 denotes catalytic activity and is a measure for the amount 
of enzyme present [335, 336]. 
BSAP is regarded as a marker for osteoblastic activity [337]. Despite very large 
intra-group variations, BSAP levels were significantly increased in the highest dose 
group (Figure 7.5). This indicates a Sr-induced increase in osteoblastic (bone-
forming) activity in this group, in agreement with previous reports [115, 120]. 
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7.3.5 Calcified tissues 
The results of the ICP-MS analysis are summarised in Tables 7.5 and 7.6. The 
analysis demonstrated that administration of strontium malonate resulted in a 
significant, dose-dependent increase in the strontium contents of both incisor and 
femur. All dose groups showed considerably higher Sr concentrations than the 
placebo group for both types of tissues. In the incisors, the Sr increased 
approximately 400 – 500 folds in the highest dose group, while femur Sr increased 
280 – 400 folds in this group. The Sr/(Sr+Ca)mol% for the four groups were 
respectively 0.015, 1.2, 5.8 and 7.7 for incisors, and 0.015, 0.6, 1.9 and 5.0 for 
femurs. In agreement with previous investigations [39, 73], these observations 
clearly demonstrate the bone-seeking properties of strontium (cf. Chapter 2). Both 
incisors and femurs showed significant differences between males and females, with 
males having the highest degree of Sr incorporation in the treated groups. This 
difference is apparently linked to differences in the gastrointestinal absorption of Sr, 
as serum Sr was also higher in males than in females. No gender differences were 
observed in the untreated control groups.  
Table 7.5 Summarised results (mean ± SD) for ICP-MS analysis of incisors from rats treated with 
strontium malonate for 26 weeks. 
 Concentration (mg g-1) 
Dose (mg kg-1 day-1) Sr  Mg P Ca 
0 (placebo) 0.103 ± 0.011 20.2 ± 2.8 165 ±16 298 ±57 
Males (n=20) 0.104 ± 0.010 21.7 ±2.9 170 ±18 289 ± 60 
Females (n=20) 0.102 ± 0.011 18.7 ± 1.6 160 ± 12 306 ± 54 
100 6.7 ±1.5 19.0 ± 2.1 156.5 ±8.3 260 ±25 
Males (n=20) 7.8 ± 1.3 20.2 ± 1.9 158 ± 10 258 ± 29 
Females (n=20) 5.6 ± 0.6 17.9 ± 1.6 154.8 ± 5.5 262 ± 22 
300 34 ± 18 18.6 ± 2.9 152.5 ± 6.8 255.3 ±64 
Males (n=20) 22.9 ± 3.0 19.4 ± 1.5 159.3 ± 3.8 256.3 ± 9.6 
Females (n=20) 17.8 ± 2.0 18.2 ± 1.2 155.3 ± 7.3 263 ± 15 
1000  45 ± 11 18.8 ± 2.9 150.8 ± 4.8 243 ± 65 
Males (n=20) 51 ± 10 19.0 ± 3.9 149.6 ± 4.9 248 ± 90 
Females (n=20) 38.4 ± 8.1 18.6 ± 1.4 152.0 ± 4.4 238 ± 17 
 
For the key apatite elements, Mg, P and Ca, the incisors revealed significant 
differences between treated groups and placebo, as well as significant gender 
differences. For Mg and P, the interactions between dose and gender were 
significant, and the analyses were therefore performed separately by gender. The 
males showed a dose-dependent reduction in incisor Mg, with significant differences 
in both the medium and high dose groups compared with placebo. Conversely, the 
females showed no significant differences between the groups. The males had 
significantly higher Mg contents than females in all groups. There was a significant 
loss of P in the highest dose groups for both sexes, but, while a significant loss was 
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found in all the treated groups in males, the females showed no significant changes in 
the low and medium dose groups. The opposing trends for Mg and P make it difficult 
to draw clear conclusions regarding the treatment effect of Sr on these elements. In 
contrast to P and Mg, Ca showed a clear trend, as Ca concentrations were 
significantly reduced for both genders in all treated groups as compared with 
placebo. This observation is in agreement with previous reports of decreasing 
mineralisation with increasing Sr dose in rats [107, 111]. 
Table 7.6 Analytical results for ICP-MS analysis of whole femur (n =24) taken from rats treated with 
strontium malonate for 26 weeks. 
 Concentration (mg g-1) 
Dose (mg kg-1 day-1) Sr  Mg P Ca 
0 (placebo) 0.0912 ± 0.0050 4.60 ± 0.25 144.1 ± 4.0 280 ± 11 
Males (n=3) 0.092 ± 0.010 4.59 ± 0.18 143.6 ± 4.5  277.6 ± 8.5 
Females (n=3) 0.0906 ± 0.0049 4.62 ±0.35 144.6 ± 4.3 283 ± 14 
100  4.3 ± 1.5 5.4 ±1.3 168 ± 40 341 ± 80 
Males (n=3) 5.3 ± 1.4 5.8 ±1.9 181 ± 58 368 ± 116 
Females (n=3) 3.2 ± 0.2 5.05 ±0.21 153.7 ± 2.7 313.0 ± 5.9 
300  11.3 ± 3.8 4.91 ±0.17 145.1 ± 5.6 274 ± 17 
Males (n=3) 14.3 ± 2.7 4.79 ±0.13 141.3 ± 3.2 260.4 ± 6.5 
Females (n=3) 8.3 ± 1.0 5.03 ±0.10 148.8 ± 5.1 287.4 ±9.9 
1000  31.2 ± 9.6  5.43 ±0.18 148.8 ± 4.5 276.4 ± 6.6 
Males (n=3) 37 ± 10 5.53 ±0.62 152.4 ± 1.4 281.5 ± 2.7 
Females (n=3) 25.4 ± 4.6 5.33 ±0.22 145.2 ± 3.1 271.2 ± 4.4 
 
Table 7.7 Summarised results for DEXA analysis of femur and vertebrae from rats treated with 
strontium malonate for 26 weeks. P-values indicate level of significance for the difference between 
each group and the placebo group (Dunnett’s test). The values have not been corrected for Sr content. 
Dose level  
(mg kg-1 day-1) 
BMD (g cm-2) 
Femur Vertebrae 
0 (placebo) 0.184 ± 0.026  0.134 ± 0.026 - 
Males (n=20) 0.187 ± 0.028  0.142 ± 0.025  
Females (n=20) 0.181 ± 0.023  0.125 ± 0.025  
100 0.202 ± 0.027 p = 0.02 0.141 ± 0.023 p = 0.49 
Males (n=20) 0.220 ± 0.025  0.149 ± 0.021  
Females (n=20) 0.184 ± 0.015  0.132 ± 0.022  
300 0.207 ± 0.037 p = 0.002 0.164 ± 0.036 p < 0.001 
Males (n=20) 0.228 ± 0.033  0.186 ± 0.029  
Females (n=20) 0.185 ± 0.028  0.142 ± 0.028  
1000  0.234 ± 0.042 p < 0.001 0.172 ± 0.041 p < 0.001 
Males (n=20) 0.249 ± 0.046  0.190 ± 0.044  
Females (n=20) 0.218 ± 0.031  0.156 ± 0.030  
 
In femur (Table 7.6), no significant differences in Mg, P and Ca concentrations 
were observed. The large variation observed in Group 2 (100 mg kg-1 day-1) is caused 
by a single sample from a male, the analysis of which showed much higher 
concentrations of Mg, P and Ca than the other samples. Suspecting the sample result 
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to be an outlier, the statistical analysis was performed both with and without the 
sample, which did not change the primary conclusions. As no gross errors could be 
identified in the analysis, the sample was included in the reported group means. 
The results of the DEXA analysis of femur and vertebrae are summarised in 
Table 7.7. Except the vertebrae in the low dose group, all groups showed significant 
increases in BMD compared with placebo. 
7.3.6 Clinical observations 
The study director reported [333] that the animals in the highest dose group 
started to show changes in teeth condition after approximately 2 months of treatment, 
seen as white teeth and rough enamel. All males and 80% of the females in this 
group had poor teeth condition during the study, and one animal from the high dose 
group was euthanized due to poor teeth. These observations are in accordance with 
previous reports of abnormal mineralisation in rat incisor after injection with SrCl2 
[332, 338]. The deleterious effects in calcified tissues following administration of 
high doses of Sr have been tentatively explained as a combination of inhibited 
calcium metabolism and distortion of the apatite crystal lattice due to displacement 
of Ca by Sr (cf. section 2.13). The present observations seem to confirm an effect on 
body levels of Ca, as the highest dose group show a reduced concentration of Ca in 
serum. This effect may be a combination of inhibited intestinal absorption and 
increased renal excretion of Ca. The high teeth Sr found in the highest dose group 
may also indicate that strontium has indeed substituted calcium in the enamel apatite 
crystal to such a degree that it affects the normal appearance and structure of the 
teeth. This is further supported by the observation that the animal that must be killed 
prematurely due to poor teeth condition had the second highest strontium 
concentration (70 mg g-1 tooth) in calcified tissue that has been observed throughout 
this entire project. 
7.3.7 Sampling sites 
In accordance with previous reports [39], the amount of Sr incorporated into the 
mineralised tissues depended strongly on the concentration of Sr in serum. Figure 7.6 
shows a clear correlation between serum Sr measured 24 hours after administration 
and incisor Sr. The OLSR residuals reveal a slight curvature, suggesting a beginning 
saturation of the incorporation mechanism at the highest serum Sr concentrations.  
As described in Chapter 2, Sr is incorporated more efficiently into newly formed 
HAp than into old. Rodent incisors grow continuously throughout the animal’s life, 
and, considering the long duration of the treatment, the incisors were therefore 
114  Chapter 7 
 
 
expected to incorporate relatively large amounts of Sr into the mineralised matrix. 
Femur bone was chosen for comparison because of the relatively low turnover rate of 
the mid-diaphyseal cortical tissue. The relationship between strontium contents in the 
incisors and femurs is shown in Figure 7.6.  
 
Figure 7.6 Relations between strontium concentrations in incisors and femur (left), and incisors and 
serum (right) in rats from the three active dose groups. OLSR: IncisorSr =  (1.31±0.08)·FemurSr + 
(1.8 ± 1.1), r2 = 0.94, p < 0.001, IncisorSr =  (1.92±0.09)·SerumSr + (6.6 ±1.2 ), r2 = 0.93, p < 0.001. 
Independent of dose, there was a significant correlation (p < 0.001) between the Sr 
concentrations in the two types of tissue.  The slope of the regression line (OLSR) is 
1.31 ± 0.08, indicating that Sr is indeed incorporated more efficiently into the 
constantly growing incisors than into the cortical bone of the femur. 
7.3.8 Correction of femur BMD measurements 
The observed increase in BMD in the active dose groups was expected to be strongly 
influenced by the large amounts of strontium deposited in the bones (cf. section 
4.3.4). In the 52-week dog study described in Chapter 8, a correction factor was 
elucidated for the influence of Sr on BMD measurements using a Norland XR-26 
DEXA scanner. This correction factor was used as a tentative correction for the 
PIXImus measurements of the 24 rat femurs in which the concentration of Sr was 
determined (Figure 7.7). After correction for Sr contents, there was a small but non-
significant decrease in BMD in the active dose-groups, confirming that the increase 
in measured BMD with increasing SrM dose was predominately caused by the 
associated increase in bone Sr, rather than an actual increase in bone mineralisation. 
It is reasonable to assume that a similar effect is present in vertebrae, and the BMD 
increase seen in Table 7.7 must therefore be interpreted with care. 
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Figure 7.7 Means and SDs (error bars) of measured () and corrected () BMD results for rat femur. 
The correction is approximate, as it was calculated using a different DEXA scanner than the PIXImus 
used in this study.  
7.3.9 A model for incorporation of Sr into hydroxyapatite 
The results presented above (Table 7.5, p. 111) seem to indicate that administration 
of high doses of SrM was associated with decreased concentrations of Ca, Mg and P. 
However, in the evaluation of the analytical results, it is important to keep in mind 
that the concentrations are expressed on a weight-to-weight basis. Consequently, the 
observed reduction in the concentrations of cations may have come about in two 
ways: 
1) An actual reduction in the amount of Ca in the apatite crystal lattice, due to 
replacement by Sr and/or disturbed Ca metabolism. 
2) A perceived reduction in the Ca/apatite mass ratio, resulting from an 
increased incorporation or adsorption of strontium in the mineralised matrix. 
Strontium’s high molar mass (88 g/mol) compared with that of calcium (40 
g/mol), increases the weight of the hydroxyapatite, which, all other things 
being equal, will be seen as a reduction in the concentrations of Ca, P and 
Mg in the dentine.  
The latter may lead to an overestimation of the resorption of Ca, P and Mg if large 
amounts of strontium are incorporated into the mineralised matrix. This point was 
made already in 1951 by McDonald et al. [97], who recognised that a drop in the 
measured mass ratio of Ca in bone ash might not be due to a decrease in the amount 
of Ca deposition, but rather to the addition of Sr to the total weight of inorganic 
matter. Under the assumption that all Ca, Mg, P and Sr found in bone is imbedded in 
the inorganic apatite matrix, we can formulate a simple substitution model to further 
investigate this effect (Figure 7.8).  
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Figure 7.8 Simplified illustration of stoichiometry behind the substitution model, which assumes that 
apatite Ca is substituted 1:1 by Sr. Alternatively, Sr may be adsorbed without replacing Ca. The figure 
was produced using Servier Medical Art [78]. 
Pure hydroxyapatite has the composition 
 Ca10ሺPO4ሻ6ሺOHሻ2 (7-3) 
As described in Chapter 2, Ca2+ in the HAp lattice can be replaced by both Mg2+ and 
Sr2+. The equation for formation of magnesium-strontium-hydroxyapatite (MgSr-
HAp) can be written as [339] 
 
ሺ10 െ ݔ െ ݕሻCaଶା ൅ ݔMgଶା ൅ ݕSrଶା ൅ 6POସଷା ൅ 2OHି ՜ 
Caଵ଴ି௫ି௬Mg௫Sr௬ሺPOସሻ଺ሺOHሻଶ (7-4) 
where x and y represent the degree of substitution by Mg and Sr, respectively. It is 
assumed that Ca is substituted 1:1 by Sr or Mg. The molecular weight (MW) of the 
substituted apatite is thus given by 
 
ܯ ெܹ௚ௌ௥ିு஺௣ ൌ ሺ10 െ ݔ െ ݕሻܯܹ஼௔మశ ൅ ݔܯܹெ௚మశ 
൅ݕܯܹௌ௥మశ ൅ 6ܯܹ௉ைరయశ ൅ 2ܯ ைܹுష 
(7-5) 
The coefficients x and y can be expressed in terms of molar ratios (MR) between the 
substituting ions and the substituted apatite: 
 ݔ ൌ ܯܴெ௚ ൌ
݊ெ௚మశ
݊ெ௚ௌ௥–ு஺௣ (7-6) 
 ݕ ൌ ܯܴௌ௥ ൌ
݊ௌ௥మశ
݊ெ௚ௌ௥–ு஺௣ (7-7) 
Similarly, the molar ratio between Ca2+ and substituted apatite can be written as 
 10 െ ݔ െ ݕ ൌ
݊஼௔మశ
݊ெ௚ௌ௥–ு஺௣ (7-8) 
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The ICP-MS analysis determines the mass ratio between the individual analytes and 
the dry calcified tissue, e.g. for Sr 
 ܥௌ௥ ൌ
݉ௌ௥
݉௖௔௟௖௜௙௜௘ௗ ௧௜௦௦௨௘ (7-9) 
In order to obtain an estimate, w, for the mass ratio between each analyte and MgSr-
HAp, the ICP-MS results must be corrected for the contents of organic material in 
the samples:  
 ݓௌ௥మశ ؠ
݉ௌ௥మశ
݉ெ௚ௌ௥ିு஺௣ ൌ
1
ܪܣ݌– ݎܽݐ݅݋ ·
݉ௌ௥మశ
݉௖௔௟௖௜௙௜௘ௗ ௧௜௦௦௨௘ (7-10) 
Based on the literature [67-69] it was expected that the apatite would constitute 60 – 
80% of the total sample weight, depending on the type of tissue. The incisors were 
expected to contain a higher ratio of HAp than the femurs, because tooth enamel 
contains very little organic material. In the present calculations, the HAp-ratio was 
adjusted to give the best fit between the model and the analytical data. Using 
equations (7-4) and (7-5), the theoretical mass ratio between Sr and HAp can be 
expressed as 
Similarly, the theoretical mass ratios for magnesium, phosphorous and calcium are 
given by 
 ݓெ௚మశ ൌ
݉ெ௚మశ
݉ெ௚ௌ௥–ு஺௣ ൌ
ݔ · ܯܹெ௚మశ
ܯ ெܹ௚ௌ௥–ு஺௣ (7-12) 
 ݓ஼௔మశ ൌ
݉஼௔మశ
݉ெ௚ௌ௥–ு஺௣ ൌ
ሺ10 െ ݔ െ ݕሻ · ܯܹ஼௔మశ
ܯ ெܹ௚ௌ௥–ு஺௣  (7-13) 
 ݓ௉ ൌ
݉௉
݉ெ௚ௌ௥–ு஺௣ ൌ
6ܯ ௉ܹ
ܯ ெܹ௚ௌ௥–ு஺௣ (7-14) 
With the mass ratios, w, determined experimentally, the molar ratios, x and y, can be 
found for each individual sample by combining the above equations, inserting the 
relevant molecular weights and solving for x and y. Figure 7.9 shows the measured 
mass ratios of Ca, P and Mg in the incisor hydroxyapatite matrix plotted against the 
molar ratio of Sr. The lines in the figure represent the theoretical mass ratios as a 
function of y according to equations (7-5) and (7-12) – (7-14). The molar ratio of 
 ݓௌ௥మశ ൌ
݉ௌ௥మశ
݉ெ௚ௌ௥–ு஺௣ ൌ
ݕ · ܯܹௌ௥మశ
ܯ ெܹ௚ௌ௥–ு஺௣ (7-11) 
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Mg, x, did not change significantly with the Sr concentrations (x was in the range 
0.83 – 1.15), and the value used in Figure 7.9 was therefore calculated as an average 
of all the teeth samples, resulting in x = 1.03. The model slopes represent the 
reduction in mass ratios of Mg, P and Ca solely due to the increase in apatite weight, 
while the intercepts correspond to the mass ratios in Sr-free apatite. The estimate of 
apatite content in the samples (equation (7-10)) affected only the intercepts, while it 
had no effect on the slopes. The figure demonstrates a very good agreement between 
the proposed model for Sr incorporation and the analytical results, indicating that at 
least a part of the perceived loss of Ca at high Sr concentrations must be attributed to 
the added weight of Sr to the apatite matrix. 
 
Figure 7.9 Analytical results (data points) and modelled lines (substitution model) for mass ratios of 
Ca, P and Mg in the hydroxyapatite matrix as a function of the molar fraction of Sr in rat incisor. The 
best correspondence between model and data was found with a teeth apatite content of 78%. The 
equations show the slopes and intercepts of the model. The molar ratio of Mg was fixed at x = 1.03 in 
the model. 
In view of the proposed incorporation mechanisms presented in Chapter 2, an 
alternative model was formulated, in which Sr was assumed to be adsorbed on the 
mineralised tissue without replacing other divalent ions (cf. Figure 7.8). The 
calculated slopes and intercepts (using ordinary least-squares regression) from the 
analytical data and the two models are listed in Table 7.8.  
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Table 7.8 Theoretical and observed (OLSR) slopes and intercepts for the relationship between the 
molar ratio of Sr (y) and the mass ratios of Mg, P and Ca in rat dentine apatite. The exchange model 
assumes that Sr replaces Ca 1:1 in the apatite crystal. The adsorption model assumes that Sr is 
adsorbed in dentine without replacing other ions. The best correspondence was found with a teeth 
apatite content of 78%. 
 Measured mass ratios p (slope = 0) Exchange model Adsorption model 
Mg (-0.19±0.09) · y + (2.55±0.35) 0.03 -0.11 · y + 2.5 -0.20 · y + 2.5 
P (-2.10±0.37) · y + (21.00±0.14) < 0.001 -0.85 · y + 18.8 -1.49 · y + 18.8 
Ca (-9.9±1.3) · y + (36.7±0.49) < 0.001 -5.46 · y + 36.3 -2.88 · y + 36.3 
 
By comparing the slopes given in the table, it is evident that, in theory, apatite 
adsorption of Sr can account for nearly all the apparent loss of Mg and P in the teeth. 
A considerable part of the perceived loss of Ca may also be explained by the 
increased weight of HAp, but even the model based on pure Sr adsorption cannot 
account for the entire reduction of the Ca content. This suggests that Ca 
mineralisation has in fact been reduced by the Sr treatment. The reason that Sr affects 
Ca more than it does Mg and P may be linked to the fact that Ca and Sr share the 
same transport pathways in the organism, causing competitive inhibition in intestinal 
absorption and perhaps also in incorporation into apatite. 
 
Figure 7.10 Analytical results (data points) and modelled lines (substitution model) for mass ratios of 
Ca, P and Mg in the hydroxyapatite matrix as a function of the molar fraction of Sr. The best 
correspondence between model and data was found with a femur apatite content of 72%. The 
equations show the slopes and intercepts of the model. The molar ratio of Mg was fixed at x = 0.2 in 
the model. 
120  Chapter 7 
 
 
The substitution model was also applied to the 24 femur samples (Figure 7.10), 
showing a very good model agreement with an estimated femur HAp content of 
72%. However, as described above (Table 7.6, p 112), the administration of 
strontium induced no significant changes in the concentrations of Mg, P and Ca in 
femur, and, as a consequence, the slopes calculated from the data points in Figure 
7.10 are not significantly different from zero. This may be due to the relatively low 
number of femur samples.  
7.4 Conclusion 
This 26-week rat study has shown that strontium administered orally as 
strontium malonate is highly bioavailable for transport to the blood and for 
incorporation into calcified tissues. 2 hours after administration, serum Sr increased 
linearly with the administered dose up to 138 mg kg-1 day-1 Sr2+. A treatment dose of 
460 mg kg-1 day-1 Sr2+ resulted in increases in Sr concentrations of up to 500 and 400 
folds in incisor and femur, respectively. Significant gender differences were 
observed, as Sr had a higher bioavailability in male rats than in females. The 
incorporation of Sr in the mineralised tissues was strongly correlated with the 
concentration of Sr in serum. 
High doses of Sr reduced Ca concentrations in both serum and incisors, 
indicating that Sr influenced Ca metabolism and the mineralisation of the dentine 
tissue. Opposing trends in Mg and P concentrations in both serum and teeth make it 
difficult to make any conclusive statements on the treatment effect on these elements. 
Treatment with SrM induced a significant increased in BMD in femur and lumbar 
vertebrae, but the measurements were much affected by the high Sr concentrations in 
the bones. After correction for Sr-content, no treatment-related change in BMD was 
observed in 24 femur samples.  
A simple stoichiometric model was proposed for incorporation and adsorption of 
Sr in hydroxyapatite. The model showed excellent agreement with the analytical data 
and it was found that the incisors and femurs contained an average of 78% and 72% 
hydroxyapatite, respectively. Finally, it was demonstrated that at least a part of the 
perceived loss of Ca in teeth was caused by the adsorption or incorporation of Sr in 
the teeth apatite.  
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CHAPTER EIGHT 
Mineral composition, bone mineral 
density and bone strength in dogs after 
52 weeks of treatment with strontium 
malonate 
8.1 Introduction 
This chapter presents a 52-week study on the effects of strontium malonate on 
mineral composition, bone mineral density and biomechanical properties of various 
calcified tissues in dogs. In order to obtain correct BMD results in the Sr-rich bones, 
the influence of Sr on the DEXA measurements was determined by analysing Sr-
doped hydroxyapatite. The effect of strontium malonate treatment on cortical and 
trabecular bone strength was studied by testing the biomechanical properties of 
femurs and vertebra biopsies. In addition, structural analysis of the bone samples was 
performed using extended X-ray absorption fine structure (EXAFS) in order to gain 
information on the local environment of the Sr-ions in the samples. 
8.2 Experimental 
8.2.1 Animals 
8.2.1.1 Study design 
The study was performed in 40 beagle dogs (20 males and 20 females) from 
Harlan Winkelmann GmbH, Germany. The in-life part of the study was conducted at 
LAB Scantox, Ejby, Denmark. The first day of treatment was designated Day 1. At 
the start of the acclimatisation period (Day -5), the animals were approximately 5 to 
6 months old with body weights within a range of 8.9 – 14.2 kg for males and 8.1 – 
12.0 kg for females. Two extra animals (one of each sex) were available until 
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completion of the pre-treatment period for replacement purposes. The animals were 
allocated to 4 groups each consisting of 4 males and 4 females per main study group, 
and 2 males and 2 females in the recovery groups (Groups 1 and 4). The animals 
were allocated so as to distribute litter-mates evenly between groups and to reduce 
inter-group mean body weight differences [340].  
8.2.1.2 Treatment 
The vehicle for preparation of the dose formulation was 0.5% carboxymethyl 
cellulose (0.5% CMC). The vehicle was prepared with de-ionized water for all 
treatment groups. The dose formulations were prepared by suspending SrM in the 
vehicle. The animals in Group 1 (control) were treated with vehicle (0.5% CMC). 
The animals in Groups 2, 3 and 4 were treated with 100, 300 and 1000 mg strontium 
malonate per kg body weight per day, respectively. Treatment of the recovery 
animals was performed daily for 52 weeks after which a treatment free period of 4 
weeks was inserted. The daily dose was given by oral gavage with a dose volume of 
5 ml per kg body weight. All animals were weighed upon arrival, one week before 
start of dosing (Day -7), on the day of group allocation (Day -1) and weekly 
thereafter. The dose for the following 7 days was calculated on the basis of the most 
recent weight. At the end of the in-life phase, the animals were killed and subjected 
to necropsy [340]. 
Table 8.1 Design of 52-week study of strontium malonate treatment in dogs. 
Group SrM dose (mg kg-1 day-1) 
SrM dose 
formulation 
(mg mL-1) 
No of animals (n) 
(main study) 
No of animals 
(recovery) 
Males Females Males Females 
1 0 0 4 4 2 2 
2 100 20 4 4   
3 300 60 4 4   
4 1000 200 4 4 2 2 
8.2.1.3 Diet and drinking water 
A commercially available diet (Teklad 2021, Harlan, Blackthorn, England) was 
offered twice daily (150 g per animal twice daily). From Day 42 the amount of diet 
was increased to 175 g twice daily. In order to allow the animals a reasonable 
growth, the amount of diet was further increased on Day 71 to 200 g and on Day 241 
to 225 g twice daily. The animals had ad libitum access to domestic quality drinking 
water. Analyses for relevant possible contaminants were performed regularly [340].  
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8.2.1.4 Blood sampling 
Before start of treatment and during Weeks 13, 26, 39 and 52, blood samples 
were taken from all animals. Blood samples were drawn from the jugular vein, 
frozen to -18°C and then analysed at a commercial accredited laboratory [340].  
8.2.1.5 Sampling for bone and teeth analysis 
The entire right femur, the entire right tibia, the calvaria (skullcap) and a tooth 
(first molar) as well as lumbar vertebrae L2-L4 were dissected from each animal. The 
bones were dissected free of as much muscular tissue as possible, wrapped in cotton 
bandage, soaked in isotonic 0.9% NaCl and placed in plastic bags. The samples were 
stored at -18ºC until analysis. 
8.2.2 ICP­MS analysis 
The procedure for the ICP-MS analysis was similar to one used for the 26-week 
study in rats described in Chapter 7. The reader is referred to Chapters 5 - 7 for 
details on instrument optimisation and validation. 
8.2.2.1 Sampling and sample pre­treatment 
Sampling of femur and skull samples was performed according to the regions of 
interest (ROI) selected for the bone densitometry measurements (cf. section 8.2.3). 
The mid-diaphyseal (mid-shaft) section of femur was sampled at the fracture site of 
the three-point bending test using a stainless steel saw. Four skull biopsies were 
sampled from the top part of the skull (Figure 8.1) using a Rochester Bone Biopsy 
Kit (7 mm i.d.). A skull sample was composed of 3 randomly selected biopsies, each 
weighing approximately 180 mg. The teeth were removed from the jaw bone using a 
clamp and a scalpel, the root was separated from the dentine/enamel with a saw, and 
the pulp was removed. 
  
Figure 8.1 Photos of a dog skullcap after sampling of biopsies (left) and a jaw bone before removal of 
the teeth (right). The first molar is seen as the middle tooth.  
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Prior to analysis, remaining adhering soft tissue was removed by submerging the 
samples in 35% H2O2 for approximate 30 min, and subsequently placing the sample 
in an ultrasonic bath for 10 minutes. The samples were then rinsed with ethanol and 
ultra-pure water. The tooth and femur samples were ground with an IKA A11 
analytical mill (cf. Chapter 6) before digestion. All samples were digested in 
microwave oven as described in Chapter 7.  
Vertebra body specimens were produced by first removing the cranial and caudal 
ends of the L3 lumbar vertebral body with a low-speed saw. A biopsy of trabecular 
tissue (5 mm i.d.) was then taken from the vertebral body using a hollow drill, and a 
specimen for mechanical testing (7 mm high) was produced by cutting the biopsy 
with a twin circular saw (Figure 8.2) 
Figure 8.2 Photos of the sampling procedure for producing vertebral body specimens for compression 
tests. The extracted vertebra biopsy was carefully removed from the hollow drill (left) and cut to 
uniform height with a twin circular saw (middle), producing a specimen used for mechanical testing 
(right).  
8.2.3 Bone densitometry 
8.2.3.1 Calibration 
The densitometry measurements were performed using a Norland XR-26 Mark 
II, X-ray bone densitometer with a pencil beam X-ray source. The instrument is used 
for routine scanning of patients at Hvidovre Hospital. The scanner performed self-
calibration on start-up, and the calibration was verified by scanning a hydroxyapatite 
phantom. The results of the phantom scans were recorded in order to monitor the 
long-term stability of the apparatus.  
8.2.3.2 Scanning 
The samples were scanned using the Small subjects mode, with a scan resolution 
of 1.0 x 1.0 mm and a scan speed of 40 mm s-1. The samples were positioned on a 2-
3 cm layer of rice placed on a 5 cm polymethylmethacrylate (PMMA, acrylic glass) 
block in order to imitate measuring conditions in the presence of soft tissue (Figure 
8.3).  
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Figure 8.3 Photos of vertebra (V), calvaria (C), tibia (T) and femur (F) positioned for DEXA analysis. 
The samples were wrapped in sodium chloride soaked cloths to prevent them from drying out. The 
PPMA plate and the bag of rice were used to simulate soft tissue and provided a useful foundation for 
positioning the samples.   
 
 
Figure 8.4 DEXA scanning image of vertebra (V), calvaria (C), tibia (T) and femur (F) from dogs. 
High density areas are shown in light colours and the lower density areas in dark colours. The squares 
mark selected regions of interest (ROI). The black squares represent ROIs for which BMD is given in 
Table 8.5: calvaria mid-section (CM), 2 x 3.5 cm; femur head (FH), 2 x 2 cm; mid-diaphyseal femur 
(MF), 2 x 2 cm. Scan resolution: 1.0 x 1.0 mm. 
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All samples were scanned in polyethylene bags while frozen, with cloths soaked 
in 0.9 g L-1 NaCl solution wrapped around each bone. In order to obtain adequate 
resolution when selecting ROIs, each sample set was scanned in two sections, with 
femur and tibia in one scan and vertebra and skull in another. A background 
correction was done for each measurement. The selected ROIs are shown in Figure 
8.4.  
8.2.4 Biomechanical analysis 
The biomechanical properties of femurs and vertebra biopsies were evaluated 
using a material testing machine (Lloyd LR 50K). 24 hours before the measurements, 
the bones were removed from the freezer, submersed in an isotonic sodium chloride 
solution (9 g L-1 NaCl in sterile water) and allowed to reach room temperature. All 
specimens were tested in hydrated condition. Femur bone strength was evaluated by 
a three-point bending test and a bending test of the femur neck. For three-point 
bending, the femurs were placed on the posterior surface on two bars spaced 75 mm 
apart, and the load was applied half-way between the bars to the anterior side of the 
mid-diaphyseal femur. For the bending test of the femur neck, the femurs were 
sawed in half across the mid-shaft using a stainless steel saw. The proximal half of 
the bone was fixed by six Allan screws and load was applied laterally to the femur 
head (Figure 8.5). The compression strength of biopsies taken from the core of 
lumbar vertebra L3 was performed by applying a compression load to the biopsy in 
the longitudinal direction as shown in Figure 4.10, p 54. 
  
Figure 8.5 Experimental setup for mechanical testing of dog femur neck strength. After sampling 
from the mid-section  
A loading speed of 2 mm min-1 and a zero-point load of 50 N were used for all 
samples. The displacement was measured as the distance travelled by the crosshead. 
Load-displacement curves were recorded and the maximum load (N), displacement 
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at failure (mm), stiffness (N/mm) and the energy absorption at failure (J) were 
calculated as shown in Chapter 4.  
8.2.5 Correction of BMD measurements 
The influence of Sr on the BMD measurements were assessed by producing six 
different mixtures of hydroxyapatite in which 0-5% of the Ca atoms were replaced 
by Sr.  
8.2.5.1 Synthesis of Sr­doped hydroxyapatite 
White solid crystals of calcium hydroxyapatite (HAp) and hydroxyapatite with 
approximately 5% (w/w) calcium substituted by strontium (Sr-HAp) were prepared 
by the method of Kumta et al. [341] with minor modifications. The synthesis of Sr-
HAp was performed according to the equation 
 9.41Ca2൅൅0.59Sr2൅൅6PO43‐൅2OH‐՜ Ca9.41Sr0.59ሺPO4ሻሺOHሻ ሺsሻ (8-1) 
190 g of trisodiumphosphate, Na3PO4, (Sigma-Aldrich) was partly dissolved in 1 L 
of ultra-pure water. After addition of 15.5 g of sodium hydroxide, NaOH, (Sigma-
Aldrich), the suspension was gently heated to approximately 50°C until all material 
was dissolved. 268 g of calcium chloride dihydrate, CaCl2·2H2O, (Fluka) and 30.4 g 
of strontium chloride hexahydrate, SrCl2·6H2O, (Fluka) was dissolved in 1 L of ultra-
pure water. The solution containing Na3PO4 and NaOH was transferred to a large 
beaker and the Sr/Ca solution was added under vigorous stirring over a time period 
of six hours. A finely-grained white precipitate was formed and the solution was 
centrifuged for 5 min at 2000 rpm and flushed 5 times in Millipore water. The 
powder was heated to 1000°C for 10 hours and allowed to cool to room temperature 
over 12 hours. The powder was ground in a mortar and the structure was confirmed 
by X-ray powder diffraction (XRPD).  
 
Figure 8.6 Photo of the PMMA block used for assessing the influence of strontium on the BMD 
results in Sr-rich bones. The DEXA measurements were performed with the rubber stoppers removed. 
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The six HAp mixtures were produced by accurately weighing appropriate 
quantities of pure Ca-hydroxyapatite and the Sr-doped apatite and transferring the 
powders to holes drilled in PMMA block. The size and of the holes and the amount 
of Sr-HAp transferred were selected so as to obtain an areal density close to that of 
the dog bone samples (0.7-1 g cm-2). BMD and BMC was measured in each hole by 
the same DEXA scanner that was used for the bone analysis. Subsequently, the exact 
Sr content in each hole was determined using ICP-MS. 
8.2.6 EXAFS 
EXAFS was performed on skull samples from all active dose groups. Femur 
samples from the 4-week study in dogs were also analysed by EXAFS. Experimental 
work and data analysis was performed by Christian G. Frankær and described 
elsewhere [342].  
8.2.7 Statistics 
The statistical treatment followed the procedures outlined in Chapter 7.  
8.3 Results 
8.3.1 Ca in serum 
Throughout the study, the concentration of calcium (not shown) was 
significantly lower for both sexes in the highest dose group (Group 4) as compared 
with the control group. In addition, the level of calcium was lower for the males in 
the medium dose group (Group 3) after 39 weeks of treatment and onwards. 
Although not statistically significant in all cases, the results indicated a dose 
dependent reduction in the calcium level for both sexes in Group 3 from Week 26 
and for Groups 2 and 3 from Week 39 and onwards.  
8.3.2 BSAP in serum 
The levels of bone specific alkaline phosphatase (not shown) were significantly 
increased throughout the entire study (Weeks 13, 26, 39 and 52 of treatment) in 
Group 4 for both males and females. On a few occasions, BSAP had also increased 
in the lower dosed groups.  
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8.3.3 Elemental analysis of calcified tissues 
The results of the ICP-MS analysis of femur, calvaria and molar are summarised 
in Tables 8.2 – 8.4 below.  
Table 8.2 Results for ICP-MS analysis of mid-diaphyseal femur from dogs treated with strontium 
malonate for 52 weeks. 
 Concentration (mg g-1) 
Dose (mg kg-1 day-1) Sr  Mg P Ca 
0 (placebo) 0.078 ± 0.013 3.32 ± 0.37 148 ± 16 328 ± 41 
Males (n=4) 0.081 ± 0.016 3.22 ± 0.43 139 ± 17 305 ± 46 
Females (n=4) 0.074 ± 0.010 3.43 ± 0.32 156.0 ± 9.9 352 ± 21 
100  15.4 ± 5.4 3.47 ± 0.20 132.0 ± 9.8 271 ± 15 
Males (n=2) 17.2 ± 6.0 3.45 ± 0.22 131.4 ± 9.9 269 ± 14 
Females (n=4) 11.6 ± 0.14 3.52 ± 0.23 133 ± 13 277 ± 19 
300  22.7 ± 6.6 3.28 ± 0.46 128.7 ± 7.9 263 ± 25 
Males (n=4) 24.0 ± 4.8 3.64 ± 0.33 135.0 ± 5.1 276 ± 11 
Females (n=4) 21.5 ± 8.7 2.93 ± 0.21 122.5 ± 3.6 250 ± 29 
1000  28 ± 12 3.38 ± 0.52 131.8 ± 9.6 275 ± 26 
Males (n=4) 29 ± 14 3.40 ± 0.34 129.7 ± 1.6  265 ± 13 
Females (n=4) 27 ± 12 3.35 ± 0.71 134 ± 14 285 ± 34 
 
The treatment with Sr resulted in a marked, dose-dependent increase in Sr 
concentrations in all the sampled skeletal sites. The highest level of Sr incorporation 
for all the active dose groups was seen in the skull biopsies, with an approximate 
350-fold increase in Sr content in Group 4 compared with the control group. Of the 
three sample types, the molar showed the lowest Sr contents in all treated groups. 
The Sr/(Sr+Ca)mol% for the four groups were respectively 0.011, 2.5, 3.8 and 4.4 for 
femurs; 0.019, 3.3, 4.7 and 6.5 for calvaria and 0.013, 0.75, 1.1 and 1.6 for teeth. In 
the placebo group, the Sr contents in the different samples were quite similar, with 
the highest natural levels found in skull. There were no significant differences in Sr 
content between males and females in any of the analysed tissues.  
The concentrations of calcium and phosphorous were significantly reduced in 
both femur and skull in all treated groups. There was not, however, any differences 
in Ca and P concentrations between any of the active dose groups. Hence, increasing 
the SrM dose from 100 to 1000 mg kg-1 day-1 was not accompanied by a decrease in 
the Ca and P concentrations.  
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Table 8.3 Analytical results for ICP-MS analysis of calvaria (skullcap) biopsies from dogs treated 
with strontium malonate for 52 weeks. 
 Concentration (mg g-1) 
Dose (mg kg-1 day-1) Sr  Mg P Ca 
0 (placebo) 0.116 ± 0.017 3.29 ± 0.13 141.0 ± 9.8 279 ± 19 
Males (n=4) 0.118 ± 0.014 3.34 ± 0.16 148.6 ± 5.5 294 ± 10 
Females (n=4) 0.114 ± 0.021 3.23± 0.057 133.5 ± 6.7 263 ± 13 
100  19.3 ± 5.2 3.48 ± 0.11 128.0 ± 3.3 253 ± 16 
Males (n=3) 22.9 ± 6.7 3.41 ± 0.046 125.6 ± 1.3 243 ± 22 
Females (n=4) 16.6 ± 0.76 3.54 ± 0.12 129.8 ± 3.2 260.9 ± 7.6 
300  27.4 ± 5.2 3.76 ± 0.16 125.9 ± 3.6 254.3 ± 8.2 
Males (n=4) 28.7 ± 4.1 3.81 ± 0.22 124.5 ± 4.9 258.0 ± 6.5 
Females (n=4) 26.2 ± 6.6 3.72 ± 0.044 127.2 ± 1.2 250.5 ± 8.8 
1000  37.0 ± 8.1 3.48  ± 0.29 125.0 ± 4.8 244 ± 12 
Males (n=4) 38 ± 11 3.56 ± 0.31 123.6 ± 5.2 242 ± 17 
Females (n=4) 35.7 ± 4.1 3.41 ± 0.29 126.4 ± 4.7 246.4 ± 5.6 
In teeth, Ca and P levels were similar in all groups. The concentration of Mg 
showed conflicting treatment responses. In the highest dose group, the Mg content 
was increased in skull, decreased in teeth while remaining unchanged in femur. The 
males had significantly higher concentrations of Mg in teeth than females.  
 
Table 8.4 Analytical results for ICP-MS analysis of molar (dentine and enamel) taken from dogs 
treated with strontium malonate for 52 weeks. 
 Concentration (mg g-1) 
Dose (mg kg-1 day-1) Sr  Mg P Ca 
0 (placebo) 0.093 ± 0.027 8.54 ± 0.97 171.1 ± 3.9 340 ± 12  
Males (n=4) 0.081 ± 0.06 9.25 ± 0.85 168.4 ± 4.1 332.5 ± 6 
Females (n=4) 0.106 ± 0.036 7.82 ± 0.32 173.7 ± 1.0 348 ± 11 
100  5.5 ± 1.8  8.6 ± 1.9 178 ± 16 331 ± 49 
Males (n=2) 6.2 ± 1.8 9.1 ± 2.2 178 ± 21 336 ± 62 
Females (n=4) 4.02 ± 0.010 7.52 ± 0.20 175.9 ± 3.0 320 ± 22 
300  7.3 ± 2.0 7.78 ± 0.96 169.9 ± 2.2 309.2 ± 9.2 
Males (n=4) 8.4 ± 2.0 8.2 ± 1.3 169.2 ± 2.8 307 ± 11 
Females (n=4) 6.3 ± 1.6 7.40 ± 0.26 170.5 ± 1.6 311 ± 8.3 
1000  11.6 ± 5.6 6.72 ± 0.71 166.5 ± 6.5 319 ± 10.6 
Males (n=4) 11.2 ± 6.0 6.72 ± 0.76 168.4 ± 7.7 326 ± 4.7 
Females (n=4) 12.1 ± 6.1 6.71 ± 0.77 164.6 ± 5.5 313 ± 11 
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8.3.4 Bone densitometry 
The results for the densitometric measurements are shown in Table 8.5. The 
bone mineral density increased significantly with the SrM dose in femur mid-shaft, 
femur head and lumbar vertebra. In skull, only Groups 2 and 3 showed significant 
increases in BMD. No gender differences were observed. A large proportion of the 
BMD increase seen in the active dose groups was expected to be caused by the 
presence of Sr. The measurements of femur and calvaria were therefore corrected for 
Sr interference by using the results from the ICP-MS analysis (cf. section 8.4.8).  
Table 8.5 Densitometry results for femur mid-shaft, femur head, calvaria (mid-section) and vertebra 
biopsies taken from dogs treated with strontium malonate for 52 weeks. 
 Bone mineral density (g cm-2)  
Dose  
(mg kg-1 day-1) 
Femur mid-shaft Femur head 
Calvaria mid-
section 
Lumbar vertebra 
L3 biopsy 
0 (placebo) 0.558 ± 0.018 0.556 ± 0.026 0.38 ± 0.10 0.151 ± 0.014 
Males (n=4) 0.562 ± 0.021 0.552 ± 0.033 0.40 ± 0.10  0.145 ± 0.017 
Females (n=4) 0.554 ± 0.016 0.560 ± 0.021 0.37 ± 0.10 0.157 ± 0.010 
100  0.705 ± 0.082 0.734 ± 0.066 0.528 ± 0.087 0.186 ± 0.022 
Males (n=2) 0.766 ± 0.094 0.777 ± 0.037 0.548 ± 0.098 0.168 ± 0.011 
Females (n=4) 0.674 ± 0.067 0.713 ± 0.070 0.513 ± 0.090 0.194 ± 0.023 
300  0.792 ± 0.095 0.845 ± 0.057 0.59 ± 0.12 0.219 ± 0.037 
Males (n=4) 0.769 ± 0.040 0.867 ± 0.034 0.529 ± 0.14 0.223 ± 0.030 
Females (n=4) 0.82 ± 0.13 0.823 ± 0.072 0.640 ± 0.091 0.215 ± 0.047 
1000  0.712 ± 0.076 0.789 ± 0.083 0.504 ± 0.054 0.215 ± 0.032 
Males (n=4) 0.700 ± 0.021 0.752 ± 0.040 0.53 ± 0.036 0.201 ± 0.049 
Females (n=4) 0.72 ± 0.11 0.83 ± 0.11 0.473 ± 0.066 0.225 ± 0.010 
 
8.3.5  Biomechanical measurements 
The results for the biomechanical measurements are presented in Tables 8.6 – 
8.8. The three-point bending test revealed a significant decrease in maximum load in 
the highest dose group. There was a slight but non-significant increase in the 
maximum load in Groups 2 and 3. Maximum displacement and work was not 
recorded for this test. The bending test of the femur neck showed significantly lower 
maximum force and absorbed energy in the highest dose group, similarly to the 
three-point bending test. The vertebra biopsies showed no significant differences 
between the groups for any parameters. No gender differences were observed. 
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Table 8.6 Biomechanical results for three-point-bending test of dog femur. M: males, F: females 
 Dose (mg kg-1 day-1) 
 0 (placebo) 100 300 1000 
Max force (kN) 2.81 ± 0.38 3.06 ± 0.35 3.08 ± 0.40 2.28 ± 0.44 
Males 3.01 ± 0.30 3.30 ± 0.47 3.14 ± 0.44 2.17 ± 0.36 
Females 2.62 ± 0.38 2.94 ± 0.27 3.01 ± 0.41 2.39 ± 0.54 
No. of animals M: 4, F: 4 M: 4, F: 4 M: 4, F: 4 M: 4, F: 4 
 
Table 8.7 Biomechanical results for femur neck bending test. 
Dose (mg kg-1 day-1) Max force (kN) Max displacement (mm)   Work (J) 
0 (placebo) 1.70 ± 0.24 3.6 ± 0.6 4.8 ± 1.2 
Males (n=4) 1.76 ± 0.32 3.5 ± 0.5 4.9 ± 1.8 
Females (n=4) 1.63 ± 0.15 3.7 ± 0.6 4.67 ± 0.63 
100  1.65 ± 0.19 3.9 ± 1.0 5.0 ± 1.1 
Males (n=2) 1.56 ± 0.19 5.1 ± 0.1 6.29 ± 0.15 
Females (n=4) 1.69 ± 0.19 3.3 ± 0.6 4.34 ± 0.46 
300  1.74 ± 0.28 4.3 ± 0.6 4.9 ± 1.3 
Males (n=4) 1.77 ± 0.35 4.2 ± 0.6 5.1 ± 1.6 
Females (n=4) 1.71 ± 0.24 4.3 ± 0.6 4.6 ± 1.0 
1000  1.29 ± 0.35 3.7 ± 0.6 3.2 ± 1.3 
Males (n=4) 1.06 ± 0.36 3.6 ± 0.5 2.48 ± 0.58 
Females (n=4) 1.52 ± 0.16 3.9 ± 0.8 4.0 ± 1.5 
 
Table 8.8 Biomechanical results for compression test of vertebra biopsies. 
Dose (mg kg-1 day-1) Max force (kN) Max displacement (mm)    Work (J) 
0 (placebo) 0.93 ± 0.29 0.39 ± 0.06 0.60 ± 0.20 
Males (n=4) 1.07 ± 0.24 0.45 ± 0.04 0.68 ± 0.17 
Females (n=4) 0.89 ± 0.14 0.37 ± 0.05 0.60 ± 0.13 
100  0.69 ± 0.28 0.63 ± 0.29 0.56 ± 0.27 
Males (n=2) 0.42 ± 0.24 0.64 ± 0.47 0.29 ± 0.11 
Females (n=4) 0.82 ± 0.20 0.63 ± 0.26 0.69 ± 0.20 
300  0.82 ± 0.37 0.43 ± 0.12 0.65 ± 0.36 
Males (n=4) 0.75 ± 0.34 0.41 ± 0.11 0.59 ± 0.28 
Females (n=4) 0.89 ± 0.43 0.45 ± 0.14 0.71 ± 0.47 
1000  0.72 ± 0.30 0.43 ± 0.13 0.57 ± 0.28 
Males (n=4) 0.57 ± 0.34 0.42 ± 0.15 0.51 ± 0.32 
Females (n=4) 0.87 ± 0.18 0.44 ± 0.11 0.65 ± 0.24 
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8.4 Discussion 
8.4.1 Ca and BSAP in serum 
The treatment effects on serum Ca and BSAP were similar to those observed in 
26-week rat (Chapter 7). As previously described, the decrease in serum Ca in the 
active dose groups is most probably due to inhibited intestinal absorption of Ca. The 
increase in BSAP indicates that treatment with SrM stimulated osteoblastic activity. 
A similar trend was seen in 4-week dog, where a significant correlation between 
serum BSAP and bone Sr was observed (Fig. 2, Appendix II). 
 
8.4.2 Effect of treatment time on Sr­incorporation 
As described in Chapter 2, the duration of treatment is an important factor for 
determining the amount of Sr incorporated into bone. In the 4-week study in dogs, 
Sr-concentrations increased up to 95 fold in femur and 30 fold in molar after 
treatment with up to 3000 mg kg-1 day-1 SrM. Although the administered doses were 
lower in the present study, it was expected that the much longer treatment time 
would allow more Sr to be incorporated into the mineralised matrix. This is 
confirmed by comparing results for groups that received the same dose of SrM in the 
two studies (Table 8.9). When the treatment time was increased from 4 to 52 weeks, 
the Sr concentration in cortical bone increased approximately 3 fold. The relatively 
high levels of bone Sr seen after only 4 weeks of treatment seems to confirm that Sr 
is incorporated firstly by an initial rapid mechanism, which is eventually saturated, 
followed by a second, slower mechanism (cf. section 2.12). 
Table 8.9 Comparison of Sr-concentrations in dog femur after 4 and 52 weeks of SrM treatment [11]. 
Treatment time 
Administered dose (mg kg-1 day-1) 
300 1000 
4 weeks 7.2  ± 1.7 mg g-1 9.5 ± 2.7 mg g-1 
52 weeks 22.7 ± 6.6 mg g-1 28 ± 12 mg g-1 
 
8.4.3 The effect of skeletal site on Sr­incorporation 
As previously mentioned, the amount of Sr incorporated into mineralised tissue is 
largely determined by the rate of bone turnover. In dogs, the highest levels of Sr 
incorporation were seen in calvaria, as all active dose groups had significantly higher 
average Sr concentrations in the skullcap than in femur and teeth. These findings are 
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most likely related to the structure of the cranial bone. In contrast to the purely 
cortical femur shaft, the calvarial bone consists of three layers: the outer table and 
the inner table are both made up by cortical bone, while the middle layer (the diploë) 
is made up by trabecular bone [343]. The higher Sr concentration in the skullcap 
biopsies may then be explained by the higher remodelling rate of trabecular bone 
compared with that of cortical bone [39], resulting in a more efficient incorporation 
of Sr . 
 
Figure 8.7 The plot shows a significant correlation between Sr concentrations in femur and molar. 
The slope of the line (OLSR) is 0.35 ± 0.06. r2 = 0.059, p < 0.001. 
In both the short-term and the long-tern study in dogs, the incorporation of Sr 
was much lower in teeth than in bone. In the 52-week study, the content of Sr in teeth 
was on average one third of the femur Sr content (Figure 8.7). This is in accordance 
with the lower remodelling rate of teeth in dogs compared with that of bone. The 
trend was opposite in rats (Figure 7.6, p 114), where the level of incorporation was 
significantly higher in teeth than in femur, reflecting the continuous modelling 
(growth) of rodent incisors [331]. 
8.4.4 Substitution model 
The substitution/adsorption model that was developed for Sr incorporation in 
bone and teeth in Chapter 7 was also applied to the data in this study. Figure 8.8 
shows the analytical data together with the modelled relationships between the molar 
ratio of Sr and the mass ratios of Mg, Ca and P. For both tissues, the substitution 
model showed a good agreement with the analytical values. The parameters for 
substitution and adsorption are presented in Table 8.10, demonstrating that a 
considerable proportion of the observed reduction in the concentrations of Ca and P 
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in these tissues (cf. section 8.3.3) is caused by the increased weight of the apatite 
matrix following incorporation of heavier Sr ions. As was the case in the rats, 
however, the model does not seem to account for all of the reduction in Ca and P, 
which suggests that the mineralisation of Ca and P was affected by the Sr treatment. 
The best fit was found by letting 70% of the bone weight be made up by apatite in 
the model. The data for teeth were fitted best using an apatite ratio of 85%, 
corresponding well to the high apatite content of enamel. While dentine and bone 
contains similar amounts of HAp, fully mature enamel contain up to 99% HAp, 
reflecting the increased demand for hardness in teeth [344].  
Figure 8.8 Analytical results (points) and modelled lines for mass ratios of Ca, P and Mg in the 
hydroxyapatite matrix as a function of the molar fraction of Sr in dog femur and calvaria. The best 
correspondence between model and data was found with a bone apatite content of 70%. The equations 
show the theoretical slopes and intercepts of the model. The molar ratio of Mg was fixed at MLMg = 
0.21 in the model. 
Table 8.10 Theoretical and observed (OLSR) slopes and intercepts for the relation between the molar 
ratio of Sr (y) and the mass ratios of Mg, P and Ca in dog bone apatite. The substitution model 
assumes that Sr replaces Ca 1:1 in the apatite crystal. The adsorption model assumes that Sr is 
adsorbed in the tissue without replacing other ions. The best correspondence was found with a bone 
apatite content of 70%. The molar ratio of Mg was set at MRMg = 0.21 for calvaria and MRMg = 0.20 
for femur. 
 Measured mass ratios p (slope = 0) Substitution model Adsorption model 
Femur    
Mg 
(0.065±0.047) · y + 
(0.460±0.017) 
0.18 
-0.11 · y + 2.5 -0.038 · y + 0.48 
P (-2.9±1.5) · y + (20.11±0.53) 0.066 -0.85 · y + 18.8 -1.46 · y + 18.5 
Ca (-9.7±4.3) · y + (43.4±1.5) 0.032 -5.46 · y + 36.3 -3.08 · y + 39.1 
Calvaria    
Mg (0.051±0.35) · y + (0.48±0.010) 0.12 -0.023 · y + 0.51 -0.041 · y + 0.51 
P (-3.75±0.61) · y + (19.89±0.26) < 0.001 -0.84 · y + 18.6 -1.46 · y + 18.5 
Ca (-8.1±1.3) · y + (39.67±0.57) < 0.001 -5.60 · y + 39.1 -3.08 · y + 39.1 
136  Chapter 8 
 
 
8.4.5 EXAFS 
X-ray absorption spectroscopy was used for analysis of femur samples from 4-
week dog, skull samples from 52-week dog and Sr-doped HAp. The EXAFS spectra, 
(k), are shown in Figure 8.9 together with the modulus of the Fourier transform of 
(k). The latter gives information on the radial distribution of electronic density 
around an average Sr atom, which can be used to identify different coordination 
spheres around Sr. By comparing the radial electron distribution functions from bone 
and Sr-doped HAp, it is observed that the coordination shells occur at similar 
distances, R, from the absorbing Sr atom, indicating that Sr has similar local 
environments in bone and Sr-doped HAp. This demonstrates that some Sr was 
incorporated into the bone hydroxyapatite lattice by substitution of Ca.  
 
Figure 8.9 Background subtracted and k3-weighed EXAFS functions, (k), (left) and radial electron 
density distributions given as the modulus of the Fourier transform of (k) (right) for 4-week dog 
femur and 52-week dog calvaria. The figures show data for samples taken from the high dose groups 
(orange), medium dose groups (blue), low dose groups (red) and 5% doped Sr-HAp (black).  
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Within the apatite lattice, the Sr atoms are highly coordinated and expected to be 
very tightly bound compared with Sr atoms bound to e.g. collagen outside the apatite 
structure. Such loosely bound Sr will result in a dampening of the EXAFS signal. 
Seeing that the spectra for bone samples have lower amplitudes than the spectrum for 
Sr-doped HAp, this suggests that some Sr is coordinated to other materials than HAp. 
This is supported by the radial electron distribution functions for the bone samples, 
which have a higher relative height for the first peak than the Sr-doped HAp, 
indicating a coordination of Sr to other material at distances around 2.5 Å. This 
distance is close to an average Sr-O distance, suggesting that Sr may be coordinated 
to oxygen atoms in collagen or water in addition to the apatite coordination.  
The spectra for the bone samples all look very similar, showing that the local 
environments for Sr are similar in all cases. Thus, the local chemical coordination of 
the Sr ions in the bones was largely independent of dose, type of bone and treatment 
time. The peak heights (amplitude) of the EXAFS spectra increased with increasing 
dose, demonstrating that more Sr was incorporated into the bone apatite with 
increasing Sr dose [342].  
8.4.6 Biomechanical measurements 
Previous studies have shown that strontium treatment improved bone strength in 
femur and vertebra in healthy rats [119] and in healed, previously fractured, tibiae in 
osteoporotic rats [121]. In this study, strontium’s effect on the biomechanical 
properties of cortical and trabecular bone was assessed by testing the strength of 
femurs and vertebrae. The mainly cortical femoral mid-shaft was subjected to a 
three-point bending test, while the trabecular bone in the core of the vertebral body 
was tested by compression. The femoral neck was tested by a bending test. This site 
contains both cortical and trabecular tissue and is a frequent site of fracture in 
osteoporotic patients [345]. The data for the biomechanical measurements was 
analysed by plotting load-displacement curves and recording the maximum load, 
maximum displacement and absorbed energy (cf. section 4.4). Figure 8.10 shows an 
example of a load-displacement curve for a three-point bend test.  
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Figure 8.10 Example of a recorded load-displacement curve for three-point bending test of dog femur. 
The highest point on the curve was taken as the load-to-failure value.   
The measurements all showed very large intra-group variances, which, in 
combination with the relatively low number of samples, made it difficult to identify 
treatment effects. It was attempted to normalise the results with respect to the size 
(weight) of the individual animals, but that did not reduce the intra-group variance. 
Bone size is a major determinant for bone strength [100, 119], and the large 
variability may therefore be due to intra-group differences in bone volume. The 
results from the two tests of femur were correlated (Figure 8.11a), the maximum 
tolerated load of the mid-shaft being 1.2 kN higher than that of the neck, irrespective 
of strength (slope = 1).  
Groups 2 and 3 showed a slight but non-significant increase in cortical strength 
(maximum load, three-point bending), while group 4 showed a significant decrease 
in strength (Figure 8.11b). A similar decrease in strength was seen in the femur neck 
in Group 4. This demonstrates that the dose of 1000 mg kg-1 day-1 induced 
deleterious effects in the bone apatite structure, comparable to the observations of 
poor teeth condition in the high dose group in 26-week rat (section 7.3.6). As 
previously discussed, the effect may be linked to the reduced bone calcium in the 
high dose groups, or to a distortion of the apatite crystal lattice due to strontium’s 
larger ion radius [12]. 
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Figure 8.11 (a) maximum loads measured for femur (mid-shaft and femur neck) were correlated. 
Mid-shaft = (1.02±0.22)·neck + (1.2±0.4), r2 = 0.40, p < 0.001. (b) maximum load of femoral mid-
shaft for the four animal groups. The strength was significantly reduced in Group 4.  
Somewhat surprisingly, no significant effects were seen in the vertebrae. Since 
trabecular tissue incorporates more Sr than cortical tissue, it was expected that any 
biomechanical effects of the Sr treatment would be evident in these samples. 
However, the intra-group variance was too large to identify any differences between 
the groups (Table 8.8). The variability may have been caused by presence of various 
amounts of cortical tissue in the biopsies. The diameter of the applied drill only just 
allowed for a trabecular biopsy to be taken from the inner part of the vertebral body, 
and some biopsies may have included some of the cortical bone making up the cortex 
of the vertebrae, which would affect the biomechanical properties of the biopsy. 
Although great care was taken to avoid it, the microstructure of biopsies may also 
have been damaged by the sampling process.  
8.4.7 Validation of bone densitometry measurements 
The accuracy of the DEXA analysis was evaluated using the hydroxyapatite 
mixture containing 0% Sr in the PMMA block. The nominal value for BMC was the 
amount of HAp transferred to the hole, while the area was calculated from the 
diameter (2.1 cm) of the hole. The nominal BMD was calculated as the ratio between 
nominal BMD and area. The accuracies of the BMD, BMC and area determinations 
were then calculated as the ratios between the measured and nominal values (Table 
8.11). The accuracy for all parameters was found to be satisfying and within 
previously reported ranges for similar instruments [240].  
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Table 8.11 Accuracy and precision (n = 15) for DEXA analysis of pure hydroxyapatite.  
 Nominal value Measured (mean ± SD) Accuracy (%) 
BMC (g) 2.66 2.82 ± 0.02 106 
Area (cm2) 3.63 3.95± 0.03 109 
BMD 0.732 0.715 ± 0.003 97.7 
 
The total repeatability of the analysis depends on the precision of the detector, 
the repeatability of the positioning of the samples and the operators’ ability to select 
the same ROI after each scan. The repeatability was evaluated by repeating 
measurements of the same set of bone samplings over several days, resulting in a 
precision of 0.9-1.0% for BMD, BMC and area of mid-diaphyseal femur. 
8.4.8 Influence of Sr on BMD measurements 
Strontium’s effect on DEXA measurements was described in Chapter 4. In order 
to obtain a reliable evaluation of the effect of SrM treatment on bone BMD, 
strontium’s influence on DEXA measurements was assessed, using mixtures of 
hydroxyapatite with various concentrations of Sr. The calculations follow the 
procedure presented by Nielsen et al. [240], who published correction factors for a 
range of different DEXA scanners. The overestimation or the relative error (RE) of 
the BMD measurement for each apatite mixture was calculated by the difference in 
measured BMD between pure Ca-HAp and the individual mixture of Sr-doped HAp: 
 ܴܧ஻ெ஽ ൌ ܤܯܦௌ௥ିு஺௣ െ ܤܯܦ௉௨௥௘ ு஺௣ܤܯܦ௉௨௥௘ ு஺௣  (8-2) 
The RE was calculated for the area and BMC in a similar fashion. After 
determination of the exact Sr-concentration in each of the six mixtures, the molar 
ratios between Sr and Sr-doped HAp were calculated, providing a measure for the 
amount of Ca atoms that had been substituted by Sr in the apatite. RE was then 
plotted against the molar ratio of Sr, showing the relationship between the amount of 
Sr present and the scanner’s overestimation of BMD (Figure 8.12). 
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Figure 8.12 The relative error of BMD measurements of hydroxyapatite at different molar ratios of 
Sr. A linear relation with a slope of kBMD = 91.0 ± 1.1 was found. 
Linearity was accepted for the data in Figure 8.12 and the overestimation was 
therefore expected to be well-described by a linear model. As expected, the intercept 
was not significantly different from zero (corresponding to no correction for pure 
HAp), and the level of overestimation was therefore calculated using OLSR for the 
model 
 ܴܧ஻ெ஽ ൌ ݇ · ܯܴௌ௥ (8-3) 
where k is the correction factor [mol HAp / mol Sr] and MRSr the concentration of Sr 
given as a molar ratio with respect to HAp. A correction factor of k = 0.910 ± 0.014 
was found. For the purpose of comparison with literature values, the correction factor 
was recalculated by using the molar fraction of Sr/(Ca+Sr) as a measure for Sr 
substitution. The resulting correction factors are presented in Table 8.12, together 
with data reported by Nielsen et al. [240]. The authors found that the correction 
factor depended on whether the HAp was placed directly on the scanner table or 
positioned between a total of 5.5 cm acrylic glass and 9.5 cm of water. In this work, 
the positioning of HAp on 2 mm of acrylic glass and 3 cm of rice resulted in 
correction factors close to those obtained without water and acrylic glass. One 
important difference is that Nielsen et al. [240] found that the estimates of the 
mineral-containing areas were not correlated to the Sr-contents in the apatites, 
whereas, in the present study, the area estimate increased systematically with 
increasing Sr-concentration. Since all the holes had the same diameter, it was 
concluded that the scanner’s edge detection was affected by the amount of Sr in the 
HAp. The reason for this effect has not been identified. 
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Table 8.12 Comparison of values for correction of strontium’s influence on DEXA measurements of 
BMC, BMD and area. The means, standard deviations and confidence intervals (CI) quoted from 
[240] are based on measurements from a range of different DEXA-scanners, with the HAp samples 
placed directly on the scanner table. 
 Present work  Nielsen et al. [240] 
Mean ± SD  Norland XR-26 Mean ± SD 95% CI 
BMC 0.0910 ± 0.0011  0.0926 0.0883 ± 0.0107 0.0794-0.0973 
Area 0.0116 ± 0.0010  0.0001 0.0025 ± 0.0074 -0.0015-0.0064 
BMD 0.0752 ± 0.0011  0.0966 0.0869 ± 0.0089 0.0794-0.0944 
BMD incl.  
areal correction 
0.0910 ± 0.011  - - - 
 
The area effect of the Sr-content was assumed to be related to the design of the 
acrylic block rather than being a general property of the DEXA-scanner. The effect 
was expected to be absent, or at least less pronounced, for the animal samples, and it 
was therefore decided to adjust the BMD correction factor for the overestimation of 
the area. This resulted in a 21% increase in the correction factor compared with that 
obtained directly from the BMD measurements.  
Using the molar ratios of Sr, MRSr, that were calculated for the evaluation of the 
substitution model (cf. sections 7.3.9 and 8.4.4), the corrected BMD in each bone 
sample can be calculated using the following formula: 
 ܤܯܦ௖௢௥௥௘௖௧௘ௗ ൌ ܤܯܦ௠௘௔௦௨௥௘ௗ1 ൅ ܴܧ஻ெ஽ ൌ
ܤܯܦ௠௘௔௦௨௥௘ௗ
1 ൅ ݇ · ܯܴௌ௥  (8-4) 
Figure 8.13 shows the effect of the BMD correction in femur. The uncorrected BMD 
results were significantly correlated with the Sr concentration in the bones, whereas 
the corrected values showed no such correlation. Thus, the interference from Sr on 
the X-ray attenuation was eliminated, allowing for a more reliable evaluation of the 
mineral density in the bones. 
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Figure 8.13 Relationships between measured () and corrected () BMD results and the directly 
determined strontium concentrations in dog femur. There is a significant correlation between 
measured BMD and femur Sr (p < 0.001), whereas the corrected BMD is not correlated to the Sr 
concentration (p = 0.33). 
Nielsen et al. [240] clearly demonstrated that the magnitude of the correction 
factor depends on whether the X-rays are also attenuated by other materials than 
apatite. Consequently, the application of a correction factor calculated from pure 
HAp was challenged by fact that the mineral phase in the real animal samples was 
surrounded by various organic materials. Made up by mineralised collagen, marrow, 
bone cells, etc. the microstructure of the bones is much more complex than the pure 
inorganic powders. Additionally, the bones were surrounded by adhering soft tissues 
and wrapped in cotton soaked in isotonic water in order to keep them hydrated for 
the subsequent mechanical measurements. Together, these tissues and materials may 
affect the interference from Sr. However, as there was no way to predict a possible 
deviation, the value determined from the HAp powders represented the best 
attainable estimate of the correction. It should be noted that other techniques for 
determination of bone mass and density, such as bone ash weight [119] and density 
fractionation [107, 112], would also be expected to be influenced by the purely 
physical effect of strontium’s high weight. 
8.4.9 Effect of SrM treatment on BMD 
The group averages of measured and corrected BMD for femur and calvaria are 
shown in Figure 8.14. As expected, the correction for Sr reduced considerably the 
average BMD in all the active dose groups, while the placebo group BMD remained 
essentially unchanged.  
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Figure 8.14 Means and SDs (error bars) of measured () and corrected () BMD results for dog 
femur and calvaria. Femurs from the animals in Group 3 (300 mg kg-1 day-1 SrM) had significantly 
increased BMD in femur compared with placebo. 
Both femur and calvaria show similar trends: compared with placebo, BMD 
increases with dose in Groups 2 and 3, while the BMD in Group 4 is marginally 
lower than in the placebo group. An analysis of variance with corrected BMD as 
response and dose group as effect showed a significant inter-group difference only in 
femur BMD. Further investigation (Dunnett’s test) revealed that Group 3 had 
significantly higher corrected BMD in femur than the placebo group (p = 0.0017). 
This indicates that a dose of 300 mg kg-1 day-1 SrM increased the mineral density of 
mid-diaphyseal femur.  
The increase in BMD is somewhat in contrast to the results of the elemental 
analysis, which showed that Ca concentrations were decreased in the active dose 
groups. In order to asses whether this disparity may be explained by the increased 
amounts of Sr in the treated groups, the molar concentrations of Sr + Ca were 
calculated, and the substitution model was used to express the concentrations with 
respect to hydroxyapatite (Table 8.13). The results showed that the molar 
concentrations of Sr + Ca were similar in calvaria in all four groups (p = 0.29), while 
Sr + Ca in femur was (barely) significantly lower (p = 0.021) in the treated groups. 
There were no differences between any of the active dose groups, demonstrating that 
loss of Ca did not increase with increased SrM dose. Still, these observations do not 
support the increase in corrected BMD seen in Groups 2 and 3. One explanation for 
this difference might be that the correction of the Sr interference on the DEXA scans 
was inadequate, due to the potential problems with soft-tissue attenuation as 
discussed above. It is also possible that the areal density measured by DEXA and the 
weight-to-weight concentrations measured by ICP-MS were affected differently by 
52-week strontium malonate treatment in dogs 145 
 
 
the SrM treatment and the addition of Sr to the bone matrix. If SrM stimulated 
formation of new bone within the bone structure, e.g. on the inner surface of the 
medullary cavity of the femurs, it might be seen as an increase in areal mineral 
density. It would not, however, necessarily be perceived as an increase in the 
concentrations of Sr + Ca as measured by ICP-MS, because of the accompanying 
increase in the total weight of the bone. As a final point, the EXAFS measurements 
showed that some of the Sr ions imbedded in the bone tissue was bound to atoms 
outside the apatite structure. Rather than substituting Ca in the apatite, these Sr ions 
may be therefore have been adsorbed as an amorphous phase of inorganic salts such 
as Sr3(PO4)2 and SrCO3. Having higher densities than hydroxyapatite [16, 346], 
presence of such compounds would influence both the DEXA measurements and 
ICP-MS analyses. 
Table 8.13 Concentrations of Ca and Sr in dog femur and calvaria. The ICP-MS results were 
converted to molar concentrations in order to asses the sum of  
Dose  
(mg kg-1 day-1) 
Concentration 
Sr Ca Sr + Ca Sr + Ca 
(mg g-1 bone) (mmol g-1 bone) (mol mol-1 HAp) 
Femur     
0 (n=8) 0.078 ± 0.013 328 ± 41 8.2 ± 1.0 10.5 ± 1.4 
100 (n=6) 15.4 ± 5.4 271 ± 15 6.94 ± 0.36 9.30 ± 0.70 
300 (n=8) 22.7 ± 6.6 263 ± 25 6.82 ± 0.66 8.96 ± 0.85 
1000 (n=8) 28 ± 12 275 ± 26 7.18 ± 0.74 8.97 ± 0.50 
Calvaria     
0 (n=8) 0.116 ± 0.017 279 ± 19 6.95 ± 0.48 9.95 ± 0.69 
100 (n=7) 19.3 ± 5.2 253 ± 16 6.54 ± 0.36 9.50 ± 0.48 
300 (n=8) 27.4 ± 5.2 254.3 ± 8.2 6.66 ± 0.21 9.73 ± 0.31 
1000 (n=8) 37.0 ± 8.1 244 ± 12 6.51 ± 0.22 9.59 ± 0.28 
 
The validity of the BMD measurements was evaluated by comparing the 
corrected BMD results with the biomechanical measurements. The inter-group 
pattern of the corrected BMD results resembles that which was seen for the three-
point bending tests of the femurs (Figure 8.11). A small (non-significant) increase in 
maximum load was observed in Groups 2 and 3 compared with placebo, while a 
significant decrease was seen in Group 4. The degree of mineralisation is a very 
important factor in determining the mechanical strength of bone [77, 100], and the 
corrected BMD was therefore expected to be related to the maximum load. Amman 
et al. [119] reported a clear correlation between BMD as measured by DEXA and 
bone strength in rat femoral mid-shaft after 2 years of treatment with SrR. However, 
the authors did not adjust the BMD results for the large concentrations of Sr (up to 
146  Chapter 8 
 
 
5.4 mol% Sr/(Sr + Ca)) present in the femurs. The measured BMD must therefore be 
assumed to have been strongly affected by the presence of Sr, and the results may 
therefore not represent the true mineral density of the bones. In the present work, the 
corrected BMD in mid-diaphyseal femur was compared with the maximum load of 
the three-point bending test (Figure 8.15).  
 
Figure 8.15 Relationship between bone strength (three-point bending) and corrected BMD for dog 
femur. Slope = 6.99±1.1, r2 = 0.56, p < 0.001. 
There was a very strong correlation between the two observations, demonstrating 
that the corrected BMD can be used as a predictor for the maximum load. The 
correlation also suggests that the increase in corrected BMD following SrM 
treatment was associated with concomitant increase of bone strength. 
8.5 Conclusion 
This study showed that Sr was readily incorporated into molar tooth, calvaria and 
mid-diaphyseal femur in dogs after 52 weeks of treatment with strontium malonate. 
The highest concentrations of Sr were found in calvaria, where administration of up 
to 460 mg kg-1 day-1 Sr2+ resulted in an approximate 350-fold increase in bone Sr 
compared with placebo. The lowest degree of Sr incorporation was seen in molar, 
which is attributed to the low remodelling rate of dog teeth. The concentrations of Sr 
in femur and molar were correlated. By comparing the femur Sr concentrations with 
those found in a 4-week study in dogs, it was observed that approximately one third 
of the Sr found after 52 weeks was incorporated already after 4 weeks, suggesting 
that initial incorporation of Sr happens by a rapid mechanism which is eventually 
saturated and replaced by a slower mechanism. All the active dose groups had 
reduced concentrations of Ca and P in both calvaria and femur. 
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EXAFS measurements indicated that Sr had substituted Ca in the bone apatite 
structure but that Sr also coordinated to other atoms, most likely oxygen in collagen 
and water. The coordination of Sr was similar in the calvaria and femur, and the 
incorporation of Sr into the HAp increased with increasing dose. A higher resolution 
in the EXAFS data would be needed in order to obtain more detailed information on 
the coordination of Sr. 
The mechanical strength of the femurs was significantly reduced in the highest 
dose group, indicating a weakening of the apatite structure. A small but non-
significant increase in strength was seen in the low and medium dose groups.  
Measurement of BMD using DEXA was found to be heavily influenced by 
presence of Sr in the mineralised matrix. A direct linear relation between 
overestimation of BMD and Sr concentration was identified, and a correction of 9% 
for a 1:10 molar ratio of Sr:HAp was determined. The correction was applied to 
BMD measurements of femur and calvaria, resulting in a significant increase in 
corrected BMD in femur mid-shaft in the group treated with 300 mg kg-1 day-1 SrM. 
The corrected BMD was found to be correlated with bone strength, irrespective of 
SrM dose. 
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9.1 Strontium’s effect on bone tissue 
This work has shown that strontium administered orally as strontium malonate 
(SrM) is highly bioavailable for transport to the blood and for incorporation into 
calcified tissues in rats and dogs. Long-term treatment with 100, 300 and 1000 mg 
kg-1 day-1 SrM (corresponding to 46, 138 and 460 mg kg-1 day-1 Sr2+, respectively) 
resulted in dose-dependent increases in Sr concentrations of up to 500 folds in rat 
incisor and 350 folds in dog femur. Significant gender differences were observed in 
both rats and dogs. In rats, Sr had a higher bioavailability in males than in females, 
while the opposite trend was seen in dogs after four weeks of treatment. Sr 
concentrations in different skeletal sites were correlated, and the degree of 
incorporation depended on the rate of turnover in the mineralised matrix. It was 
observed that approximately one third of the Sr found after 52 weeks was 
incorporated already after 4 weeks. This suggests that initial incorporation of Sr 
proceeds by a rapid mechanism which is eventually saturated and replaced by a 
slower mechanism. High doses of Sr reduced Ca concentrations in both serum and 
calcified tissues, indicating that Sr influenced Ca metabolism and the mineralisation 
of the bones and teeth.  
A stoichiometric model was proposed for incorporation of Sr in hydroxyapatite. 
The model showed excellent agreement with the analytical data and it was found that 
respectively 70 – 72% of femur, 78% of rat incisor and 85% of dog molar was made 
up by hydroxyapatite (HAp). The model demonstrated that a part of the perceived 
loss of Ca in the calcified tissues was caused by the adsorption or incorporation of Sr 
in the HAp. EXAFS measurements indicated that some apatite Ca was substituted by 
Sr in the SrM-treated animals and that the incorporation increased with increasing Sr 
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dose. However, Sr also coordinated to other atoms, most likely oxygen in collagen 
and water. 
The mechanical strength of dog femur was slightly but non-significantly 
increased in the low and medium dose groups, while the highest Sr dose group 
showed significantly reduced bone strength, indicating a weakening of the apatite 
structure at the highest dose. 
Measurement of BMD using DEXA was heavily influenced by presence of Sr in 
the mineralised matrix, and a direct linear relation of 9% for a 1:10 molar ratio of 
Sr:HAp was identified. By applying the correction, a significant increase was 
observed in corrected BMD in femur mid-shaft in the group treated with 300 mg kg-1 
day-1 SrM. The corrected BMD was found to be clearly correlated with bone 
strength, irrespective of SrM dose. This strongly indicated that the increase in 
corrected BMD following SrM treatment was associated with concomitant increase 
of bone strength. 
9.2 Methodology 
Direct measurements of the treatment effects of SrM on bone were complicated 
by the fact than Sr affects bone both on the cellular and molecular level. 
Incorporation of Sr ions into the apatite matrix affected evaluations of bone 
mineralisation by both DEXA and ICP-MS. Adjustments for Sr contents were 
therefore essential in order to correctly interpret the results.  
ICP-MS proved to be a very suitable analytical technique for determining key 
bone elements in serum and mineralised tissues due to its high accuracy, multi-
element capability, low quantification limits and broad linear range. The low natural 
concentrations of Sr in serum required application of a high-sensitivity desolvation 
unit for sample introduction, which constituted a major improvement in performance 
with respect to sample consumption, sensitivity, precision and oxide levels compared 
with a conventional cross-flow nebuliser.  
The measurement uncertainty associated with the ICP-MS analysis was 
frequently underestimated when applying conventional calibration procedures. To 
obtain reliable uncertainty estimates, calibration data from many different days were 
pooled into one data set. This new principle of processing calibration data 
successfully provided a satisfactory estimate of the measurement uncertainty related 
to the ICP-MS analysis, ensuring reliable determinations of the analytes of interest. 
Substantial differences between the LOQ and lower limit of analysis (LLA) were 
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observed, and it was suggested that the LLA is a useful parameter for estimating the 
lowest concentration at which a sample can be reliably analysed at an RSD of less 
than 50%. 
9.3 Outlook 
It would be of great interest to examine further the impact of SrM on bone 
mineral density and strength. In order to obtain more conclusive results about the 
beneficial effects of Sr, it might be suggested to set up an animal study with lower 
treatment doses, longer treatment time and, ideally, with more animals in each dose 
group. With respect to the current results, it would be of interest to normalise the 
biomechanical measurements with respect to the physical dimensions (e.g. thickness 
or cross-section) of the bones. Bone size is a major determinant of bone strength, and 
adjusting the biomechanical results for bone volume might therefore reduce the 
variability within the dose groups, thus allowing for a stronger identification of 
potential treatment effects.  
Further method development is necessary in order to achieve a satisfactory 
accuracy for determination of P in serum using ICP-MS. The main objective would 
be to identify and overcome the disturbing interferences. Application of another 
internal standard than Rh might also be of use.  
A better resolution of the EXAFS data would be very useful for drawing more 
detailed conclusions about the position and coordination of Sr in bone tissue. This 
would require collection of a new set of EXAFS data over a higher energy range. For 
the purpose of comparison, EXAFS spectra of collagen coordinated to Sr may also 
be useful.  
As a final point, the role of the malonate anion has not been specifically 
investigated in this project. In order to obtain a complete picture of the biological 
effects of SrM treatment, it might be worthwhile to include analysis of malonate in 
any future animal studies of SrM.  
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Appendix I 
Investigation of hydrolysis of organic phosphorus 
compounds using stopped­flow analysis 
1 Introduction 
In view of the poor accuracy observed in the determination of phosphorous in 
serum using ICP-MS (cf. Chapter 5), the potential of flow injection analysis (FIA) 
and sequential injection analysis (SIA) for quantification of P in biological fluids was 
explored. These methods have been used extensively for quantification of P in 
environmental samples [1-4] and were thought to constitute suitable alternatives to 
ICP-MS. The most widely used method for determination of inorganic P is the 
molybdenum-blue spectrophotometric method, in which orthophosphate reacts with 
an acidified molybdenum reagent to form phosphomolybdate heteropolyacid, which 
is then reduced to form a blue compound and determined spectrophotometrically [1, 
2]. Though most of the phosphate bound to organic compounds is unable to react 
directly with molybdenum, the highly acidic conditions may cause hydrolysis of 
some organic P compounds. This would make organic P available for reaction with 
molybdenum and lead to an overestimation of the inorganic P concentration. The aim 
of this work is to investigate three model P compounds, glucose-6-phosphate (G6P), 
phytic acid and penta-sodium triphosphate, to asses the extent of hydrolysis during P 
determination using the molybdenum-blue method.  
2 Experimental  
All glassware and bottles were cleaned overnight in nutrient free detergent 
(Neutracon®), rinsed three times with ultra-pure water (18.2 M), soaked in 10% 
(v/v) HCl for 24 h and again rinsed three times with ultra-pure water. All solutions 
and reagents were prepared with ultra-pure water. A 100 mg/l PO4-P stock solution 
was prepared by dissolving 0.4393 g of dried potassium dihydrogen orthophosphate 
in 1 l of ultra-pure water. Organic P stock solutions were prepared as shown in Table 
1. Working standards were prepared by dilution of the stock solutions. 
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Table 1 Preparation of organic P stock standards. Fresh stock solutions were prepared every day.  
Compound 
Amount transferred 
(mg) 
Final volume 
(ml) 
Stock concentration 
(mg l-1 P) 
Glucose-6-phosphate 96.3 100 100 
Phytic acid 396.2 100 1000 
Triphosphate 395.9 100 1000 
 
2.1 Flow method 
Two reagents were prepared: ammonium molybdate (5 g ammonium molybdate 
and 17.5 ml sulphuric acid in 500 ml ultra-pure water) and tin(II)chloride (0.1 g 
tin(II)chloride, 1 g hydrazinium sulphate and 14 ml sulphuric acid in 500 ml ultra-
pure water). The measurements were performed using an in-house flow injection 
analyser (Figures 1 – 2) at the University of Plymouth and a FIAlab-3200 SIA 
instrument (Figure 3) at Monash University. 
 
Figure 1 The flow injection analyser used for phosphate analysis at the University of Plymouth. 
 
The FIA manifold consisted of two peristaltic pumps, PTFE tubing, a flow cell and 
an injection valve (Figure 1). All electronics, such as detectors, amplifiers and LED 
are contained in a gray housing. The analyser is connected to a PC via a USB 
connection. The valve is turned by applying pressurised N2 gas. The pump tubing 
used for the FIA reagent streams are shown in Table 2. The system is designed for 
determination of phosphate using the molybdenum-blue method with tin(II)chloride 
as a reductant and detection at 690 nm. Pump 1 runs at 40 rpm and is used to propel 
Pump 1 controls 
Pump 2 controls 
Detector amplification switch  Valve fill/inject switch 
Flow cell
Sample loop 
Reaction coils 
Optical fibre
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the carrier (ultra-pure water), molybdenum and tin(II)chloride streams. Pump 2 runs 
at 20 rpm and is used to fill the sample loop.  
Table 2 Pump tubing (Elkay accu-rated) used with the flow analyser. 
Stream Colour code 
Carrier White/White 
Acid molybdate Orange/White 
Tin(II)chloride Orange/Yellow 
 
 
Figure 2 The multi-reflection flow cell. Red light from the LED is 
visible at the end of the fibre on the right hand side [5]. 
 
 
 
Figure 3 The FIAlab sequential injection system used for analysis of organic phosphate. 
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Details on the principles and operation of the SIA apparatus are given elsewhere [6, 
7]. 
2.2 Batch method 
Four reagents were prepared, sulphuric acid (70 ml concentrated sulphuric acid 
diluted with 500 ml ultra-pure water), ammonium molybdate (15 g ammonium 
molybdate in 500 ml of ultra-pure water), ascorbic acid (5.4 g ascorbic acid in 100 
ml ultra-pure water) and potassium antimonyl tartrate (0.34 g potassium antimonyl 
tartrate in 500 ml ultra-pure water). A working reagent was prepared (fresh every 
time) by mixing 
1. 75 ml sulphuric acid solution 
2. 25 ml ammonium molybdate solution 
3. 25 ml ascorbic acid solution 
4. 12.5 ml potassium antimonyl tartrate solution 
20 ml of sample or calibration standard was transferred to a 25 ml volumetric flask, 4 
ml working reagent was added and the flask was filled to the mark with ultra-pure 
water and inverted several times. The reagent-sample solution was immediately 
transferred to a 1 cm quarts cell, and the absorbance (λ = 890 nm) was measured at 
selected reaction times (5-35 min) by leaving the cell in the spectrophotometer and 
taking 3-5 replicate readings when desired.  
3 Results 
3.1 Flow injection 
The flow analyser has two different amplification settings. Typical calibrations 
are shown in Figure 4. The x10 setting increases the sensitivity with a factor of 10 
compared with the 1x setting. The high amplification (LOD: 0.5 µg l-1 P) is 
recommended for determination of phosphate concentrations below 10 µg l-1 P.  
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Figure 4 Calibrations with the detector amplification set on x1 (a) and x10 (b). The sensitivities were 
4.08 and 41.2 mV l µg-1, respectively. 
 
3.2 Stopped flow 
If the sample-reagent mixture is stopped within the flow cell, the rate of the 
colour reaction can be measured by monitoring the change in absorbance. Under 
normal circumstances, a program to automatically stop the flow precisely at the 
appropriate time could easily be created in the LabView software. However, due to 
noise problems, the onboard pumps could not be used, and hence external pumps had 
to be applied. The flow was therefore stopped manually and the correct timing was 
observed with the aid of a stop watch. Using the SIA system, the stopped-flow 
procedure and the data collection could be fully automated by the accompanying 
software.  
3.2.1 Inorganic phosphate 
In order to assess the timing and response of the flow analyser, a series of 
orthophosphate standards were analysed. The time between sample injection and the 
point where the flow was stopped was eventually set to 22 s. The (instantaneous) rate 
of reaction at a given time can be determined by the slope of the tangent drawn to the 
absorption curve (Figure 5). 
(a) (b) 
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Figure 5 Stopped Flow analysis of 50 µg l-1 PO4 using the FIA apparatus.  
The reaction rate is given by the slope of the tangent drawn to the curve 
(dashed line). 
 
As can be seen from Figures 6-8, the rate of reaction increases with increasing 
phosphate concentration.  
 
Figure 6 Sections of response curves for 0-200 
µg l-1 PO4. 
Figure 7 Reaction rate as a function of initial 
phosphate concentration. 
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Figure 8 Recorded data from stopped flow analysis of organic phosphate compounds. Stopping the 
flow provide an incubation time for reaction rate measurements [7]. The stop-flow curves up to 4700 s 
originate from analysis of calibration standards containing 0-1 mg L-1 PO4-. 
 
3.2.2 Reaction order 
Let us assume that the general reaction 
 ܣ ൅ ܤ ܥ (1) 
has the rate law 
 ݎ ൌ െ ݀ሾܣሿ݀ݐ ൌ െ
݀ሾܤሿ
݀ݐ ൌ
݀ሾܥሿ
݀ݐ ൌ ݇ሾܣሿ
௡ሾܤሿ௠ (2) 
where r is the rate, k the rate constant and n + m the order of reaction. If the reactant 
B is present in large excess, we can write 
 ݎ ൌ  ݇ሾܣሿ௡ሾܤሿ௠ ൌ ݇Ԣሾܣሿ௡, ݇ᇱ ൌ ݇ሾܤሿ௠ (3-1) 
which can be rearranged to 
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 ln ݎ ൌ ln ݇Ԣ ൅ ݊ lnሾܣሿ (4) 
 
With the reagents (ammonium molybdate and tin(II)chloride) in excess, a plot of 
ln(rate) against ln[PO4] is expected to form a straight line with slope n. Figure 9 
shows that the plot is indeed linear with a slope of 0.99, indicating a reaction order of 
1 with respect to phosphate, in accordance with previous reports [8]. This shows that 
the flow analyser is capable of producing reliable kinetic measurements using the 
stopped-flow technique and that the instrument is very suitable for the current 
investigation.  
Figure 9 ln r vs. ln[PO4]. The slope of the fitted line is 0.99, indicating 
a first order reaction (see text). 
 
3.2.3 Organic phosphate compounds 
As the most labile of the three investigated organic P compounds, G6P was expected 
to be the most susceptible to hydrolysis. However, the slopes of the response curves 
for 0-200 µg l-1 G6P (Figure 10) were constant within the noise level. Figure 11 
shows the calculated reaction rate as a function of the G6P concentration. No 
significant relation was found (the slope of the fitted line is not significantly different 
from zero).  
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Figure 10 Overlaid sections of response curves for 
0-200 µg l-1 P- glucose-6-phosphate. 
Figure 11 Reaction rate vs. glucose-6-phosphate 
concentration. No significant relation was found.  
 
Seeing that no measurable hydrolysis had taken place with G6P, it was assumed that 
similar results would be obtained for triphosphate and particularly phytic acid. 
Hence, it was decided not to continue the investigation of these compounds using the 
flow injection analyser. Similar results were reached using the SIA instrument.  
3.3 Batch measurements 
With the flow injection analyser, data could be collected for no longer than 5 min per 
analysis. To allow for a longer reaction time, the batch method described in section 
2.2 was applied. 
3.3.1 Inorganic phosphate 
Standards of 10-100 µg l-1 PO4 were mixed with the working reagent and used to 
calibrate the spectrophotometer (Figure 12) at reaction times of 5, 12 and 20 min. 
The highest absorbance was seen after 12 min (Figure 13), confirming the 
recommendation stated in the SOP. 
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Figure 12 Batch method calibration. The reagent-sample 
mixture was left to react in the flow cell for 12 min as 
recommended in the SOP. 
Figure 13 Absorbance of 50 µg l-1 
phosphate at reaction times of 5, 12 
and 20 minutes. The error bars 
show the standard deviation 
(precision). 
  
3.3.2 Organic phosphate compounds 
The sensitivity of the batch method (LOD: 3 µg l-1 P) was much lower than that of 
the flow injection analyser, and therefore much higher concentrations of the organic 
P compounds were required. The analysis of 2 mg l-1 G6P (Figure 14a) showed an 
absorbance maximum at a reaction time of 18-20 min, after which the response 
decreased. The PO4 concentration after 20 min was 13 µg l-1, corresponding to 0.7% 
hydrolysed G6P. However, this low concentration of PO4 may well be explained by 
impurities in the stock G6P compound, as the certificate only guarantees > 95% 
purity. The decrease in absorbance after 20 min indicates that there was no ongoing 
formation of reactive PO4 and therefore no (measureable) hydrolysis of G6P within 
35 min. The 5 mg l-1 G6P solution showed maximum absorbance after 12 min 
(Figure 14b), corresponding to 16 µg l-1 PO4 and 0.3% hydrolysed G6P. Again, the 
presence of reactive PO4 may be a result of impurities.  
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Figure 14 Glucose-6-phosphate, 2 mg l-1 (a) and 5 mg l-1 (b). The bar charts show the concentration of 
PO4 after different reaction times. The error bars show the standard deviation (precision). 
 
The absorbance of 1 mg l-1 phytic acid (Figure 15a) was below or very close to the 
limit of detection after 5 and 12 min. After 20 min the PO4 concentration was 8 µg 
l-1, corresponding to 0.8% hydrolysis. 10 mg L-1 phytic acid (Figure 15b) had an 
absorbance maximum after 12 min with a PO4 concentration of 21 µg L-1, 
corresponding to 0.2% hydrolysed phytic acid. As was the case with G6P, these low 
concentrations of reactive PO4 may not be caused by hydrolysis of dissolved organic 
P, but instead by impurities in the stock compound. 
Figure 15 Phytic acid, 1 mg L-1 (a) and 10 mg L-1 (b). The bar charts show the 
concentration of PO4 after different reaction times. The error bars show the standard 
deviation (precision). 
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The response pattern of 1 mg L-1 triphosphate (Figure 16a) was very similar to that of 
5 mg L-1 G6P and 10 mg L-1 phytic acid. At the absorbance maximum at 12 min 
reaction time, the PO4 concentration was 15 µg l-1, corresponding to 1.5% hydrolysis. 
In contrast, the 10 mg L-1 triphosphate solution (Figure 16b) showed a steady 
increase in PO4 concentration with time. After 5 min the PO4 concentration was 35 
µg L-1, increasing to 65, 79 and 98 µg L-1 PO4 after 12, 20 and 30 min, respectively. 
This suggests that triphosphate was hydrolysed continuously during the 30 min. The 
average reaction rate from 5 to 30 min was 2.4 µg L-1 min-1 PO4, and the PO4 
concentration after 30 min corresponded to 1% hydrolysis.  
 
  
Figure 16 Triphosphate, 1 mg L-1 (a) and 10 mg L-1 (b). The bar charts show the concentration of PO4 
after different reaction times. The error bars show the standard deviation (precision). 
4 Conclusion 
The flow injection analyser and the SIA instrument used in the present work are 
capable of producing reliable kinetic measurements using the stopped-flow 
technique. The investigation showed that the acidic reagents used with the 
molybdenum-blue method caused no or very little hydrolysis of the three organic P 
compounds. In all cases, less than 2% of organic P was hydrolysed after 12-35 min 
exposure to the acidic environment. In fact, the concentrations of reactive PO4 were 
so low that they may only be the results of impurities in the stock compounds. Thus, 
the molybdenum-blue method may be a feasible method for determination of P in 
biological fluids.  
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Abstract The strontium content of serum, bone, marrow,
and teeth was determined by inductively-coupled plasma
mass spectrometry (ICP–MS). Significant correlations were
obtained after the data were subjected to quality assurance
(QA) performed according to validated procedures. After four
weeks of treatment with strontium malonate, strontium levels
increased from 76±9 μg g−1 in placebo-treated dogs to levels
of 7.2±1.7 mg g−1, 9.5±2.7 mg g−1, and 9.8±2.7 mg g−1 in
groups treated with 300, 1000, and 3000 mg kg−1 day−1,
respectively. Strontium induced a highly significant increase
in the bone formation marker, bone-specific alkaline phos-
phatase (BSAP), and an excellent correlation was found with
the bone-strontium content. In females, the placebo-treated
group showed a decrease in BSAP of 53%, whereas the
three strontium malonate-treated groups showed an increase
of 60, 276, and 278% for the groups treated with 300,
1000, and 3000 mg kg−1 day−1, respectively. For males the
corresponding values were −44%, +142%, +194%, and
+247% increases in BSAP in the placebo, 300, 1000, and
3000 mg kg−1 day−1 groups respectively.
Keywords Chemometrics/statistics . Quality assurance .
Mass spectrometry/ICP–MS . Pharmaceuticals
Introduction
Early investigations [1, 2] revealed the beneficial effect of
non-radioactive strontium on the structure of cartilage and
bone. McCaslin and Janes [2] showed that patients suffering
from bone pain, as a result of osteoporosis, experienced
relief after oral intake of strontium lactate. The nature of the
anion in strontium compounds has been investigated in detail
with respect to transfer across cell membranes, and it has
been suggested that strontium ions are able to coordinate
rather strongly to small organic ligands. The introduction of
strontium ranelate [3] (Protelos®) as a potent pharmaceutical
for prevention and treatment of osteoporosis has initiated a
search for other strontium salts with elevated skeletal
efficacy and/or bioavailability of ionic strontium.
Bone turnover is mediated by mainly two types of cell,
osteoclasts and osteoblasts, responsible for bone degrada-
tion and formation [4]. In-vitro studies have revealed that
strontium ranelate can increase DNA synthesis and bone
matrix protein production by osteoblasts, and, furthermore,
on osteoclast cultures, a decreased maturation rate and
resorbing activity has been observed [5, 6]. It is well
established that strontium stimulates the formation of bone
volume [7], and strontium is the only trace-metal of bone
that can be positively correlated with the compression
strength of bone [8]. The mineralized tissue of bone contains
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approx. 40% organic material and 60% inorganic material,
predominantly hydroxyapatite Ca10(PO4)6(OH)2, the calcium
of which can to some extent may be substituted by strontium
or other double-charged metallic ions. Strontium may be
incorporated into the mineralized bone matrix by two main
mechanisms. If strontium is present when apatite crystal
formation is initiated in newly synthesized osteoid (i.e.
organic bone matrix), it may be directly incorporated in the
crystals, and affect the formation and properties of the
inorganic matrix. A second mechanism involves hetero-ionic
exchange of constituent ions of the apatite crystals with
strontium ions present in the micro-environment. By this
mechanism calcium in the inorganic bone matrix can be
substituted with strontium [9].
In adults the bone is continuously remodelled, whereas
remodelling of the dentine in teeth is very slow or even
absent. This means that the propensity for incorporation of
strontium in teeth is smaller in adult humans and also in
other higher mammals. The mineral content, and the ratio
between the different types of mineral in bone can be
determined by ICP–MS, which allows detailed study of the
interrelation of inorganic species that are constituents of
bone. After four and eight weeks of treatment, the strontium
content of the rat femur increased proportionally to
strontium dose within the range 35–140 mg kg−1 day−1
administered as strontium ranelate [10]. Strontium uptake
by rat bone saturated at doses close to 255 mg kg−1 day−1
after 10 days. However, several factors influence the incor-
poration of strontium bymineralized tissues—dose, strontium
concentration of the plasma, gender, the duration of treatment
and the bone type, or rather the turnover rate of the tissue.
With respect to the last factor, the strontium content of
trabecular bone of monkeys was higher than that of cortical
bone after 13 weeks of treatment, in accordance with expec-
tations, as trabecular bone has a substantially higher turnover
rate than cortical bone [10].
In order to study the interrelationship between the more
common metals of group II, a four-week study of beagle
dogs was initiated in which the animals were treated with
strontium malonate, Sr(C3H2O4) [11], by oral gavage [12].
Growth, clinical status, mineral content of bone and teeth,
and serum levels of bone-specific alkaline phosphatase
(BSAP), a marker for bone formation, were studied. The
magnesium, calcium, and strontium content of the miner-
alized tissues was measured by ICP–MS in cortical bone
and in teeth after the four-week treatment. Analysis of
bone and teeth has previously been performed by atomic
absorption spectrometry [13–18] but the technology is
prone to interferences. No interferences have been identi-
fied in the determination of strontium in bone and teeth by
ICP–MS [19–21]. All the results from this analysis were
subjected to data processing that complied with the
methods of the Eurachem/CITAC guide and the measure-
ments were validated by analysis of a standard reference
material (NIST SRM 1486 Bone Meal).
Experimental
Chemicals
The chemicals used were of at least p.a. grade and the bone
samples were treated with nitric acid (Merck Suprapur),
hydrochloric acid (Merck Suprapur), and hydrogen peroxide
(Riedel–de Haën p.a.). Millipore water was used for
dilutions throughout. The measurements were validated by
using the standard reference material NIST SRM 1486 Bone
Meal.
Sample pretreatment
Only the cortical part of the femur was used for analysis.
Soft tissues, such as marrow, flesh, and pellicle, were
removed from the bone samples by use of a scalpel prior to
further processing. Each bone was cleansed by immersion
in hydrogen peroxide (30%) in a beaker for one hour. The
beaker was subsequently placed in an ultrasonic bath for
ten minutes. The bone was then flushed with ethanol and
water, dried, and immersed in liquid nitrogen for one hour.
Roberts et al. [19] showed that the loss of analyte from the
bone to the hydrogen peroxide solution and to ethanol was
relatively minor. The bone was then placed in a plastic bag
and crushed with a hammer to small pieces. In order to
ensure homogeneity, about two grams of bone pieces were
sampled from the bag by incremental sampling [22] and
dried at 110°C for five hours. Two samples, denoted A and
B, each containing approx. 0.5 g bone pieces, were weighed
accurately for the analysis. The teeth were cleaned in a
similar fashion, but no fractionation was necessary prior to
digestion.
Digestion of samples
In order to ensure complete digestion of bone residues, the
samples were digested under hydrothermal conditions in a
microwave oven (Anton-Paar MW3000). A rotor of eight
quartz vessels contained samples weighing 0.45–0.60 g in a
solution of 5 mL conc. nitric acid, 0.5 mL conc. hydrochloric
acid, and 3 mL of conc. hydrogen peroxide. The pressure
controlled the progress of digestion and the power was
ramped up to 1200 W at a rate of 100 W min−1, and the
maximum pressure was set at 80 bar that was reached after
approx. 12 min. When this limit was reached, the power
was reduced, to maintain the maximum pressure for three
minutes.Within this period of time, the temperature continued
to rise thus reaching its maximum after digestion for 25 min.
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ICP–MS analysis
For analysis of strontium, the ICP–MS is virtually free
from spectral interferences and isobaric overlap. Addition
of 20 mg L−1 Al, Ba, Ca, Fe, K, Mg, Na, Zn, phosphate, or
sulfate to a solution containing 200 μg L−1 strontium did
not induce any interferences in the determination of stron-
tium. The measurements were performed with an ICP–MS
instrument (Perkin-Elmer Elan 5000) equipped with a cross-
flow nebuliser. The operating conditions and all measured
isotopes are listed in Table 1. All isotopes were analysed in
the peak-hop mode.
Most frequently, only the more abundant isotope, 88Sr,
has been used for strontium analysis [19–24]. In this
investigation the four naturally occurring non-radioactive
isotopes of strontium, 84Sr, 86Sr, 87Sr, and 88Sr, were
analysed. Elements of mass higher than 82 amu are usually
free from spectral interferences from polyatomic species
[24], which makes analysis of strontium practically free
from interferences. Low LODs (3s) were obtained for
determination of elements in bone, compared with values
reported earlier [16–20]. Analysis of hair, however, could
be performed at an LOD of 7 ng g−1 [25]. The LODs of this
study were determined as LOD(24Mg)=0.7 μg L−1, LOD
(44Ca)=30 μg L−1, LOD(64Zn)=0.4 μg L−1, LOD(88Sr)=
0.04 μg L−1, and LOD(138Ba)=0.3 μg L−1.
Animal study
Twenty-four beagle dogs (12 males and 12 females;
approximately 6 months old at the start of the study) were
allocated to four groups. The animals in one group (placebo/
control) were treated with vehicle (0.5% carboxymethylcel-
lulose) whereas the animals in the other three groups were
treated with daily doses of 300, 1000, and 3000 mg strontium
malonate kg−1, respectively. The strontium malonate was
administered in suspensions of 10 mg mL−1 by oral gavage
in the morning before the dogs were given food. The dogs
were given two daily meals and had free access to drinking
water. The strontium content of the available drinking water
was 2.6±0.6 mg L−1, which is a high level that character-
ises the local hard water. Blood samples were taken at
baseline and at the end of the study for analysis of BSAP.
At study start and at administration of the last dose, more
frequent sampling at 0, 1, 2, 4, 8, and 24 h was performed
to assess strontium pharmacokinetic properties. At the end
of the study period, the animals were killed and femur,
vertebrae (L2–L4), and teeth (front incisors) were extracted
and stored frozen until analysis.
BSAP method
Before the start of treatment and before termination of the
treatment, blood samples were taken from all animals. The
animals were fasted overnight before blood samples were
taken, but water was available. Blood samples were drawn
from the jugular vein. At least 3 mL blood was taken for
clinical chemistry in plain glass tubes for serum. Measure-
ments for BSAP were performed with an automated assay
using a Hitachi 902 immuno-analyzer according to the
manufacturer’s instructions. Validated control serum sam-
ples were included in each analytical run.
Results and discussion
Uptake and elimination of strontium
Mean serum strontium concentrations at baseline before
initiation of treatment were 62±15 and 56±7 μg L−1 for
females and males, respectively. The areas under the curves
(AUC) [26] were calculated for plasma concentration–time
from 0 to 24 h after strontium malonate administration and
for the maximum serum strontium concentration (Cmax).
After adjusting for baseline, the control group Cmax ranged
from 3–24 μg L−1. For the three active-dose groups Cmax
fell within the ranges 22–109 mg L−1 for the 300 mg kg−1
dose, 39–126 mg L−1 for the 1000 mg kg−1 dose, and 24–
180 mg L−1 for the 3000 mg kg−1 dose. The corresponding
ranges for AUC were 31–367 h μg L−1, 248–863 h μg L−1,
415–1570 h μg L−1, and 308–3465 h μg L−1. Thus,
substantial variation of both values was observed. When
linearity between administered dose levels and AUC and
Cmax was assessed, the results demonstrated that for both
quantities there was an increasing trend with dose.
However, it was also demonstrated that these trends were
not linear. Further, comparisons of the individual dose
Table 1 Elan 5000 ICP–MS operating conditions
RF Power 800 W
Plasma Ar flow 13 L min−1
Nebulizer Ar flow 0.80 L min−1
Sample injection flow 1.4 mL min−1
Working pressure 1 × 10−8 bar
Background pressure 2 × 10−10 bar
Sweeps per reading 2
Readings per replicate 1
Points per spectral peak 3
Number of replicates 5
Time per reading 300 ms
Dwell time 150 ms
Isotopes measured 24Mg, 42Ca, 43Ca, 44Ca, 64Zn, 67Zn,
68Zn, 84Sr (84Kr), 86Sr (86Kr),
87Sr (87Rb), 88Sr, 136Ba (136Xe, 136Ce),
137Ba, 138Ba (138La, 138Ce)
Correction for potentially interfering isotopes (in parentheses) is
performed by the instrument software
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levels showed that the AUC increased more from the
300 mg kg−1 dose to the 1000 mg kg−1 dose than from the
1000mg kg−1 dose to the 3000 mg kg−1 dose. This indicated
saturation in absorption, which was more pronounced for
the highest-dose groups than for the medium-dose groups.
The individual dose groups were also compared. When
the dose was raised 3.33-fold from 300 mg kg−1 to
1000 mg kg−1, a ratio of 1.53 was found for the AUC. For
the 3000 mg kg−1 and 1000 mg kg−1 doses the ratio estimate
was 1.11. For Cmax, the corresponding ratio estimates were
1.21 in both comparisons. Both for AUC and for Cmax
the bioavailability was lower for males than for females
with ratios of 0.80 and 0.67, respectively. The gender-by-
dose-group interaction was significant for Cmax (P=0.0013)
and marginally significant for AUC. Due to the presence of
an interaction effect, no conclusion can be drawn on the
gender comparison [27, 28].
Strontium in bone
The natural strontium levels in bone and teeth were equal,
while the strontium content of marrow was approx. half the
bone value. The bar plot of Fig. 1 shows that the level of
strontium increased by a factor of 85–100 for the low-dose
group and by a factor of 110–145 for the two high-dose
groups, compared with the placebo group. Beside the
expected significant difference in strontium content of the
control group and the treated groups, analysis of variance
(ANOVA, not shown) for the results for bone showed that
whereas significantly more strontium was incorporated into
the bones of the females in the two highest-dose groups
compared with the low-dose group, no such difference
was observed in the males. This result demonstrates that,
at least for the females, the incorporation of strontium
increased when the dose increased from 300 mg kg−1 day−1
to 1000 mg kg−1 day−1 while an increment in dose to
3000 mg kg−1 day−1 did not increase amounts of strontium
in the mineralized tissues substantially in this four-week
intervention study. A similar saturation tendency has previ-
ously been reported in rats [10]. Additionally, this observation
may be regarded as being in accordance with the pharma-
cokinetic analysis, which indicates saturation at the highest
dose levels.
Effect of strontium on markers and bone turnover
The anabolic effects of strontium treatment on bone turnover
were assessed by quantification of bone specific alkaline
phosphatase (BSAP) as a specific marker of bone formation.
Strontium resulted in a dose-dependent increase in BSAP
for both males and females in the groups treated with 300
and 1000 mg kg−1 day−1, while no further increase was
observed in the 3000 mg kg−1 day−1 group. During the
course of the study the placebo-treated females showed a
decrease in BSAP of 53%, whereas the three strontium
malonate-treated female groups showed increases of 60%,
276%, and 279% for the groups treated with 300, 1000, and
3000 mg kg−1 day−1. For males the corresponding values
were −44%, +142%, +192%, and +247% increase in BSAP
in the placebo, 300, 1000, and 3000 mg kg−1 day−1 groups,
respectively. The BSAP increase depends linearly on bone
strontium content (Fig. 2), showing a highly significant
(P < 0.001) positive correlation (r2=0.83, ordinary least-
squares regression). These observations indicate that stron-
tium induced a dose-dependent increase in bone formation
up to a dose level of 3000 mg kg−1 day−1. This is in accor-
dance with previous investigations in which strontium in
the form of strontium ranelate increased bone formation
and, in addition, reduced bone resorption [29], though, to
the best of our knowledge, a direct correlation with bone
strontium levels has not previously been reported. It is
noted that both BSAP and strontium measurements have
Fig. 1 Bar plot of the strontium content of (a) bone and (b) teeth of
dogs after oral administration of strontium malonate at doses of 0,
300, 1000, and 3000 mg kg−1 day−1. Light grey bars indicate male,
dark grey bars indicate female. The error bars indicate combined
biological uncertainty and instrument uncertainty. All four isotopes of
strontium (84Sr, 86Sr, 87Sr, 88Sr) were analysed
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been carried out with sufficient accuracy for this correlation
to be observed.
Magnesium in bone
Magnesium levels in bone were assessed in all groups
(Fig. 3). A dose-dependent decrease was observed from the
placebo group to the 1000 mg kg−1 day−1 dose group, while
no further decrease in the highest-dose group was found.
No significant gender difference was observed. This
indicates that strontium displaces magnesium from bone,
when present in large quantities.
Calcium in bone
The calcium content of the femur bone was determined by
quantifying three isotopes 42Ca, 43Ca, and 44Ca. Figure 4
shows calcium levels in all groups from the study, and it is
apparent that calcium levels are very similar ranging from
249±9 mg g−1 Ca in the placebo group to 276±22 mg g−1
Ca in the group treated with 300 mg kg−1 day−1. Calcium
levels showed less variability in the control group, which
indicates that strontium may result in a somewhat larger
individual variability in the calcium content. The average
Sr/Ca ratio in the bones of the control group was 1:3300,
while in the treated groups, the ratios were 1:40, 1:28, and
1:26 for doses 300, 1000, and 3000 mg kg−1 day−1, respec-
tively. These latter ratios approached the maximum value of
1:10 that was reported by Boivin et al. [30]. On a normal
diet, the Sr/Ca ratio in human bone is approx. 1:1000,
which is comparable with the ratio found in blood [31].
Zinc and barium in bone
A few additional elements which might affect the balance
between calcium and strontium in bone, were also analysed.
Zinc and barium were thus identified and determined at
levels of 85±15 μg g−1 and 2.4±1.4 μg g−1, respectively.
The amounts of these two elements were not found to be
affected by administration of strontium.
Strontium and calcium in teeth
Strontium levels in the teeth of the treated groups were
approximately a factor of four lower than the levels seen in
femurs. The strontium content of the control group was
75±14 μg g−1, which is almost identical to the strontium
levels in bone seen in the placebo group. In the strontium
malonate groups, the strontium level in teeth increased to
1.6±1.0 mg g−1, 2.3±0.7 mg g−1, and 2.2±1.1 mg g−1 in
the 300, 1000, and 3000 mg kg−1 day−1 groups, respec-
tively (Fig. 5). This suggests that saturation is observed in
the investigated dose range, and that already the 1000 mg
kg−1 day−1 group shows maximum incorporation of stron-
tium. The lower level of strontium incorporated in teeth
compared with bone is in accordance with the lower
remodelling of the mineralized matrix of teeth. Calcium
levels in the teeth were similar in all groups, with relatively
small intra-individual variability. The correlation between
the strontium content of bone and teeth of treated and
untreated dogs was R=0.523 (P < 0.05). The slope of the
correlation line, a=0.229, suggests that strontium was
incorporated in bone at a rate four to five times higher
than the rate of uptake in teeth.
Strontium and calcium in bone marrow
Only 16 bone samples contained sufficient amounts for
analysis of marrow. In the control group, the concentrations
ranged from 8 μg g−1 to 77 μg g−1, while the strontium
treated groups showed strontium levels ranging from
0.2 mg g−1 to 2.6 mg g−1. This demonstrates that the
Fig. 2 Correlation of serum BSAP levels with bone strontium content
at the end of treatment in the treated groups (P < 0.001). The slope of
the line is 0.39±0.04 and the intercept is 0.67±0.31
Fig. 3 The magnesium content of bone depicted as a function of
dose. The error bars represent the standard deviation within the
groups. The most abundant isotope, 24Mg, was used for the analysis
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strontium malonate treatment induces a significant increase
in strontium content in also the non-mineralized tissue of
bone, but the magnitude of the effect is difficult to estimate
accurately, owing to the incomplete availability of suitable
samples. There was no significant indication of increased
bone-marrow-strontium content with increased dosing,
suggesting that uptake of strontium by this tissue may
already be close to saturation at the lowest administered dose
(300 mg kg−1 day−1). Only a limited number of studies with
analysis of strontium in bone marrow are available in the
literature [23, 32], and they might not be directly
comparable with the current results because the conditions
of analysis and the types of sample are very different. The
results of the strontium measurements showed that the
strontium content of the control group was much higher
than that reported by Hasegawa et al. [23], who analysed
human-bone marrow and found 0.027 μg g−1 (wet weight).
However, the contents were determined at a level much
lower than the content of 180 μg g−1 (dry weight) reported
by Gawlik et al. [32], who used neutron-activation analysis
(NAA) for the analysis. According to the explanation by
Hasegawa et al. [23], the origin of the large difference is
related to the presence of amounts of small bone fragments
that must be separated from the matrix by spinning the
sample in a centrifuge. However, careful microscopy of the
samples of bone marrow in the current investigation did not
reveal such bone fragments. The calcium content of bone
marrow also varied substantially but no significant changes
were observed as a result of strontium treatment. The calcium
content of marrow was determined as 13±7 mg g−1.
Quality assurance
One of the key problems of chemical analysis is related to
discrimination between uncertainties imposed by the in-
strument and the biological variation. It is expected that
the biological variation by far exceeds the uncertainty of
measurement but in a relatively well defined matrix, such
as the bone matrix, the biological variation was lower (Fig. 2)
than the biological variation of other types of sample, e.g. in
samples of marrow. Initial investigations revealed that the
choice of standards for the construction of the calibration
Fig. 5 The strontium content of
teeth measured by ICP–MS after
four weeks of dosing with
strontium malonate. All four
isotopes of strontium (84Sr, 86Sr,
87Sr, 88Sr) were analysed. Dogs
1–6, control group; dogs 7–12,
Sr dose 300 mg kg day−1; dogs
13–18, Sr dose 1000 mg kg
day−1; dogs 19–24, Sr dose
3000 mg kg day−1
Fig. 4 The calcium content of
the femur bones of dogs deter-
mined by ICP–MS analysis of
42Ca, 43Ca, and 44Ca. Two sub-
samples, denoted A and B, from
each dog were analysed. Dogs
1–6, control group; dogs 7–12,
Sr dose 300 mg kg day−1; dogs
13–18, Sr dose 1000 mg kg
day−1; dogs 19–24, Sr dose
3000 mg kg day−1
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line might affect the standard deviation of the results. In
addition, the measurements could be performed by applying
ordinary linear regression including correlation terms [33–
35], by applying weighted linear regression [36], or by
functional relationship estimation by maximum likelihood
that can be downloaded as an add-in to the MS Excel
software from the homepage of the Analytical Methods
Committee [37]. A slight and almost unrecognisable
curvature to the calibration measurements, depicted as a
function of concentration, was found to significantly affect
the measured concentration of unknowns. In general, by
applying a wide calibration range there was a tendency to
obtain concentrations too high, compared with expected
values. It was thus found that the optimum range of cali-
brations was from 0–200 μg L−1 for the isotopes 84Sr, 86Sr,
87Sr, and 88Sr. The key results associated with the three
methods of analysis were determined as shown in Table 2.
Within this range of concentrations a Wald–Wolfowitz test
[36, 38] showed that the sequence of signs of residuals was
randomly distributed. Since all the results were equal within
the limits of the standard deviation, the least laborious
method of ordinary-linear regression with correlations was
chosen for the analysis. This certified that the results could
be obtained at the lowest possible STDEV within the linear
range of concentrations.
Before measurement an uncertainty budget was con-
structed on the basis of the methods stipulated in QUAM
[39] and the uncertainties of the calibration line including
terms of correlation [40]. The relative uncertainties are
presented in Fig. 6, where the major contributions to the
uncertainty budget were calculated on the basis of an
Ishikawa diagram (not shown). By far, the major contribu-
tion to the uncertainty originated from the spread of data
around the calibration line, that is, uncertainties related to
dilution and weighing were of minor importance to the total
uncertainty (Fig. 6). This notion may be illustrated by
investigating one particular measurement of strontium in
bone, which yielded a result of 76.5±1.3 μg g−1, by applying
the full uncertainty budget including correction for triangu-
lar distributions and square distributions [39]. However,
omission of these corrections for abnormal distributions
provided exactly the same result, whereas the result was
marginally different, 76.5±1.2 μg g−1, when using only the
STDEV of calibrations. The reliability of these results was
maintained by applying many standards, samples, and
replicates to the analysis. The reliability of the analysis
depends on the number of replicates according to the
central-limit theorem [41].
NIST SRM 1486 bone meal contains 264±7 μg g−1
strontium, and the reported uncertainty refers to an
extended uncertainty [39, 41] that was based on numerous
replicates. In Fig. 6 a is shown a Shewhart chart of 45
replicates of the determination of strontium by ICP–MS.
All the four isotopes were applied to the analysis, and the
average concentration was thus determined as 255.0±
6.8 μg g−1 (Fig. 7a). A t-test showed that this value was
close to the certified value but significantly lower (95%
level of confidence) than the concentration stipulated for
the SRM (t=8.93 > 1.68= t0.05(N=45)). It should be noted
that 5–7 of the measurements were determined very close to
the certified value and 16 replicates were found within the
Table 2 Estimates and uncertainties of parameters from ordinary least squares regression (OLSR), weighted least squares regression (WLSR),
and functional relationship estimation by maximum likelihood (FREML) [32]
Regression 84Sr 86Sr 87Sr 88Sr
OLSR
Slope (cps L mg−1) 5.57±0.07 99.6±1.1 71.18±0.49 816±7
Intercept (cps) −4±7 38±107 12±48 852±731
WLSR
Slope (cps L mg−1) 5.56±0.11 100.1±1.2 71.44±0.83 820±10
Intercept (cps) −4±7 13±3 7±7 85±53
FREML
Slope (cps L mg−1) 5.56±0.11 100.1±1.2 71.44±0.84 820±10
Intercept (cps) −4±7 13±3 7±7 85±53
Fig. 6 The uncertainty budget of analysis of strontium in bone. The
contributions to the total uncertainty u(cSr) are represented by the
symbols: u(mbone), uncertainty of the weight of bone; u(V1) and u(V2),
uncertainty of volume of dilution; u(P), uncertainty of volume of
pipette; u(ICP–MS), uncertainty of ICP–MS measurement; and u
(trace), uncertainty of traceability
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limits of the certified value. This distribution of data com-
plies with the properties of a normal distribution, and the
results of Fig. 7a thus demonstrate the importance of many
replicates being applied to the analysis. The recovery was
97%, which could be related to a loss of material during
the procedure of digestion. However, this is contradicted
by simultaneous determinations of calcium in the NIST
reference material, as shown in the Shewhart chart of
Fig. 7b, where a perfect match (100% recovery) was
obtained between measured values and the expected value
(N=17). Similarly, the concentrations of Mg, Zn, and Ba
were determined in the reference material, and a satisfac-
tory correspondence was obtained for Mg and Zn also
(Table 3).
The validity of the calculated uncertainties may be
verified by applying an F-test to the uncertainties of the
uncertainty estimated by the uncertainty budget (Fig. 6) and
comparing with the uncertainty of the experiment (Fig. 7a
and b). The uncertainty of Fig. 6 was estimated as 8.1 μg g−1
by calculating the effective number of degrees of freedom
by use of the Welch–Sattertwaite equation and applying it
to the extended uncertainty [39, 41]. The F-test thus
provided a test value of 1.42 that is not significant at 45
degrees of freedom (F0.05(45, 45)=1.64). Therefore, it may
be concluded that the uncertainty of the uncertainty budget
predicts well the observed uncertainties, which is the
requirement for statistical control.
Conclusions
Samples of bones, teeth and bone marrow were analysed by
ICP–MS after careful sample preparation. The procedure
was validated on the certified reference material NIST SRM
1486 bone meal, which provided a recovery of 97% for
strontium and a reliable estimate of the uncertainties thus
confirming statistical control. The strontium content was
determined at high precision corresponding to an RSD of
1.5% for the strontium isotopes 86Sr, 87Sr, and 88Sr, and
slightly lower precision for the less abundant isotope 84Sr.
Strontium malonate showed high bioavailability and was
generally well tolerated when administered to dogs by oral
gavage over the four-week study period. At the investigated
dose levels the pharmacokinetic analysis indicated satura-
tion at the highest dose level (3000 mg kg−1 day−1).
Strontium malonate induced a significant increase in bone
formation apparent as a highly significant increase in the
circulating levels of BSAP. Analysis of the mineralized
tissues of bone and teeth revealed a significant increase in
strontium content.
Strontium was incorporated into both teeth and bone but
uptake by teeth was approximately a factor of five lower
than that of bone, in accordance with the lower rate of
remodelling of dentine compared with bone. The increased
strontium content was not correlated with a corresponding
decrease in the content of calcium, which remained constant
in all groups. Within the of low dose group the calcium
content increased slightly but in general the calcium content
of bone, marrow, and teeth was found to be virtually
unaffected by administration of strontium malonate.
The magnesium content of bone was lower in the group
treated with 3000 mg kg−1 day−1 strontium malonate,
which may be interpreted as substitution of magnesium by
strontium.
Fig. 7 Shewhart charts of determination of (a) strontium and of (b)
calcium over a long period of time. The horizontal straight line indicates
the average value of all determinations and the dotted lines represent
the limits given by the uncertainty. The thick dotted line represents the
position of the certified value of NIST SRM 1486 bone meal, and the
concentrations connected by thick lines represents the average value for
each day
Table 3 Analysis of NIST SRM 1486 Bone Meal
Element Result Certified value
Mg 4.4±0.4 4.66±0.17
Ca 266±10 265.8±2.4
Zn 0.124±0.022 0.147±0.016
Sr 0.255±0.008 0.264±0.007
Ba 0.189±0.008 –
Mean values ± standard uncertainty according to the uncertainty
budget, both in units of mg g−1
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Appendix III 
 
Parameters for ordinary least-squares regression and weighted least-squares 
regression. X denote standard concentrations and Y is the corresponding instrument 
response. m is the number of standards, n the number of sample replicates and w is 
the weight [1, 2]. 
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